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The purpose of this thesis was to investigate the effect of a dietary intervention 
designed to increase tissue incorporation of omega 3 polyunsaturated fatty acids (n-
3 PUFA) on oxygen consumption during submaximal exercise, and to investigate 
the acute inflammatory cytokine response to different intensities of cycling in trained 
men. 
Study 1. The cytokine response to two cycling modalities: 1) pre-loaded 
performance trial and 2) high intensity interval trial. 
 
This study investigated the effect of two cycling protocols on plasma concentrations 
of pro-inflammatory and anti-inflammatory cytokines. Fourteen moderately trained 
healthy males completed two cycling protocols 1 week apart, 1) a 1-hour pre - 
loaded cycling time trial with the first 45 minutes corresponding ~70% of maximal 
work load and 2), 12 x 1 minute high intensity intervals corresponding to 100% of 
maximal workload (workload was based on an incremental test to exhaustion). 
Blood samples were obtained from the antecubital vein pre and immediately post 
each exercise trial, for the determination of plasma cytokine concentrations. 
Additional saliva samples were collected at the same time points to validate their 
relationship and agreement with plasma samples for measurement of IL-1β. 
Results: IL-6 increased more markedly following the pre-loaded time trial (mean ± 
standard deviation), 2.56 ± 3.30 pg./ ml to 6.68 ± 4.48 pg./ ml respectively (a 161% 
increase) compared to the interval trial 2.16 ± 2.05 pg./ ml to 2.95 ± 2.24 pg./ ml (a 
37% increase) (time * trial interaction p = 0.015). IL-4 and MCP-1 concentrations 
increased, and VEGF decreased following both trials combined (main effect of time 
IL-4, p = 0.013, MCP-1, p = 0.002, VEGF, p = 0.016). No changes were observed 
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in other cytokine concentrations. A significant correlation between plasma and saliva 
IL-1β concentration was only observed in samples obtained post the time trial (r = 
0.807, p = 0.009), expressed as concentration: osmolality, r = 0.781, p = 0.013). In 
conclusion, a 1-hour pre-loaded cycling trial resulted in a greater increase in IL-6 
compared with 12 x 1min interval trial. Acute post exercise increases in IL-4 and 
MCP-1, and a decrease in VEGF were observed post both trials on average. 
Furthermore, the relationship between plasma and saliva for the measurement of 
IL-1β concentration was inconsistent and lacked agreement. Saliva did not prove to 
be a valid alternative method of measurement to blood plasma for the measurement 
of IL-1β. 
 
Study 2. Validation of the use of a fingertip capillary dry blood spot method to 
determine percentage incorporation of n-3 PUFA and n6 into erythrocyte cell 
membranes. 
 
This study investigated the relationship and agreement between dry blood spot 
samples (DBS), and isolated erythrocytes (from venepuncture whole blood 
samples), for the measurement of percentage PUFA status in 10-trained cyclists. 
Blood samples were collected on three occasions over an 8-week period (baseline, 
at 4 weeks and at 8 weeks) to determine percentage tissue incorporation of total n-
6 PUFA, AA, LA, total n-3 PUFA, EPA and DHA. On each occasion, two sample 
types were obtained from each participant. 1), isolated erythrocytes from whole 
blood taken from the participant’s antecubital vein. 2), a whole blood fingertip 
capillary sample spotted on to a Guthrie absorbent card pre-soaked in butylated 
hydroxytoluene. The n-3 PUFA and n-6 PUFA content of both samples was 
determined by gas chromatography and mass spectrometry. Results: Isolated 
erythrocyte samples had a significantly higher percentage content of EPA, AA, total 
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n-6, EPA + DHA and n-6/ n-3 PUFA and a lower content of ALA when compared to 
fingertip capillary DBS samples. No differences between methods were observed 
for DHA and total n-3 PUFA values. Linear regression showed there was a 
significant correlation (R) between the two types of measurement for EPA (R2 = 
0.64, p = 0.005) but not for other fatty acids. Bland and Altman analysis showed 
moderate agreement between methods for EPA (mean difference = 1.12% with 95% 
limits of agreement -1.43% – 3.67%). In conclusion, the current study suggests 
fingertip capillary DBS sampling is a valid method for determining the EPA status of 
individuals but not for other n-3, n-6 PUFAs. 
 
Study 3. The effect of an 8-week high n-3 PUFA and low n-6 PUFA (H3-L6) dietary 
intervention, on erythrocyte fatty acid incorporation, and its effect on the oxygen 
cost of submaximal exercise and 2OV

peak in trained cyclists. 
 
This study investigated the effect of an 8-week dietary intervention (designed to 
increase n-3 PUFA and reduce n-6 PUFA (to less than 2.5% of average daily kcal 
intake)) on 2OV

peak and oxygen consumption ( 2OV
 ) during submaximal exercise. 
14-trained male cyclists were randomly assigned to two independent groups. The 
experimental group received 8 x 1g capsules per day of n-3 PUFA (2600mg EPA 
and 1800mg DHA), and followed a dietary intervention designed to reduce n-6 
PUFA intake (H3-L6). The placebo group received 8 x 1g capsules per day of 
organic soy oil and a pseudo dietary intervention that maintained their habitual 
daily n-6 PUFA intake. Blood samples were obtained from the participant’s 
antecubital vein, pre supplementation, at week 4 and at week 8, for the analysis of 
erythrocyte incorporation of n-3 PUFA and n-6 PUFA. Pre and post the dietary 
intervention, participants completed 4 x 7mins submaximal cycling on a Lode 
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ergometer at four discontinuous incremental power outputs. Steady state oxygen 
consumption ( 2OV
 ), tissue oxygen saturation index (TSI%), deoxygenated 
haemoglobin (deoxy-HHb), heart rate (HR bpm), blood pressure (BP mmHg), and 
rating of perceived exertion (RPE), were assessed during each cycling bout. 
Following a 15-minute rest, participants performed an incremental cycling ramp 
test to exhaustion (intensity increasing by 30 W∙min -1) for the determination of 
2OV

peak (L/min). Results: H3-L6 significantly increased erythrocyte % content of 
total n-3 PUFA, EPA and DHA compared to the placebo group over the 8 week 
intervention (time * group interaction, total n-3 PUFA, p = <0.001, EPA, p = 
<0.001, DHA, p = 0.001), and significantly reduced total n-6 PUFA, LA and AA 
(time * group interaction, total n-6 PUFA, p = <0.001, LA, p = 0.004, AA, p = < 
0.001). There were no differences in 2OV

peak (group * time, p = 0.56). During 
steady state submaximal cycling, there were no differences in oxygen 
consumption 2OV
  L/min (group * time * power level, p = 0.49), TSI% (p = 0.43) or 
deoxy-HHb (p = 0.56). Furthermore, no changes were observed in HR, BP, MAP 
or RPE. In conclusion, despite the dietary intervention successfully increasing 
erythrocyte n-3 PUFA percentage and reducing n-6 PUFA incorporation over an 8-
week intervention period, there was no effect on oxygen consumption during 
submaximal exercise or 2OV

peak performance.  
In summary, this thesis provides evidence that IL-6 increases more markedly in 
response to a 1 hour pre-loaded cycling time trial compared to 12 x 1 minute 
intervals. For both cycling trials combined, there was an increase in anti-
inflammatory IL-4 and MCP-1, and a decrease in VEGF. Furthermore, saliva did 
not prove to be a valid alternate measurement method to blood plasma for the 
measurement of IL-1β.  
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This thesis demonstrated that an 8-week H3-L6 dietary intervention successfully 
increased erythrocyte incorporation of n-3 PUFA and reduced n-6 PUFA. 
However, the intervention failed to induce significant alterations in oxygen 
consumption during submaximal exercise or 2OV

peak performance. In addition, 
when quantifying an individual’s n-3 PUFA and n-6 PUFA status, fingertip capillary 
DBS sampling proved to be a valid method for the measurement of EPA but not 
for other fatty acids. Therefore, the DBS method was not considered a suitable 
replacement for the isolated erythrocytes method when quantifying an individual’s 
n-3 PUFA and n-6 PUFA status.  
 VII 
TABLE OF CONTENTS 
Table of Contents 
ABSTRACT .................................................................................................................... II 
TABLE OF CONTENTS ................................................................................................... VII 
LIST OF TABLES ............................................................................................................ IX 
LIST OF FIGURES .......................................................................................................... XI 
ACKNOWLEDGEMENTS ............................................................................................... XII 
DECLARATION............................................................................................................ XIII 
LIST OF ABBREVIATIONS ............................................................................................ XIV 
CHAPTER 1 INTRODUCTION .......................................................................................... 1 
CHAPTER 2 REVIEW OF LITERATURE .............................................................................. 8 
2.1 SCOPE OF THE REVIEW .................................................................................................... 9 
2.2 OMEGA-3 PUFA AND 6 FATTY ACIDS, DIETARY SOURCES & METABOLISM ....................... 10 
2.2.1 OMEGA-3  AND 6 PUFA ELONGATION AND SATURATION ............................................... 10 
2.2.2 N-3 PUFA’S AND CURRENT RECOMMENDED INTAKES .................................................... 12 
2.2.3 EVOLUTION AND THE BALANCE OF OMEGA-6 AND OMEGA-3 FATTY ACIDS IN THE 
HUMAN DIET ............................................................................................................................. 14 
    2.3 THEORETICAL BASIS FOR N-3 PUFA SUPPLEMENTATION  EFFECT ON  INFLAMMATION ..... 15 
2.4 STUDIES THAT HAVE EXAMINED INFLAMMATORY CYTOKINE RESPONSES TO EXERCISE ... 17 
2.4.1 THEORETICAL BASIS FOR N-3 PUFA SUPPLEMENTATION AND ITS EFFECT EXERCISE 
PERFORMANCE AND RELATED PHYSIOLOGICAL VARIABLES .................................................... 22 
2.4.2 EPA AND DHA EFFECT ON THE VASCULAR FUNCTION AND NO ...................................... 24 
2.4.3 EPA AND DHA EFFECT ON CARDIAC MYOCYTES AND HEART RATE ................................. 27 
2.4.4 EPA AND DHA, SKELETAL MUSCLE AND MITOCHONDRIAL MEMBRANE COMPOSITION 
AND BIOENERGETICS ................................................................................................................ 29 
2.4.5 EPA AND DHA AND EFFECT ON RED BLOOD CELL DEFORMABILITY ................................ 30 
2.5 OMEGA-3 FATTY ACIDS, HUMAN PERFORMANCE AND ASSOCIATED PHYSIOLOGICAL 
VARIABLES ......................................................................................................................... 32 
2.6 METHODOLOGICAL DIFFERENCES AND TIME COURSE OF SUPPLEMENTATION ................ 43 
2.7 BIOMARKERS TO QUANTIFY N-3 PUFA STATUS .............................................................. 44 
2.8 SUMMARY .................................................................................................................... 45 
2.9 THESIS AIMS ................................................................................................................. 45 
CHAPTER 3 THE CYTOKINE RESPOSE TO TWO CYCLING MODALITIES: 1) PRE-LOADED 
PERFORMANCE TRIAL AND 2) HIGH INTENSITY INTERVAL TRIAL. ................................. 47 
INTRODUCTION .................................................................................................................. 48 
METHODS .......................................................................................................................... 51 
RESULTS ............................................................................................................................. 57 
DISCUSSION ....................................................................................................................... 66 
CHAPTER 4 VALIDATION OF THE USE OF A FINGERTIP DRY BLOOD SPOT METHOD TO 
DETERMINE CELLULAR N-3 AND N-6 INCORPORATION IN COMPARISON TO VENOUS 
BLOOD ERYTHROCYTE ANALYSIS ................................................................................. 76 
INTRODUCTION .................................................................................................................. 77 
 VIII 
METHODS .......................................................................................................................... 80 
STATISTICAL ANALYSIS ........................................................................................................ 82 
RESULTS ............................................................................................................................. 83 
DISCUSSION ....................................................................................................................... 93 
CHAPTER 5 THE EFFECT OF A HIGH N-3 AND LOW N-6 PUFA DIETARY INTERVENTION ON 
ERYTHROCYTE N-3 PUFA PHOSPHOLIPID INCORPORATION AND ITS EFFECT ON 
SUBMAXIMAL INCREMENTAL EXERCISE AT FOUR DIFFERENT WORK RATES AND 
MAXIMAL AEROBIC FITNESS ( 2OV

 max)........................................................................ 98 
INTRODUCTION .................................................................................................................. 99 
METHODS ........................................................................................................................ 104 
RESULTS ........................................................................................................................... 114 
DISCUSSION ..................................................................................................................... 135 
CHAPTER 6 GENERAL DISCUSSION ............................................................................. 143 
CONCLUSIONS ....................................................................................................... 158 
REFERENCES ............................................................................................................. 162 
APPENDIX ................................................................................................................. 196 
APPENDIX 1 ...................................................................................................................... 197 
APPENDIX 2 ...................................................................................................................... 199 















LIST OF TABLES 
 
2.1 Adult consumption of LA and ALA acids in a selection of countries 
 
12 




2.3 Some of the proposed mechanisms and biochemical effects of n-3 
polyunsaturated fatty acids (n-3 PUFAs) 
 
15 
2.4 Studies that have examine the effect of n-3 PUFA on exercise 
performance and related physiological variables  
 
42/43 
3.1 Participants physical characteristics 
 
52 
3.2 2 x 2 ANOVA main interaction effects between trial (pre TT, pre INT 
post TT and post INT) and time (pre to post TT and pre to post INT) on 
cytokine values for 11 cytokines.  
 
62 
   
3.3 Pearson’s correlation to compare the relationship between 1) Plasma 
& Saliva IL-1β and 2) Plasma & SC: O IL-1β values for TT pre, TT post, 
INT pre and INT post. 
 
63 
   
3.4 Pearson’s correlation to compare the relationship between 1) Plasma 
& Saliva IL-1β and 2) Plasma & SC: O IL-1β percentage change in IL-
1β concentration (percentage change pre to post exercise relative to 
100) following the TT and INT 
 
64 
3.5 Bland and Altman level of agreement between PLA & SAL percentage 
change (relative to 100) in IL1-β TT and INT  
 
65 
4.1 Participant physical characteristics 
 
80 
4.2 Outlier identification values and case number 
 
83 
4.3 Mean difference comparison of blood fatty acid percentage content 
derived from DBS and venous methods 
 
86 
4.4 The relationship between blood fatty acid percentage content derived 
from DBS and venous methods 
 
87 
4.5 Bland and Altman agreement between DBS and venous methods and 
simple linear regression of the mean of the two methods (X) and the 
difference between the two methods (X-Y) to determine the presence 
of systematic bias. 
 
88 
4.6 Mean percentage blood sample fraction fatty acid content and the 
magnitude of difference between Venous erythrocyte and DBS values 
in the current study compared to previous studies 
 
94 
5.1 Relative composition of EPA and DHA in each individual FO capsule 





5.2 Participant total kcal intake and n-3/ n-6 PUFA levels in the FO and 
SO group before the dietary manipulation was applied compared to 
when it was applied during the supplementation period 
 
111 
5.3 Participant characteristics 
 
114 
5.4 Changes in erythrocyte fatty acid content (%) at week-0, week-4, and 
week-8 of the supplementation period. 
 
122 
5.5 Changes in erythrocyte fatty acid content % (main fatty acids of focus) 





  (L/min) values pre and post the intervention in the FO and SO 
group at each power level 
 
124 
5.7 HR (bpm) pre and post intervention in the FO and SO group at each 










TSI % pre and post the supplementation period in the FO and SO group 
at each power level 
 
Deoxy HHb, pre and post supplementation in the FO and SO group at 
each power level 
 
Post Hoc Bonferroni corrected t-tests to examine differences in pre/ 










5.11 Systolic BP (mm/Hg) pre and post the supplementation period in the 
FO and SO group at each power level 
 
130 
5.12 Diastolic BP (mm/Hg) pre and post the supplementation period in the 
FO and SO group at each power level 
 
131 
5.13 Mean arterial pressure (MAP mmHg) pre and post the 
supplementation period in the FO and SO group at each power level 
 
132 
5.14 Maximal test data, pre and post the intervention in the FO and SO 
group. 
121 
   
   









LIST OF FIGURES 
 








2.3 The commonly proposed anti-inflammatory effect of n-3 PUFAs via 
competitive inhibition of the AA cascade and Cox 2 pathway. 
 
17 
2.4 Schematic diagram of the multiple physiological factors that interact as 
determinants of performance, velocity or power output. Redrawn from 
Joyner & Coyle (2008).   
 
25 
3.1 Bland and Altman level of agreement of between plasma and saliva 
assays to determine % change in IL1-β values following the exercise 
trials (A) TT (B) INT (C) TT (With saliva values expressed as 




4.1 Participant samples used for analysis 
 
83 



















HR (bpm) values pre and post the intervention in the FO and SO 
 
TSI% values pre and post the intervention in the FO and SO 
















This work was carried out on a part time basis at the University of Kent School of 
Sport and Exercise Sciences. As such, I am grateful to the University of Kent. 
I have had the privilege to work under the supervisors, Professor Louis Passfield 
and Dr Glen Davison. I am extremely grateful to them for imparting their knowledge 
and experience on me through the duration of this PHD, and for their help and 
support as supervisors and colleagues. Furthermore, thank you to Dr Mark Burney 
and Dr James Hopker in their roles as Director of Post Graduate research. 
 
I would like to acknowledge Nordic Naturals for providing the omega 3 supplement 

























No part of this thesis has been submitted in support of an application for any 
degree or other qualification of the University of Kent, or any other University or 
Institution of learning. 
 
Signed: L. Hale  
Date:   27/ 03/ 18
 XIV 
LIST OF ABBREVIATIONS 
 
AA Arachidonic acid  
ALA  alpha-linoleic acid 
ALA alpha  
ANOVA  
bFGF 
Analysis of variance acid fibroblast growth factor-basic 
Fibroblast growth factor-basic 
BHT  Butylated hydroxytoluene  
BP Blood pressure 
Ca2+ Calcium 
CHD  Coronary heart disease  
CV Cardiovascular 
DBS  Dried blood spot  
DHA  Docosahexaenoic acid l acids  
EDTA  Ethylene diamine tetra acetic acid 
EPA  Eicosapentaenoic acid 
FA  Fatty acid  
FFQ Food frequency questionnaire 
FO Fish oil  
GC Gas chromatography  
HR Heart rate 
ICC Intra-class correlation  
IFN- γ Interferon gamma  
IL-10 Interleukin 10 
IL-1 α  Interleukin 1 alpha 
IL-1β Interleukin 1 beta 
IL-2 Interleukin 2 
IL-4 Interleukin 4 
IL-6 Interleukin 6 
IL-8 Interleukin 8 
INT Interval  
LA  Linoleic acid  
LC Long Chain   
LCPUFA  Long chain polyunsaturated fatty acids 
MAP Mean arterial pressure 
 XV 
MCP-1 Monocyte chemoattractant protein-1 
MUFA  Monounsaturated fatty acids  
n-3 PUFA Omega 3 
n-6 PUFA Omega 6 
NIRS Near Infrared spectroscopy  
NO Nitric oxide 
O2 Oxygen  
PBMC 
SO 





Phosphate buffered saline  
 




Polyunsaturated fatty acids 




Soluble fms-like tyrosine kinase-1 
SD   Standard deviation 
TNF- α  Tumour necrosis factor alpha  
TSI% Tissue saturation index (percentage)  
TT Time trial 
TTE Time to exhaustion 
VEGF Vascular endothelial growth factor  
2OV
































Due to the physiological demands of training and competition, athletes are 
constantly seeking effective dietary interventions, food supplements and ergogenic 
aids to improve their performance and recovery. Many athletes consume 
supplements daily with focus on a number of possible benefits including, delaying 
fatigue, maximising metabolic capacity, improving lean mass, protection for immune 
function, to aid recovery and maintain good health. Oily fish and fish oil supplements 
contain long chain n-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic 
acid (EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3). Long chain n-3 
PUFAs are historically recognised for their role in growth and development 
(Simopoulos, 2007), in the treatment and prevention of cardiovascular disease 
(Marchioli et al., 2002), and for the management of hypertension, diabetes and 
autoimmune conditions such as rheumatoid arthritis (Simopoulos, 1999). 
The consumption of n-3 EPA and DHA PUFA, results in the incorporation of n-3 
PUFA into various human tissue cells in a dose response manner (Institute of 
Medicine, 2005., cited in European Food Safety Authority, Scientific opinion on the 
tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic 
acid (DHA) and docosapentaenoic acid (DPA), 2012). The predominant fatty acid 
usually found in the tissue cell membranes of humans consuming a diet high in 
omega 6 fatty acids (n-6 FA) is arachidonic acid (AA; 20:4 n-6). A common 
explanation for the benefits of n-3 in the human diet is its modulatory effect on the 
production of inflammatory mediators (Simopoulos, 2002). 
When the human diet is supplemented with EPA and DHA, cellular incorporation 
of n-3 PUFA is at the expense of AA. EPA competes with AA, and inhibits AA 
eicosanoid synthesis derived from the cyclooxygenase-2 and 5-lipoxygenase 
pathways. This  reduces the production of inflammatory mediators from 
inflammatory cells (Mickleborough et al, 2009). This  leads to a reduction in the 
production of prostaglandin E2 metabolites, which cause platelet aggregation, 
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vasoconstriction, and induce inflammation (Mickleborough, 2008., Weylandt et al, 
2012). Recent studies have identified that n-3 PUFAs are responsible for the 
production of anti-inflammatory mediators known as protectins, resolvins and 
maresins (Chapkin, et al, 2009). It is possible that the typical modern western diet, 
rich in n-6 PUFA, shifts the body’s physiological state into one that is pro-
thrombotic & pro-aggregatory resulting in increased blood viscosity, vasospasm, 
and vasoconstriction (Simopoulos, 2007). This may increase risk factors for 
disease states such as cardiovascular disease (Mozaffarian & Wu, 2011), cardiac 
arrhythmia (Endo & Arita, 2016) and can exacerbate autoimmune/ inflammatory 
diseases such as rheumatoid arthritis and asthma (Mickleborough 2013).  
The hemodynamic influence of EPA and DHA supplementation in the health setting 
was first evaluated in the 1970’s.  Bang and Dyerberg carried out several pioneering 
pilot studies on Greenland Eskimos that demonstrated that a diet high in n-3 PUFA’s 
was linked to low rates of coronary heart disease. This was theorised to be due to 
EPA consumption and it’s antithrombotic, and cholesterol lowering effect (Bang & 
Dyerberg, 1980). These early studies created a new focus on the importance of n-3 
PUFA’s in the health setting, specifically the potential cardiovascular benefits of 
enriching the diet with EPA and DHA (Dyerberg et al, 1978., Dyerberg & Sinclair, 
1980). A breadth of experimental and epidemiological studies have been carried out 
since then, to further investigate n-3 PUFA’s, and their effect on cardiovascular 
health and disease. Many of these studies suggest there is an inverse relationship 
between increased n-3 PUFA intake and the incidence of mortality and morbidity 
(Rissanen et al, 2000). The cardio protective effects of fish oil are related to a 
number of mechanisms including reduced inflammation, enhanced endothelial 
function (Shah et al,  2007), decreased blood pressure (Tousoulis et al, 2014), 
reduced heart rate (Mozaffarian et al., 2005), and enhanced myocardial oxygen 
efficiency (Pepe, 2002). 
 4 
The therapeutic action of n-3 PUFA on cardiovascular factors and inflammation in 
the health setting brings into question whether some of these actions are 
transferable to healthy individuals. It has been recognised that n-3 PUFA’s may 
confer benefit in the athletic context (Simopoulos, 2007). A number of studies have 
shown that dietary fish oil supplementation may improve a variety of cardiovascular 
factors that could possibly influence exercise performance. Such factors include the 
enhanced deformability of erythrocytes (RBC deformability), increased artery 
diameter, and improved blood flow during exercise (Walser et al, 2008). Such 
modifications may lend themselves to improved oxygen delivery and potentially 
enhanced performance. Recent studies in young healthy participants confirm that 
increased dietary n-3 PUFA can modulate a number of cardiovascular mechanisms. 
N-3 PUFA supplementation has lowered HR at submaximal and peak exercise 
intensities and reduced whole body oxygen consumption during submaximal 
exercise (Peoples et al , 2008). Further observations include reduced rating of 
perceived exertion (RPE), reduced diastolic blood pressure and heart rate at 
submaximal exercise intensities (Buckley, Burgess, Murphy, & Howe, 2009). Many 
studies have reported positive effects of n-3 PUFA supplementation on 
cardiovascular variables; however, it has not yet been substantiated if these effects 
translate into performance improvements. N-3 PUFA supplementation for 3 weeks 
(6g/ day) did not improve 2OV

max, max power or a performance trial (time to 
complete a set amount of work) in trained healthy cyclists compared to the placebo 
group (Oostenbrug et al, 1997). N-3 PUFA supplementation failed to influence the 
performance of a treadmill run to exhaustion in Australian rules footballers (Buckley 
et al, 2009) or the performance of a cycling time trial in young healthy adults (Da 
Boit et al, 2015). However, Zebrowska et al. (2015) reported that 1.1g/ day n-3 PUFA 
significantly increased 2OV

max and endothelial function in elite male cyclists. Further 
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work is warranted to investigate n-3 PUFA and cardiovascular benefits in the 
exercising population. 
N-3 PUFAs exert an immunomodulatory effect reducing the production of 
Inflammatory mediators, and are responsible for the production of anti-inflammatory 
mediators known as protectins, resolvins and maresins (Chapkin, et al, 2009). N-3 
PUFA may act as a nutritional countermeasure to exercise induced inflammation 
(Simopoulos, 2007). Inflammation is the normal biological response to injury, 
infection and stress, and in the athletic context, it is necessary for adaptation to 
exercise. However when inflammation becomes excessive and uncontrolled it can 
contribute to tissue damage disease and the loss of physiological function. (James, 
Gibson, & Cleland, 2000).  In previous studies, much attention has been focused on 
circulatory cytokine concentrations to examine the extent of the exercise induced 
pro and anti-inflammatory response. Much of the research has investigated long 
duration endurance exercise such as marathon and ultra-marathon events (Nieman 
et al., 2003), down-hill running and eccentric exercise (Peake, 2005). After a 
marathon race, inflammatory cytokines, IL1β and TNFα increased 1.5 and 2 fold 
respectively and IL-6 increased markedly (100 fold) (Ostrowski, 1998). These 
events produce extensive muscle damage likely to cause large changes in the 
cytokine/ immune response. Elevated TNFα and IL1-β levels have been reported 
following 1.5 and 2 hours of cycling (Cox et al., 2010; Brenner et al., 1999 
respectively). However, in several studies, changes in systemic levels of 
inflammatory TNFα and IL1β could not be detected or only very small changes were 
measurable in plasma after eccentric exercise (Smith, 2000; Hirose, 2004). 
Ostapiuk-Karolczuk et al. (2012), observed increases in IL-6 and anti-inflammatory 
IL-4 immediately post 90 minutes running at 65% 2OV

max. There are a number of 
explanations for the equivocal results regarding pro and anti-inflammatory 
responses to exercise. These are related to the mode/ intensity and duration of 
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exercise as well as the sensitivity of the assay used to analyse cytokine 
concentrations (Pedersen & Hoffman Goetz, 2000). Although the majority of 
previous research has examined the inflammatory response to heavy prolonged or 
eccentric exercise, it remains to be elucidated if short term cycling exercise results 
in an acute inflammatory or anti-inflammatory cytokine response. Therefore, the first 
purpose of this thesis was to investigate the acute cytokine response to cycling 
sessions of differing duration and intensity. More specifically to investigate the 
cytokine response to a 1-hour preloaded time trial and a high intensity interval 
session. It was hypothesized that both trials would produce an increase in IL-6 and 
inflammatory cytokines, and the increase would be more marked in the 1 hour 
cycling trial. 
The second purpose of the thesis was to develop a suitable dietary intervention to 
increase erythrocyte phospholipid incorporation of n-3 PUFA. Previous researchers 
in the exercise field have employed a range of supplementary protocols ranging 
from 1.3g of n-3 PUFA per day (660mg EPA and 440mg DHA) for 3 weeks 
(Zebrowska et al., 2004), to 6.5g of n-3 PUFA per day (2000mg EPA and 1300mg 
DHA) (Raastad et al., 1997). N-6 PUFA and n-3 PUFA compete for enzymatic 
conversion and incorporation into tissues, therefore, lowering background dietary 
intake of n-6 PUFA could augment the incorporation and action of n-3 PUFA. No 
studies have evaluated the effect of lowering the background dietary intake of n-6 
PUFA whilst simultaneously increasing n-3 PUFA in the exercise setting. It was 
hypothesised that an 8-week integrated dietary intervention to increase n-3 PUFA 
intake and to reduce the background dietary n-6 PUFA intake (H3-L6) would 
increase erythrocyte incorporation of n-3 PUFAs, EPA and DHA and would reduce 
n-6 PUFA, AA and LA. 
The third purpose of this thesis was to investigate the effect of (H3-L6) on oxygen 
consumption during submaximal exercise in trained men. Previous researchers 
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investigating n-3 PUFA and its effect on oxygen consumption have based their 
findings on 2OV
  or 2OV

max measurements (Raastad et al., 1997; Zebrowska et 
al., 2004; Peoples et al., 2008; Da Boit et al., 2015). Whole body O2 consumption 
measured via expired gases closely reflects O2 consumption in the active muscles 
during steady state light to moderate exercise (Grassi 1996). However, inferences 
on the relationship between 2OV
  and M 2OV

 can be made using near-infrared 
spectroscopy (NIRS), therefore muscle oxygen delivery and extraction will be 
examined in addition to 2OV

. It was hypothesised that n-3 PUFA supplementation 




The following review of literature will discuss some of the available research in 






































2.1 SCOPE OF THE REVIEW 
The potential beneficial effects of n-3 PUFA on the maintenance of health and 
disease states has become an increasingly popular and important area of research. 
In the past 50 years, epidemiological and clinical studies have suggested that 
increasing dietary intake of n-3 PUFA (specifically eicosapentaenoic acid (EPA, 20:5 
n-3) and docosahexaenoic acid (DHA, C22:6 n-3) is associated with a number of 
improvements in health status. Previous studies have focused their attention on n-
3 PUFA and their role in cardio protection, antiarrhythmic effects, lowering of 
plasma, triglycerides (GISSI – Prevenzione investigators, no author, 1999, cited in 
Rissanen, et al, 2000), anti-thrombotic, and reduced atherosclerotic effects (Calder, 
2012). In addition, studies have examined n-3 PUFA and its effects on endothelial 
relaxation, lowering of blood pressure and it’s anti-inflammatory effects (Mozaffarian 
& Wu, 2011). The foundation of these potential n-3 related mechanisms are 
embedded in clinical, health related studies. Few human studies have examined the 
inflammatory response to endurance exercise, particularly in relation to cycling. In 
addition, few studies have examined n-3 PUFAs and their effect on exercise related 
variables, performance or capacity. The following literature review will introduce the 
nature of n-3/ n-6 PUFAs, dietary sources and metabolism. The theoretical basis of 
n-3 PUFA and its modulation of inflammation, and cardiovascular mechanisms will 







2.2 OMEGA-3 AND 6 FATTY ACIDS, DIETARY SOURCES & 
METABOLISM 
Omega 3 and 6 fatty acids are essential fatty acids (EFA) in the diet. The human 
body cannot synthesize them without regular consumption. The essential omega 6 
and omega 3 fatty acids are linoleic acid (LA) (18:2 n-6) and alpha linolenic acid 
(ALA) (18:3 n-3) respectively. It is possible to distinguish a polyunsaturated fatty 
acid (PUFA) as n-3 or n-6 PUFA by the position of the first double bond in its carbon 
chain (see figure 2.1). LA is found in dietary sources such as plants and seeds,  ALA 
is mainly found in green leafy vegetables (Aarsetoey et al., 2012), in oils such as 
soybean oil, rapeseed oil and some nuts and seeds including flaxseeds and walnuts 
(Graham & Burdge, 2005). EFA’s are metabolised or elongated into longer carbon 
chain PUFA’s of 20 and 22 carbons by the addition of double bonds.  In humans, 
arachidonic acid (AA n-6) is metabolised from LA. 
 
 Figure 2.1. Structural formulas for n-3 PUFA α linoleic acid and n-6 PUFA linolenic 
acid Simopoulos (1991). FIGURE REDACTED  
 
2.2.1 OMEGA-3 AND 6 ELONGATION AND SATURATION  
Eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3) 
are two important fatty acids related to human health. Both EPA and DHA can be 
synthesized from ALA by desaturation and elongation in the liver (Mozaffarian & 
Wu, 2011) (see figure 2.2). Since both n-3 PUFA and n-6 PUFA metabolism occurs 
using the same pathway, they potentially compete for the same desaturation and 
elongation enzymes. However, desaturase enzymes 4 and 6 preferentially elongate 
n-3 PUFA when sufficient substrate is available in comparison to n-6 PUFA 
(Mickleborough, 2008). ALA conversion to EPA and DHA in humans is estimated to 
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be approximately 8 – 20% (EPA) and 0.5 – 9% (DHA). EPA and DHA concentrations 
in tissue cells and plasma are much higher than ALA (Graham & Burdge, 2005). 
Typical consumption of ALA (n-3) is approximately 10-fold lower than LA (n-6). 
Table 2.1 demonstrates how intake can vary greatly across different sample 
populations.   
Figure 2.2 Essential fatty acid metabolism desaturation and elongation of n-6 















Table 2.1 Adult consumption of LA and ALA in a selection of countries Graham & 






   
  
   
  
          
          
          
          
          
          
          
          





2.2.2 N-3 PUFA’S AND CURRENT RECOMMENDED INTAKES 
Current international health guidelines suggest a number of different 
recommendations for n-3 PUFA intake. Some are based upon volume of fish 
consumed, for example, the American Heart Association guidelines (see table 2.2) 
and others are based on approximate milligrams or grams per day (Scientific 
Advisory Committee on Nutrition, United Kingdom see table 2.2). The literature 
regarding specific dietary recommendations for the intake of n-3 PUFAs, EPA/ DHA, 
and other n-3 PUFAs is equivocal. There is little consensus regarding the optimal 
daily intake for a number of reasons. Studies carried out on n-3 PUFAs have focused 
on many different types of heathy and disease state populations and the 
mechanisms assessed in these studies vary. It is known that EPA and DHA 
incorporate into different tissues at different rates. For example, EPA is incorporated 
more efficiently into erythrocyte membranes than DHA (Gans et al., 1990). In 
skeletal muscle phospholipids, a significantly higher amount of n-3 PUFA 
incorporation has been observed in trained versus untrained athletes, independent 
of dietary fatty acid profile or muscle fibre type. This could be explained by changes 
in fatty acid metabolism related to exercise training (Andersson et al., 2000., Helge 
et al., 2001). Therefore, optimal daily-recommended dosage would need to take into 
consideration the population of focus and the desired mechanism of effect. With 
reference to common n-3 PUFA dosages adopted in the exercise literature, the 
higher end of daily intakes considered safe by the European Safety Authority (2-6g/ 
day) are often employed in an attempt to enhance performance or modulate 
cardiovascular variables (Lindley, 2007; Weylandt et al., 2015; European Food 
Safety Authority (EFSA), scientific opinion related to the tolerable upper intake level 
of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and 
docosapentaenoic acid (DPA) 2012). Studies that have provided daily doses in this 
range have observed enhanced brachial artery diameter and blood flow (Walser et 
 13 
al., 2006; 2008) and reduced heart rate and oxygen consumption during 
submaximal exercise (Peoples et al., 2008). Studies have also reported no effect of 
n-3 PUFA supplementation on exercise performance, heart rate or oxygen 
consumption (Da Boit et al., 2015). Therefore, the mechanisms of n-3 PUFA and 
the dosage required to reveal them is equivocal.  
Table 2.2 Recommendations for n-3 PUFA intake for the prevention of 





































2.2.3 EVOLUTION AND THE BALANCE OF OMEGA-6 AND OMEGA-3 FATTY 
ACIDS IN THE HUMAN DIET  
Anthropological and epidemiological studies suggest that human dietary fat intake 
has changed significantly in the past 160 years. It is estimated that there is a 
deficiency of n-3 PUFA intake in the modern western diet with an unbalanced ratio 
of n-6 PUFA to n-3 PUFA of 15/ 1 to 16/ 1, rather than 1/1. This is the ratio observed 
in the diet of wild animals and is the presumed traditional ratio of fats required in the 
human diet (Simopoulos, 1991). Human metabolism requires both n-3 and n-6 
PUFAs. EPA and DHA concentrations in plasma, cells and tissues can be increased 
with the consumption of oily fish for example sardines and mackerel, or through 
supplementation with fish oil/ krill oil (Graham & Burdge, 2005., Tou et al., 2007). 
Increased n-3 PUFA intake results in changes in tissue fatty acid composition. In 
particular, the competitive incorporation of n-3 PUFA in relation n-6 PUFA in cell 
phospholipids (Mickleborough et al., 2008). This influences the physical properties 
of the cell resulting in modification in the activity of cell signalling, membrane 
receptors, gene expression and the production of lipid mediators (Calder, 2006). 
Table 2.3 details a more comprehensive list of some of the biological mechanisms 
associated with EPA and DHA. 
Table 2.3 some of the proposed mechanisms and biochemical effects of n-3  









2.3 THEORETICAL BASIS FOR N-3 PUFA SUPPLEMENTATION AND ITS 
EFFECT ON INFLAMMATION 
Inflammation is the normal biological response to injury, infection and stress and is 
necessary for adaptation to exercise. Although inflammation is a normal response, 
when it becomes excessive and uncontrolled it can reduce physiological function. 
(James et al., 2000). Increased levels of inflammatory mediators such as TNFα, IL-
1β, and IL-6 are destructive, chronic overproduction can cause issues related to 
muscle wasting and loss of bone mass (Calder, 2006). Limited recovery during times 
of increased physiological stress in athletes may lead to local inflammation 
developing into chronic systemic inflammation characterised by chronic fatigue and 
or the prevention of exercise adaptation (Gleeson, 2006). This can be further 
provoked when the diet is high in n-6 relative to n-3 PUFA, when arachidonic acid 
(AA), becomes the primary lipid incorporated into immune cell membrane 
phosphlipids. The AA derived inflammatory pathway involves the production of AA 
derived eicosanoids, prostaglandins, leukotrienes and other factors related to 
inflammation. AA is metabolised by cyclooxygenases (COX), an enzyme 
responsible for the production of biological mediators known as prostanoids 
(Lindley, 2007).  From AA, monocytes synthesise prostaglandin E2 (PGE2) and 4 
series leukotrienes. When the diet is enriched with n-3 PUFA EPA and DHA for a 
period of weeks to months, these long chain PUFA’s are preferentially incorporated 
in to cell membranes and reduce the production of AA derived PGE2 and 4 series 
leukotrienes (Lee et al., 1985). This is due competitive inhibition of the metabolism 




Figure 2.3. The commonly proposed anti-inflammatory effect of n-3 PUFA’s via 









A greater abundance of n-3 PUFA EPA and DHA in immune cells increases the 
production of EPA derived inflammatory mediators, and eicosanoids such as PGE3 
and 5-series leukotrienes. The significance of this particular cascade is that EPA 
derived inflammatory mediators are less inflammatory in comparison to those 
derived from AA (Bagga et al., 2003). Therefore, changes in immune cell 
phospholipid composition may affect the function of these cells including changes 
to cell signalling pathways, and the type of inflammatory and anti-inflammatory 
mediators produced (Calder, 2007). In addition, EPA and DHA are precursors of a 
group of mediators, resolvins, protectins and maresins, which play a role in resolving 
the inflammatory response (Calder 2012). EPA and DHA produce the series E and 
D resolvins by aspirin-acetylated COX-2 produced in the endothelial cells of the 
vasculature, and by 5-LOX (in leukocytes). DHA also forms protectins in leukocytes. 
These mediators may decrease the production of inflammatory cytokines 
(Weylandt, 2012). Cytokines are a category of proteins known to be important as 
signals for cellular communication and in mediating immune function (Peake et al, 
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2005). They are produced locally in response to tissue damage, injury and infection. 
These cytokines, (some of which can be pro inflammatory and anti-inflammatory) 
coordinate the arrival of immune cells to treat the inflammatory response including 
monocytes, lymphocytes and neutrophils (Pederson, 2000). In exercise studies, the 
cytokines most commonly measured Include, Interleukin – 1 (IL-1), Intelerukin - 6 
(IL-6) and Tumour Necrosis Factor alpha (TNF- α). Prostaglandin E2 is also an 
important mediator of the production of inflammatory cytokines (Ostrowski et al, 
1998).  
 
2.4 STUDIES THAT HAVE EXAMINED THE INFLAMMATORY 
CYTOKINE RESPONSE TO EXERCISE   
One of the main mechanisms by which n-3 PUFA may influence exercise 
performance and recovery is through modulation of inflammation. It is therefore 
important to consider the inflammatory cytokine response to exercise in particular 
regarding endurance cycling. The latter part of this literature review focuses on the 
effects of increased dietary n-3 PUFA on oxygen consumption in trained cyclists. It 
is important for us to understand the cytokine response to exercise, as it may be an 
underlying factor influencing the cardiovascular response to fish oil 
supplementation. The following review examines the typical cytokine response to a 
variety of different exercise modalities.  
Since the 1980s a breadth of studies have examined immune function and 
inflammatory responses to high intensity interval training (Croft et al., 2009; Robson 
Ansley, 2006), endurance exercise (Suzuki et al., 2000; Nieman et al., 2001; 
Ostrowski, 1999) and intermittent team sport based exercise (Elliakim et al., 2009). 
Inflammatory responses to over training, overreaching and underperformance 
syndrome (UPS) have also been of interest (Halson et al, 2003). Evans et al. (1986) 
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examined the effects of eccentric cycling for 45minutes duration on plasma IL-1 
levels. 3 hours post exercise, IL-1 levels increased in all five untrained men with no 
change in trained men suggesting that training may exert a degree of adaptation to 
lowering the inflammatory response. In early studies, IL-1 was identified as the 
primary inflammatory cytokine responsible for post exercise induced plasma 
changes identified by researchers such as Cannon and Kluger (1983) and Evans et 
al (1986). However, these studies were carried out using a thymocyte proliferation 
bioassay (prior to the availability of recombinant IL-1 proteins) which also measures 
IL-6; therefore, IL-6 may have been responsible for the induction of inflammation. In 
follow up to this, there are a number of studies that reported no significant exercise 
induced increase in IL-1 levels in plasma (Cannon et al, 1991; Halkjaer & Pederson 
1994). 
The majority of studies dated pre 2000 that examined the inflammatory response to 
exercise considered one mode of exercise with a single group of participants. 
Brenner et al. (1999), was the first study that examined the cytokine response to 
three different types of exercise in the same group of participants. Eight moderately 
fit males were randomly allocated to four exercise conditions – All out (5 minutes of 
cycle ergometer exercise at 90% 2OV

max), circuit training (Standard Circuit training 
routine including 5 types of exercise, 3 sets of 10 at 60 -70% RM), long (two hours 
of cycle ergometer exercise at 60 - 65% 2OV

max), control (participants remained 
seated for five hours). Blood samples were analysed for creatine kinase (CK), 
natural killer cell counts (NK) and plasma levels of Interleukin-6 (IL-6), Interleukin 
10 (IL-10) and tissue necrosis factor (TNFα). CK levels were elevated 72 hours 
following circuit training. NK counts increased significantly during all three types of 
exercise, the largest increase was in relation to all out exercise and the lowest 
increase was observed in the long exercise bout. NK values returned to pre exercise 
baseline levels within 3 hours of recovery. In Brenner et al. (1999), cytokine 
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responses were most marked in relation to the long exercise bout, which resulted in 
a significant increase in plasma IL-6 (peaking at 3 hours post exercise) and TNFα 
(peaking at 72 hours into the recovery period). No changes were observed in 
response to circuit training exercise. IL-6 is known to increase in response to 
prolonged exercise in an exponential fashion (Gokhale, 2007). Prolonged physical 
exercise or exercise that induces muscle damage is associated with elevations in 
pro-inflammatory cytokines such as IL-1 and TNFα (Moldoveanu et al., 2000). 
Increases in TNFα post exercise have been reported in response to prolonged 
exercise such as marathon running (Camus et al., 1997),  250-km road cycling 
(Gannon et al,. 1997) and following 2 hours of cycle ergometer exercise at 60% 
2OV

max (Brenner, 1999). In contrast, TNFα and IL1β could not be detected, or only 
very small changes were measurable in plasma after eccentric exercise (Smith, 
2000; Hirose, 2004). A possible explanation for variable findings in previous 
research may be due to differences in mode and duration of exercise. Hirose (2004) 
employed 6 sets of 5 eccentric actions of the elbow flexors at 40% of maximum 
isometric strength, while Smith (2000) employed 4 sets of 12 eccentric bench press 
and leg curl repetitions at 100% 1 repetition max (1RPM). Although these protocols 
are damaging they are not as prolonged as marathon running, distance cycling, and 
therefore may not have been of sufficient stimulus to evoke an inflammatory 
response. Peake (2005) investigated plasma cytokine changes in relation to 
exercise intensity and muscle damage in well-trained male runners and triathletes. 
The exercise conditions included 1) treadmill running for 1 hour at 60% 2OV

max, 2) 
treadmill running for 1 hour at 80% 2OV

max, and 3) downhill treadmill running at 10% 
gradient for 45 minutes at 60% 2OV

max.  Blood samples collected immediately pre 
and post exercise indicated that treadmill running at 80% 2OV

max had a greater 
effect than 60% or downhill running on increasing plasma concentrations of IL-1ra, 
 20 
IL10, IL-12, and PGE2. Both Brenner (1999) and Peake (2005) appear to indicate 
that inflammation is most likely to occur following long and intense exercise rather 
than exercise of shorter more moderate intensity and duration.  
The inflammatory response may also be modulated by the health state of an 
individual. For example, Cox (2007), examined the cytokine response to three 
treadmill-running tests in healthy and illness prone runners. On three separate 
occasions, participants were required to run for 30 and 60 minutes at 65% 2OV

max, 
and to perform 6 x 3 minute intervals at 90% 2OV

max. Post exercise anti-
inflammatory cytokines IL-10 and IL1-ra concentrations were lower in the illness 
prone group and the IL-6 response was 84 – 185% higher.  
More recently, Landers-Ramos (2014) investigated the cytokine response to 
aerobic exercise in trained and untrained men. 10 endurance trained and 10 
healthy males completed a 30-minute treadmill run at 75% 2OV

max. A comparison 
of pre to post exercise cytokine values indicated a 165% increase in IL-6 post 
compared to pre exercise however there was no significant difference between 
groups in values for TNFα, IL-6, VEGF, bFGF, PIGF, or sFIT-1.  
It would appear from the literature reviewed thus far, that prolonged exercise 
induces several components of the inflammatory response with significant increases 
in TNFα, IL-6. (Nieman, 2000; Calle & Fernandez, 2010). Differences in findings 
across studies are largely due to a number of factors for example the exercise mode/ 
type of muscle contraction and intensity of effort across trials. The training status 
and age of participants (Gokhale, 2006) and the health of the participants (for 
example the number of episodes of upper respiratory symptoms per year) (Cox, 
2007). In addition, the timing of blood sample collection, post exercise varies in 
previous work.  
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When considering the sequence of appearance of anti-inflammatory and pro-
inflammatory cytokines it has previously been established that IL-6 is produced and 
appears in the circulation following the onset of exercise. This is followed by the 
production of pro-inflammatory TNFα and IL1-β, and then the anti-inflammatory 
cytokines such as IL-4 and IL-10 (Koch, 2007; Peak et al., 2005). Ostapiuk-
Karolczuk et al. (2012), aimed to clarify the time sequence of cytokines and 
inflammatory mediators following the performance of 90-minute running trial at 65% 
2OV

max in healthy participants. IL-4, IL-6 and IL-10 increased significantly following 
exercise. Pro inflammatory cytokines IL-1β and TNFα were detected 6 hours post 
exercise. It was concluded that exercise stimulated the production of inflammatory 
cytokines first (within approximately 20 minutes post exercise), and anti-
inflammatory cytokines were produced in the hours following exercise. In previous 
studies, cytokines were measured at regular intervals such as 6, 12, 24 and 72 hours 
post exercise or immediately pre and post exercise.  In addition, participant fatigue 
levels and feeding instructions prior to testing can affect hormone levels and 
subsequent cytokine elevation. For example when carbohydrate is ingested prior to 
or fed during exercise the rise in IL-6 is attenuated (Nieman et al, 1998; Steesberg 
et al, 2000). Steesberg et al. (2001), reported that IL-6 concentration was elevated 
earlier in a glycogen depleted leg (60 min following the onset of exercise), compared 
to a non-glycogen depleted leg (120 minutes following the onset of exercise). 
Therefore, muscle glycogen status is considered a stimulus for the transcription of 
the IL-6 gene. 
The cytokine response to exercise and the specific mechanisms involved are not 
clear. Further research is required in both high intensity and endurance exercise to 
establish a model of the typical inflammatory response for trained athletes. In 
addition, there is no controlled study to date (of our knowledge) that has looked at 
the inflammatory response specifically to cycling exercise at different intensities. 
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The majority of previous studies have addressed cytokine responses to exercise 
known to induce an extreme inflammatory response and muscle damage such as 
marathon running (Camus et al, 1997) 250-km road cycling (Gannon et al 1997), 
treadmill running at high and low intensities of differing durations & downhill running 
(Pederson 2005). The intention of the initial study in this thesis was to investigate 
cytokine responses to both interval and 1 hour cycling exercise. This would provide 
important information regarding the extent of cytokine changes that occur in 
response to different cycling intensities and durations.  
 
2.4.1 THEORETICAL BASIS FOR N-3 PUFA SUPPLEMENTATION AND ITS 
EFFECT ON EXERCISE PERFORMANCE AND RELATED PHYSIOLOGICAL 
VARIABLES  
It has been established that n-3 PUFAs appear to have anti-inflammatory properties 
due competitive inhibition of the metabolism of AA when dietary EPA and DHA 
increases (Calder, 2007). In the exercise field there is also interest in the 
cardiovascular effects of n-3 PUFA supplementation and it’s potential to lower 
exercising heart rate and whole body oxygen consumption (Peoples et al., 2008; 
Hingley., 2017). Furthermore, there is evidence to suggest that n-3 PUFA may 
improve endothelial function possibly due to increased nitric oxide production 
(Zebrowska, 2014). Together these findings suggest that n-3 PUFA may modulate 
some of the cardiovascular factors know to influence endurance performance (see 
fig 2.4).  Endurance trained athletes employ a variety of training techniques to 
enhance exercise performance. Successful endurance performance (in this 
instance, endurance cycling) is dependent on the athlete’s ability to maintain power 
or velocity over the duration of performance. Elite road cycling time trial races can 
vary from 10 minutes to approximately 60 minutes (for a 50 km time trial). Based on 
typical duration, time trials are predominantly dependent on aerobic metabolism 
 23 
(Støren et al., 2013) which consists of the components, 2OV
 max and exercise 
economy (Joyner & Coyle 2008). During training and racing, athletes are often 
working at  high fractions of oxygen consumption (performance 2OV
 ) and maximal 
oxygen consumption ( 2OV

max) (Joyner & Coyle, 2008). It has been reported that 
professional road cyclists can perform workloads of approximately 90% 2OV

max for 
time periods of 60 minutes or more (Lucia et al., 2002). An athlete’s 2OV

max (which 
for elite athletes is in the range of 70 – 85ml kg-1 min-1) is a product of the ability of 
the heart to maintain a high cardiac output and increase stroke volume (Martin et al, 
1986). It is also determined by the oxygen carrying capacity of the blood, the volume 
of blood flow to the muscle and the extraction of oxygen from the blood by the 
exercising muscles (Saltin & Strange, 1992; Bassett and Howley, 2000). The 
oxidative capacity of the muscle is also important regarding an individual’s lactate 
threshold, and where this occurs in relation to their 2OV

max (Joyner and Coyle, 2008) 
(see figure 2.3). N-3 PUFA supplementation may assist in modulating some of the 
physiological factors that relate to endurance performance particularly submaximal 
oxygen uptake, maximal oxygen uptake and performance 2OV

. This is based on 
previous evidence that n-3 PUFA supplementation increased artery diameter and 
improved blood flow during exercise (Walser et al, 2006), lowered HR at 
submaximal and peak exercise intensities and reduced whole body oxygen 
consumption during submaximal exercise (Peoples et al , 2008). In addition n-3 
PUFA supplementation has improved oxygen economy, reduced rating of perceived 
exertion (RPE), reduced diastolic blood pressure and heart rate at submaximal 
exercise intensities (Buckley et al., 2009). 
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Fig 2.4. Schematic diagram of the multiple physiological factors that interact as 











Previous research regarding n-3 PUFA supplementation and its effects on 
endurance performance have commonly employed a test of oxygen efficiency, 
whole body oxygen consumption and 2OV

 max tests in their methods (Oostenbrug et 
al., 1997; Raastad et al., 1997; Zebrowska, 2004). In the following section, we will 
review some of the main n-3 PUFA mechanisms that relate to the endurance 
performance model.  
 
2.4.2. EPA AND DHA EFFECT ON THE VASCULAR FUNCTION AND NO  
The vascular endothelium is an important contributor to circulatory homeostasis. 
Since the 1970s, the dynamic properties of the vasculature have become better 
understood. N-3 PUFAs have a therapeutic effect on endothelial dependent 
vascular function (Tagawa et al., 2002) including improved vasoregulatory 
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properties of the endothelium (Mozaffarian & Wu, 2011). In addition, n-3 PUFAs are 
theorised to reduce oxidative stress and damage to endothelial cells (Tagawa et al, 
2002). In clinical research, it is known that patients with atherosclerosis or coronary 
artery disease have impaired brachial artery endothelial dilation. Ultrasound has 
been employed in studies to examine flow mediated dilation and the dilation of 
coronary vessels by acetylcholine (Neunteufl et al., 2000). DHA and EPA 
supplementation has been shown to enhance acetylcholine - induced vasodilation 
in forearm and coronary vessels, suggesting there is a therapeutic benefit in disease 
states (Fleischhauer et al 1993). Improvements in endothelial function accompanied 
with a decrease in resting heart rate have been observed in healthy volunteers 
following supplementation with 300mg of EPA and 200mg DHA per day for two 
weeks. This effect was also accompanied by a reduction in resting heart rate without 
affecting mean arterial pressure.  It was concluded that it was likely that n-3 PUFA 
fatty acids may have changed the fluidity of endothelial cell membranes, promoting 
enhanced production or release of NO (Shah et al., 2007). N-3 PUFA is also 
theorised to augment skeletal muscle blood flow by the blunting of norepinephrine, 
which influences vasoconstriction in the muscle (Chin et al, 1993). The mechanism 
responsible for improved endothelial dependent vasodilation (EDV) is elusive. 
Vascular studies have demonstrated that fish oil can improve endothelial function 
and vascular tone in healthy individuals (Khan et al., 2002). It is possible that affects 
may be due to increased production and or release of endothelium derived NO 
(Black, 1979),  increased expression of nitric oxide synthase (Nishimura et al, 2000), 
improved sensitivity of vascular smooth muscle cells to NO, and  lowered production 
of endothelial adhesion molecules reducing leukocyte-endothelial interaction 
(Robinson & Stone, 2006). The latter may be a result of the anti-inflammatory action 
of n-3 PUFAs. EPA competes with the cyclooxygenase pathway producing a less 
inflammatory series of prostaglandins, thromboxanes, prostacyclins and 
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leukotrienes for example decreased IL-6, and TNFα (Mickleborough, 2013; Wu and 
Meininger, 2002). N-3 PUFA supplementation reduces platelet aggregation 
inflammation and vasoconstriction (Simopoulos, 2007). This raises questions 
regarding the potential of n-3 PUFA supplementation to facilitate blood flow in the 
exercising individual and to reduce the production of exercise induced inflammatory 
mediators. Attenuated vasoconstriction may also be the reason for the reported 
reduction in systemic vascular resistance and systolic/ diastolic blood pressure 
following n-3 PUFA supplementation (Mozzafarian et al, 2005). 
Walser et al. (2006) reported that 6 weeks of dietary supplementation with DHA and 
EPA enhanced brachial artery dilation and blood flow during rhythmic handgrip 
exercise at 30% of MVC in healthy males and females. This provides some support 
for the augmented blood flow observed in previous health related studies (Shah et 
al, 2007) and the potential for this to occur in the exercise setting. It can be argued 
however that Walser et al, (2006) used an exercise mode that recruited a small 
muscle mass which makes it difficult to infer if similar results would be observed in 
endurance exercise where a larger muscle mass is recruited. Walser and Stebbins 
(2008), reported that a 6-week supplementation intervention with 3g EPA and 2g 
DHA per day enhanced stroke volume and cardiac output during 10 min moderate 
cycling exercise in healthy subjects. In addition, there was a trend for a decrease in 
systemic vascular resistance (SVR) in healthy subjects. N-3 PUFA may have 
attenuated vasoconstriction via the sympathetic nervous system and/ or augmented 
skeletal muscle vasodilation during exercise. These studies provide further 
evidence that n-3 PUFAs may potentially enhance blood flow and oxygen delivery 
during exercise.  
It is also important to consider the effects of training on study outcomes. Training 
results in structural and functional remodelling of arteries “the athlete’s artery”. It has 
been suggested that training can influence endocrine and or neural factors that 
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control how arteries respond (Green, et al, 2012).  Therefore, the results obtained 
from studies on healthy participants may not necessarily be transferable to the 
trained individual.  
 
2.4.3. EPA AND DHA EFFECT ON CARDIAC MYOCYTES AND HEART RATE 
The beneficial effects of n-3 PUFAs specifically EPA and DHA and their relation to 
cardiovascular health was discovered in the late 1960’s when it was observed that 
the Inuit population who consumed a diet rich in n-3 PUFA, had low incidence of 
coronary heart disease and myocardial infarction (Mozaffarian & Wu, 2011). This 
study was followed up with large epidemiological trials such as the GISSI 
Prevenzione trial (No Author, 1999 cited in Ninio, et al, 2008) that provided further 
evidence to support the therapeutic effects of n-3 PUFAs on myocardial infarction 
patients.  As a result of this, the American Heart association (AHA) produced a 
scientific statement recommending that individuals with coronary artery disease, or 
elevated triglyceride levels should consume >1g/ day of n-3 PUFA’s (EPA + DHA) 
to reduce the risk of a coronary event and to maintain cardiac function (Kris-Etherton 
et al., 2003). Supplementation with EPA and DHA may modulate HR through a 
number of mechanisms. A breadth of health related studies has examined n-3 PUFA 
supplementation and its antiarrhythmic effect (Mozaffarian & Wu, 2011). Ex vivo cell 
studies have examined the stabilizing effects of n-3 PUFA on cardiac myocytes and 
in a meta-analysis of randomised controlled trials, n-3 PUFA supplementation 
reduced resting heart rate by 1.6 beats/ min (Mozzaffarian et al, 2005).  
Supplementation with n-3 PUFA increases cellular saturation of cardiomyocytes 
with EPA and DHA (Garg et al, 2006). This results in physical changes in the cardiac 
myocyte cell membrane by altering what is referred to as  “rafts” and “caveolae” that 
hold membrane bound proteins, and fatty acids important for cell signalling (Endo & 
Arita, 2016). This modulates ion channel function for example Na+ and T-type 
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Calcium channels (Endo & Arita, 2016) and affects the generation of an action 
potential. N-3 PUFAs alter the kinetic properties of voltage gated sodium channels 
which results in an increase in the refractory period, decreasing the excitability of 
the myocardium (Leaf et al., 2003).  This may be the reason why n-3 PUFA 
supplementation has been shown to increase left ventricular end diastolic volume 
and ejection fraction in primates, reducing rate pressure product and thus indicating 
improved oxygen efficiency of the myocardium (M 2OV
 ) (McLennan et al., 1992, 
cited in Pepe & McLennan, 2002). Pepe et al. (2002) tested the effects of 16 weeks 
of n-3 PUFA supplementation on ventricular haemodynamics and M 2OV
  in rodents. 
Isolated hearts were worked at a variety of loads. M 2OV

 was reduced in the hearts 
of rodents (fed with an n-3 PUFA rich diet) whilst maintaining the same cardiac 
output and work done. This is indicative of improved ventricular function and 
myocardial oxygen efficiency. Interestingly this effect was observed at higher 
workloads and independent of changes in vascular function. This may indicate that 
n-3 PUFA directly improves the O2 efficiency of the myocardium.  
Several studies have reported that fish oil supplementation has reduced heart rate 
during submaximal exercise. This effect has been observed during, treadmill 
running to exhaustion (Buckley et al., 2009), 20 minutes cycling at low and moderate 
intensities (Walser et al., 2008), 1 hour of cycling at 55% 2OV

peak (Peoples et al., 
2008) and 30 minutes cycling at intensities equivalent to 2 and 3-mM of blood 
Lactate (Kawabata et al., 2014). Conversely Da Boit et al., (2015) observed no 
changes in exercising heart rate. Da Boit employed a cycling protocol, where 
subjects performed a set workload at 70% 2OV

max (equating to approximately 90 
minutes of exercise). It is unclear why these findings differed. Further research is 
warranted to investigate the effects of n-3 PUFA on factors such as HR and 2OV
  
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consumption during exercise at different intensities in the same population group. 
Further detail on these studies is presented in section 2.5. 
 
2.4.4. EPA AND DHA, SKELETAL MUSCLE AND MITOCHONDRIAL 
MEMBRANE COMPOSITION AND BIOENERGETICS  
Dietary fatty acid intake is known to influence the incorporation of fatty acids into the 
body’s stored and structural lipids for example, in blood serum, erythrocyte 
phospholipids, adipose tissue and skeletal muscle tissue (Andersson, 2002). N-3 
PUFA incorporation into skeletal muscle tissue, may affect its metabolic function via 
anchoring of membrane proteins, and altering permeability and fluidity (Stubbs & 
Smith 1984). In addition, how much n-3 PUFA EPA and DHA is incorporated into 
cells may be dependent on the tissue type for example cardio-myocytes take up 
large amounts of DHA, in addition, DHA is preferentially incorporated into skeletal 
muscle membrane composition (Peoples & McLennan, 2010). Altering dietary 
PUFA intake is also thought to influence the DHA content and function of the lipid 
bilayer of whole skeletal muscle (Owen et al., 2004; Dangardt et al., 2012 cited in 
Herbst et al., 2014). DHA is known to be important in the cell membranes of 
mitochondria for the function and organization of proteins in the phospholipid bilayer 
(Tsalouhidou et al., 2006). Therefore n-3 PUFA may affect mitochondrial function 
and bioenergetics (Herbst et al., 2014). A limited number of studies have 
investigated how dietary n-3 PUFA supplementation influences mitochondrial 
membrane fatty acid composition and its function. There is evidence that n-3 PUFA 
incorporation into myocardial membranes reduces myocardium oxygen 
consumption (M 2OV
 ) without any change in cardiac output or work done. These 
changes were due to improved coronary blood flow and oxygen extraction (Pepe et 
al, 2002). In addition, Peoples and McLennan (2008) found fish oil supplementation 
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lowered heart rate and reduced whole body oxygen consumption during 
submaximal exercise (55% of peak workload until fatigue). Changes in 
mitochondrial metabolism and improved calcium handling as a result of n-3 PUFA 
supplementation may have contributed to these findings (Pepe and McLennan 
2002). Alternatively, there is evidence that n-3 PUFAs can shift substrate 
metabolism to preferentially utilise glucose, requiring less O2 to break down per mole 
than fat (Frayn, 1983, cited in Peoples et al., 2008). The evidence to substantiate 
improved mitochondrial respiration following n-3 PUFA supplementation is elusive. 
Herbst, (2014) investigated the effects of n-3 PUFA supplementation on 
mitochondrial incorporation of fatty acids, mitochondrial bioenergetics and 
submaximal substrate metabolism in skeletal muscle (vastus lateralis). 
Measurement of O2 consumption was performed on permeabilized fibres using an 
oxygraph-2K. ADP respiratory kinetics were determined in the presence of creatine. 
N-3 PUFA was readily incorporated into mitochondrial cell membranes but was not 
associated with maximal mitochondrial function. ADP sensitivity and ADP stimulated 
respiration (during submaximal exercise) was increased which could possibly 
improve the efficiency of ATP resynthesis during exercise, or may affect ATP 
synthase activity. The exact mechanisms remain ambiguous additional work needs 
to examine muscle n-3 PUFA’s and mitochondrial bioenergetics.  
 
2.4.5 EPA AND DHA AND EFFECT ON RED BLOOD CELL DEFORMABILITY  
Red blood cell deformability refers to the resilience of RBC’s to change shape under 
an applied force or sheer stress as they pass through the circulation. RBC 
deformability decreases during exercise, and this may negatively affect blood flow 
(Oostenbrug et al., 1997). Reduced RBC deformability is thought to be a result of 
free radical production in response to exercise, which in turn increases peroxidation 
of fatty acids (FA) in RBC phospholipids (Ooestenbrug et al., 1997). Several studies 
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have found that supplementation with n-3 PUFA and its incorporation into RBC 
phospholipids reduces RBC deformability (Cartwright et al., 1985; Terano et al., 
1983), enhancing the transport of RBCs through the circulation (Bruckner et al, 
1987). Theoretically, n-3 PUFA supplementation may influence exercise 
performance or performance related variables by reducing the viscosity of the blood, 
in turn affecting peripheral blood flow and potentially cardiac output (Cartwright et 
al, 1985., Kobayashi et al, 1985). Both of these are important components that 
determine maximal aerobic capacity. It should be noted however, that well trained 
aerobic athletes generally have reduced blood viscosity compared to healthy 
subjects (Letcher, 1981). Previous research investigating the effect of n-3 PUFA on 
RBC deformability has been carried out on healthy subjects or clinical populations. 
Therefore, supplementation may affect athletes differently due to them already 
having lower viscosity levels at baseline. Guezennec et al, (1989) examined the 
effect of a 6 week supplementation period (delivering 1,080 mg EPA and 720 mg 
DHA/ day),  on the characteristics of RBC membranes in 14 male subjects following 
hypobaric exercise (consisting of one bout of 1h cycling at 70% 2OV

max at sea level, 
and one bout at simulated altitude of 3000m in a hypobaric chamber). The exercise 
induced decrease in RBC deformability was supressed in the n-3 PUFA 
supplemented athletes. In contrast (Oostenbrug et al., 1997), examined the effect 
of a 3-week n-3 PUFA supplementation period (6g/ day) on time trial cycling 
performance (1 hr time trial), RBC deformability and lipid peroxidation in trained 
cyclists. Exercise reduced RBC deformability, however fish oil supplementation did 
not alter this effect. In addition, there was no effect of n-3 PUFA on exercise 
performance. In long chain PUFA studies the effects of lipid peroxidation is an 
important consideration. RBC membrane n-3 PUFA content increases significantly 
following supplementation, therefore it is important to consider that the benefits of 
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n-3 PUFA could be counteracted by the negative effects of lipid peroxidation 
(Mickleborough, 2013). 
 
2.5 OMEGA-3 FATTY ACIDS, HUMAN PERFORMANCE AND 
ASSOCIATED PHYSIOLOGICAL VARIABLES  
A number of potential benefits of n-3 PUFA have been described, many of these 
effects have been observed in the health context and in disease states. Some of 
these factors, if translated effectively to the athletic population may have the 
potential to enhance physical performance. There is clear evidence that n-3 PUFA 
fatty acid supplementation may have the potential to modulate a number of 
endurance related physiological mechanisms such as, Improved myocardial 
efficiency, whole body oxygen efficiency, reduction in resting/ exercising heart rate 
and increased vascular dilation and blood flow. The following review of n-3 PUFA 
and endurance exercise literature is presented as a time line. N-3 PUFA and 
exercise induced inflammation is reviewed separately in section 2.6 as an 
underlying factor that may influence blood flow and cardiovascular mechanisms.  
A limited number of human studies have been carried out that examine n-3 PUFA 
supplementation and exercise performance. Leaf and Rauch (1988) was the first 
study to report that fish oil supplementation of 6g per day increased treadmill based 
2OV

max performance however; there was no observed benefit on 2OV

max when the 
daily dosage of fish oil was increased to 12g/day. An increase in 2OV

max following 
n-3 PUFA supplementation has not been confirmed by the majority of subsequent 
studies. Raastad et al. (1997) supplemented 15 male soccer players with 5.2g fish 
oil per day for 10 weeks. Plasma levels of EPA and DHA significantly increased 
however, no changes in 2OV

max performance were observed in the fish oil group 
compared to the placebo group. Leaf and Rauch (1997) originally used a percentage 
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grade treadmill test to examine 2OV

max, with running maintained at a constant speed 
(modified Bruce protocol). Raastad (1997) criticized this protocol, as the participants 
running technique and motivation may have influenced 2OV

max values. This 
relevance of this point is further supported by an increase in maximal heart rate of 
8 beats/ min observed in the low dose n-3 PUFA condition with no change at all 
observed when the fish oil dose was increased (Leaf and Rauch 1997). Due to the 
limitations identified, Raastad et al., (1997) adopted a step based protocol with 
treadmill speed increasing 1km∙h-1 at a constant grade of 3˚. No differences were 
observed in exercise performance (maximal aerobic power, anaerobic threshold or 
running performance) or measures of red blood cell deformability in response to 
supplementation with n-3 PUFA. There was however a reduction in plasma 
triglyceride levels in the fish oil group. Zebrowska et al (2014) is the only other study 
that has reported an improvement in VO2peak, accompanied by reduced heart rate at 
peak power and improved flow mediated dilation in cyclists supplementing with n-3 
PUFA.  
Oostenbrug et al., (1997) supplemented well-trained male cyclists with 3 weeks of 
fish oil 6g/ day or a placebo. The participants carried out a cycling time trial ~1 hr in 
duration (pre-fixed absolute workload based on 70% of Wmax). No differences were 
observed in Wmax, 2OV

max, or time trial performance in the n-3 PUFA supplemented 
group. In addition, no change in blood cell deformability was observed.  
Peoples et al. (2008) examined the effect of n-3 PUFA  supplementation on O2 
efficiency in 16 well-trained male cyclists. No differences in peak O2 consumption or 
peak workload was observed between groups pre or post supplementation. Heart 
rate was significantly reduced during increasing workload and at 2OV

peak in the fish 
oil supplemented group. Whole body O2 consumption and heart rate was 
significantly lower in the fish oil supplemented group compared to the control group 
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throughout a ~60min submaximal exercise test at sustained intensity (55% of peak) 
to exhaustion. In addition, rate pressure product (RPP) (heart rate x systolic blood 
pressure) was significantly lower during submaximal exercise in the fish oil 
supplemented group. This study indicated further evidence that n-3 PUFA modifies 
O2 utilization by the heart and skeletal muscle. Improved mitochondrial efficiency 
may be one of the mechanisms contributing to improved efficiency. Peoples et al. 
(2008) observed no change in peak O2 consumption in the n-3 PUFA supplemented 
group, this did not support the earlier findings of Leaf and Rauch (1997). Possible 
reasons for this may include the control Peoples et al. (2008) employed in their study 
by recruiting participants who were well trained and in a controlled phase of their 
training programme, this reduced possible fluctuations in peak O2 consumption as 
a result of training adaptation. Peoples (2008) employed a submaximal ~60min 
(55% 2OV

max) sustained exercise intensity test to exhaustion which is known to be 
affected by within subject variability and does not necessarily substantiate any 
performance improvement (Jeukendrup et al 1996). Time trials may be a better 
indicator of performance improvement however oxygen consumption is not the only 
limiting factor in the performance of higher intensity time trial protocols (Levine, 
2008).  
N-3 PUFA and its influence on blood flow has been considered as one of the 
contributing factors for improved exercise economy. Walser et al. (2006) previously 
demonstrated that n-3 PUFA EPA and DHA supplementation enhanced vasodilation 
and blood flow to the exercising skeletal muscle during repeated handgrip 
contractions. However, HR and BP responses were not examined. To effectively 
investigate the effects of n-3 PUFA supplementation on HR and BP, a larger muscle 
mass or exercise modality that uses the whole body is required. Therefore, Walser 
and Stebbins, (2008) examined the effect of 6 weeks supplementation of n-3 PUFA 
on HR, BP, SVR, SV and CO during a 20 min cycle ergometer test. The protocol 
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included 10 minutes of cycling at low intensity where parasympathetic tone was still 
present (HR 90 – 100 bpm), and 10 minutes at a moderate cycling intensity where 
vagal tone would be minimal and the sympathetic nervous system would be 
activated (HR ≥ 125 bpm). N-3 PUFA supplementation increased SV and CO and 
tended to decreases SVR during moderate intensity cycling. A decrease in resting 
MAP pressure was observed, and there were no changes in heart rate during 
exercise or at rest. It has been suggested that fish oil reduces sympathetic 
norepinephrine-induced vasoconstriction in exercising skeletal muscle (Chin et al, 
1993). This may also explain why these changes were observed in the moderate 
workload rather than the low intensity cycling load. Walser and Stebbins (2008), 
found resting mean arterial pressure (MAP) was reduced (88 ± 5 vs. 83 ± 4 mm Hg 
pre and post treatment respectively) this is a relatively small change and previous 
studies have also only recorded small changes of approximately ~2% (2-4mm Hg) 
(Geleijnse et al,2002). It could be possible that the large increase in blood pressure 
that accompanies whole body exercise may mask any small n-3 PUFA influence. 
The short duration of the exercise protocol and the fixed intensity should also be 
taken into consideration, as it does not reflect the real life training and performance 
load of cyclists.  
Few studies have examined the effect of n-3 PUFA supplementation directly on 
performance. Buckley et al. (2009) examined the effect of 5 weeks of n-3 PUFA 
DHA rich supplementation on endurance performance, recovery from exercise and 
HR in 29 professional Australian football league players. Erythrocyte n-3 PUFA 
content was almost doubled during the supplementation period however; it was not 
associated with any improvements in time trial performance or in recovery 
(measured by the performance of a subsequent time trial). Serum triglyceride levels 
and HR reduced during submaximal exercise by ~ 8 beats/ min however; there was 
no change in peak heart rate. This agrees with the findings of Peoples et al. (2008), 
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where a reduction in HR was observed during steady state exercise. However, 
Peoples et al. (2008) also observed reduced heart rate during incremental loads to 
exhaustion (including peak heart rate) in the n-3 PUFA supplemented group. Both 
Buckley (2009) and Peoples (2008), employed submaximal trials to exhaustion 
however different modes of exercise were performed, treadmill running and cycling 
respectively.   
More recently (Nieman et al, 2009) employed a more multifaceted research design 
to examine the effect of 6 weeks of n-3 PUFA supplementation on exercise 
performance, inflammation and immune measures in trained cyclists, following 3 
days of intense exercise. Each day consisted of steady state cycling for 3 hours 
(57% Wmax) with a 10km time trial inserted in the final 15 minutes of each 3 hour 
session. There was no change observed in immune markers (blood leukocytes, C-
reactive protein, creatine kinase, Salivary-IGA, and myeloperoxidase) or 
inflammatory mediators (IL-1ra, IL-6, and IL-8). No changes were observed in 
exercise performance. However, it should be noted that this study used a relatively 
low dose of fish oil 2.4g/ day (2g EPA and 0.4g/day DHA) in comparison to other 
studies (see table 2.4). 
Zebrowska et al. (2014) evaluated the effect of 3-weeks of n-3 PUFA 
supplementation on 2OV

max in 13 male elite cyclists. In addition, serum nitric oxide 
(NO), asymmetric dimethyl arginine (ADMA) concentration, and vascular indexes of 
brachial artery dilation were determined using ultrasound. The results demonstrated 
there was an improvement in 2OV

max in the fish oil supplemented group and 
elevated resting and exercise serum NO levels in comparison to the placebo group. 
Furthermore elevated NO improved flow mediated dilation (FMD). It was concluded 
that incremental exercise stimulated NO production however; NO production was 
further increased following supplementation with n-3 PUFA. Improved vascular 
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 / HRmax changes observed in the study. In addition, n-3 PUFA reduced 
HR at maximal power in the n-3 PUFA supplemented group. These results are in 
agreement with Shah et al. (2007), where a 2-week intake of n-3 PUFA significantly 
increased brachial artery flow mediated vasodilation.  
Krill oil is an alternative rich source of EPA and DHA supplementation. The DHA 
content of krill is similar to oily fish however; the EPA content is greater (Tou et al. 
2007). Studies show higher n-3 PUFA incorporation into erythrocyte cell membranes 
with krill oil in comparison to fish oil supplementation (Ulven et al. 2011, cited in 
Salem & Kuratko, 2014). Da Boit et al. (2015), examined 6 weeks of krill oil 
supplementation on exercise performance and markers of immune function. 19 
males and 18 females were randomly assigned to consume krill oil daily for 6 weeks 
(2g/ day) or placebo (2g/ day). No changes were observed in measures of immune 
function (IL-6, IL-10, IL-17 and IFNϒ) post supplementation however, NK cell 
cytotoxic activity and mononuclear cell IL-2 production increased three hrs post 
exercise. In addition, as exercise intensity increased PGE-2 production also 
increased. The lack of an increase in other immune markers is in agreement with 
Yaqoob et al, (2000) and Gray et al, (2014). In addition, Da Boit, (2015) found no 
effect of Krill oil supplementation on time trial performance (time to complete a set 
workload), oxygen consumption or exercising heart rate. In previous human 
research studies, n-3 PUFA modification of heart rate or oxygen efficiency has 
typically been observed at lower exercise intensities. Da Boit et al, (2015) used a 
time trial workload that was equivalent to ~70% 2OV

max (~ 10 min time trial). Due to 
ambiguous results in previous literature, it is clear that studies need to examine the 
effect of n-3 PUFA on HR and 2OV
  at a variety of different workloads in the same 
population. It should also be noted that the supplementation level of EPA and DHA 
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in Da Boit et al. (2015), was much lower than used in previous studies (see table 
2.4). The authors also noted blood samples had not been taken during the baseline 
exercise test for direct comparison.  
During submaximal steady state exercise oxygen consumption ( 2OV
 ) is influenced 
by both cardiac output, an individual’s oxygen carrying capacity and muscle oxygen 
uptake (Joyner & Coyle 2008). There is evidence that n-3 PUFA supplementation 
may improve cardiac and skeletal oxygen efficiency translating into reduced whole 
body oxygen use during exercise Raastad et al (1997). Peoples et al. (2008), 
previously reported DHA rich n-3 PUFA supplementation reduced the oxygen cost 
of submaximal intensity steady state exercise in trained male endurance athletes. 
Kawabata et al. (2014), questioned if it was the combined effect of aerobic training 
and fish oil consumption that resulted in these observations. Kawabata et al (2014) 
investigated the effect of EPA rich n-3 PUFA supplementation on exercise economy 
(EE), during moderate intensity submaximal exercise. The participants were non-
aerobically trained men (in contrast to Peoples, (2008) who employed trained 
athletes). Half the group consumed fish oil supplements 3.6g FO per day containing 
0.914g EPA and 0.399g DHA, while the placebo group consumed 3.6g of medium 
chain triglycerides. Pre and post supplementation participants completed a 2OV

max 
test and a steady state submaximal test on a cycle ergometer (30 minutes at 2 mmol 
lactate workload followed by 30 minutes at 3 mmol workload with a 10 min rest 
between sessions). EPA and DHA erythrocyte levels significantly increased in the 
n-3 PUFA supplemented group and a negative linear correlation was observed 
between the increase in erythrocyte EPA levels and whole body oxygen uptake 
during submaximal exercise. There was no significant change in 2OV

max pre to post 
supplementation. These findings regarding 2OV

max are in agreement with Raastad 
et al. (1997), and Peoples et al. (2008), who reported that 8g/ day of FO 
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supplementation did not affect maximal oxygen consumption. The observed 
improvement in oxygen efficiency during submaximal exercise in the n-3 PUFA 
supplemented group supports the improved exercise economy findings by Peoples, 
(2008). In addition, there were no significant changes noted in HR or VE. RPE was 
significantly reduced in the FO group in both the incremental exercise and during 
the steady state trial. FO may have contributed to participants performing the 
exercise at a lower perceived intensity. The observed improvement in exercise 
economy should be treated with some caution as random allocation of participants 
resulted in fitness differences between groups it was noted that the 2OV

max of the 
n-3 PUFA supplementation group (pre supplementation) was significantly lower 
than that of the control group, which may have affected their response to 
supplementation. 
 More recently, the research has moved towards the examination of n-3 PUFA 
mechanisms in conditions of increased exercise stress. Oxygen efficiency/ 
utilisation related mechanisms linked to n-3 PUFA might reveal themselves or 
compensate an athlete performing under such conditions. Hingley et al. (2017) 
investigated the effects of 8 weeks of DHA rich n-3 PUFA supplementation on high 
intensity cycling bouts and subsequent cycling time trial performance in 26 trained 
endurance athletes whilst in a state of fatigue. This study aimed to investigate the 
effects of n-3 PUFA on a different exercise modality to previous research, by 
recruiting a greater percentage of type II muscle fibres. Hingley et al, (2017) found 
no effect of fish oil on maximal cycling power (3 x 6 seconds), or on repeated 
Wingate cycling (6 x 30 seconds with 150 seconds active recovery). In addition, 
there was no observed effect of supplementation on time trial performance (5 
minutes cycling as hard and as fast as possible in a fatigued state) or isometric 
strength of the quadriceps (determined by three maximal voluntary quadriceps 
contractions). This is in accordance with previous research findings (Oostenburg et 
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al., 1997; Buckley et al., 2009; Nieman et al., 2009 and Da Boit et al., 2015). 
However, oxygen consumption expressed relative to workload was significantly 
lower on average over the 5 min maximal cycling time trial, (compared with baseline 
values) in comparison to the placebo group. This difference was most notable in the 
first two minutes of the high intensity 5-minute cycling bout. These observations 
might be explained by n-3 PUFA and a compensatory effect when an athlete is in 
oxygen deficit. Whether this might be due to modulation of 2OV
  kinetics or 
amplitude is unclear (Burnley & Jones, 2007). In contrast, no changes were noted 
in the supplementation group during 10 minutes of steady state exercise. The fish 
oil dose in this particular study was relatively low dose compared to previous studies 
see (table 2.4)
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Table 2.4 Studies that have examine the effect of n-3 PUFA on exercise performance and related physiological variables  




Main effect  FO levels 








Wmax &  prefixed 
workload time 
trial based on 
70% Wmax ~1 
hour 
6g fish oil daily 17.6% 
EPA, 12.5% DHA 
 2% reduction in RBC 
deformability. No 
change observed in TT 
or Wmax 
increase in n-3 
PUFA from 5.2 - 
7g/100g fatty 
acid in FO group  















6.5g fish oil (2g/ day 
EPA and 1.30g/day 
DHA) or 6.5g corn oil  
 
*Participants 
recognized the taste of 
the oil therefore single 
blind 
10 weeks  No change in 2OV

max 
or running performance  
Raised EPA 
(175%) and 
DHA(40%) in the 
total lipid fraction  









13 elite male 
cyclists 
Within subject 
cross over  
Serum NO, 
ADMA, 2OV
 max  
1.3g (660mg EPA and 
440mg DHA)  
3 weeks Elevation in resting and 
exercise serum NO 






























Main effect  FO levels change in 
blood  










Rhythmic hand grip 
exercise  
6g fish oil daily 
3000mg EPA, 
2000mg DHA 
6 weeks  Enhanced brachial artery 
dilation and blood flow 
No biomarkers 
mentioned in this 
paper  
Buckley et al 
(2009) 







10 min SS running 
at 10km h. 2 x TTE 
tests (the second 
to serve as a 
measure of 
recovery) 
6 x 1g sunflower oil 
or 1.56g DHA 0.36g 
EPA 
5 weeks TG, diastolic BP and HR 
reduced during submaximal 
exercise no change in TTE 














20 min cycle 
ergometer test 10 
min at low intensity 
and 10 min at 
moderate intensity  
6g fish oil daily 
3000mg EPA, 
2000mg DHA 
6 weeks  SV CO and SVR augmented 
during moderate intensity 
cycling and lowered MAP at 
rest  
No biomarkers 
mentioned in this 
paper  








double blind  
3 days of training 
each day = 2 hours 
of submaximal 
cycling followed by 
a 10K time trial  
2.4g fish oil daily 
(2000mg EPA and 
400mg DHA)  
6 weeks  No Change in immune 
markers or inflammatory 
mediators IL-1ra, IL-6 and 
IL-8) No change in 10K 
cycling performance  
Plasma levels of 
EPA increased 311% 
and DHA 40% 
Da Boit et al, 
(2015) 
18 female 





 peak  
70% peak time trial 
set amount of work 
as quickly as 
possible  
2g Krill oil daily 
(60mg EPA and 
30mg DHA)  
6 weeks  Increased IL-2 in stimulated 
PBMCs no change in IL-6, 
IL-4, IL-10, IL-17 and IFN-y. 
No effect on time trial 
performance or O2 cost of 
exercise or HR  
Significant 75% 
increase in 
erythrocyte EPA and 
21% increase in DHA 
fatty acid 




2.6 METHODOLOGICAL DIFFERENCES AND TIME COURSE OF 
SUPPLEMENTATION  
Previous n-3 PUFA and exercise related studies vary in exercise modality, 
participant-training status and the dose/ duration of the supplementation protocol 
(see table 2.4). Supplementation, protocols vary in duration (typically between 3 – 
10 weeks) and daily dosage of total n-3 PUFA and EPA to DHA ratio. Time course 
studies suggest increased EPA and DHA result in cellular peak concentrations 
within 4 weeks of the start of supplementation, and this is correlated to the amount 
of daily dose (Yaqoob et al., 2000; Healy et al., 2000). Metcalf et al. (2007), observed 
peak incorporation into cardiac myocytes within 30 days with a high n-3 PUFA 
dosage of (6g/day). The time course of n-3 PUFA incorporation in blood and adipose 
tissue following supplementation has been studied previously. Increases in n-3 
PUFA incorporation in to erythrocyte membrane phospholipids have been observed 
within 1 week (Metherel, 2009 cited in McGlory et al., 2014). Significant Increases 
in n-3 PUFA content of adipose can take up to 12 months to incorporate (Browning, 
2012, cited in McGlory et al., 2014). 
McGlory et al. (2014) examined the weekly time course of n-3 PUFA incorporation 
into erythrocytes and skeletal muscle tissue in 10 healthy males who supplemented 
with 5g/ day of n-3 PUFA fish oil for 4 weeks. Venous blood samples and muscle 
biopsies were collected pre, post and at weekly intervals during supplementation. 
N-3 PUFA content and anabolic signalling proteins were assessed. N-3 PUFA 
content of skeletal muscle phospholipids was increased in 2 weeks and continued 
to increase up until week 4. This was also accompanied by alterations in anabolic 
signalling expression (although it should be noted this study did not have a control 
group to compare these increases to participants served as their own control). The 
 44 
time phase required to detect skeletal muscle changes in PUFA incorporation was 
longer than that reported in erythrocytes (i.e. 2 weeks in skeletal muscle tissue 
compared to 1 week in erythrocytes), this may be due to the time course differences 
in the speed of tissue turnover. In addition, muscle and blood PUFA levels correlated 
well after 2 and 4 weeks of supplementation. Previously skeletal muscle 
phospholipid levels have increased ~two fold following 8 weeks of supplementation 
(Smith, 2011). McGlory et al. (2014), found a similar increase within 4 weeks. This 
may be due to the dose and high EPA concentration of the n-3 PUFA supplement, 
it was double the concentration of EPA in comparison to Smith, (2011) at 3500mg 
vs 1860mg/ day, DHA was 900mg. Previous studies have suggested that skeletal 
and heart muscle in particular incorporate high levels of DHA following 
supplementation with n-3 PUFA (Charnock et al., 1992; Owen et al., 2004). In 
addition, increased DHA levels may be linked to changes in muscle function, 
increased insulin sensitivity and modified substrate selection (Pan et al, 1995).  
 
2.7 BIOMARKERS TO QUANTIFY N-3 PUFA STATUS 
The saturation of EPA and DHA in red blood cell membranes (RBC) in relation to 
total fatty acid content is referred to as the omega 3 index. The RBC half-life is 4-6 
times longer than in serum (Cao et al., 2006) therefore; RBC EPA and DHA content 
may be a more valid as a biomarker for predicting long-term PUFA intake. This has 
been confirmed with correlation to food frequency questionnaires (FFQ) (Sun et al 
2007). It may also be a valid marker to predict myocardial tissue levels of EPA and 
DHA (Harris, Sands & Windsor et al 2004). Myocardial membrane EPA and DHA 
levels are highly correlated to erythrocyte membrane incorporation. In humans and 
animals, myocardial cells generally incorporate more n-3 PUFA (in particular DHA) 
than erythrocytes (McLennan, 1992; Owen, 2004). 
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2.8 SUMMARY  
Given the proposed benefits of n-3 PUFA in the health context, there is increasing 
speculation regarding the potential benefits that n-3 PUFA supplementation might 
have in the athletic context in particular with regard to its influence on 
cardiovascular variables, inflammation and muscle metabolism. The review of 
literature presents some of the relevant n-3 PUFA related mechanisms that are 
still not completely understood. Some of the inconsistencies in previous research 
such as dosage/ length of supplementation protocol, modality of exercise and type 
of trial selected make it difficult to draw comparisons between study findings. 
There is a need for carefully planned systematic research to unpick n-3 PUFA and 
exercise related mechanisms.  
 
2.9 THESIS AIMS 
This main aims of this thesis were firstly to examine the acute inflammatory 
response to cycling. There is little research currently available on the cytokine 
response to different modes and intensities of cycling.  As this may be an underlying 
target for n-3 PUFA action, further research is necessary to understand the cycling 
inflammatory model.  
A further aim was to determine if an 8 week high n-3 PUFA low n-6 PUFA dietary 
intervention would elicit changes in oxygen consumption during submaximal cycling. 





max measurement. The current thesis will examine local skeletal 
muscle tissue oxygenation/ extraction (using near infrared spectroscopy) over 
different intensities of submaximal cycling.  
Prior to examining n-3 PUFA and exercise related effects, a greater understanding 
of the use of biomarkers to substantiate participant compliance with PUFA 
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supplementation was required. In studies that employ athletic individuals 
(particularly in the field setting) the use of inexpensive, rapid analysis techniques 
are important. Therefore, a further aim of this thesis was to validate the 
measurement of fatty acids in dry blood spot samples (DBS) in relation to the current 
gold standard procedure of RBC separation and subsequent erythrocyte fatty acid 
analysis.  The experimental studies in this thesis were designed in order to answer 
the following research questions  
1) Does 1-hour of pre-loaded submaximal cycling result in a different cytokine 
response (post exercise) compared to high intensity interval cycling? 
2) Is the fingertip whole blood DBS method of determining an individual’s fatty 
acid status a valid method, in relation to isolated erythrocyte analysis 
(considered gold standard)? 
3) Does high n-3 PUFA supplementation, coupled with dietary modification to 
lower n-6 PUFA intake, successfully increase n-3 and decrease n-6 PUFA 
incorporation into erythrocyte phospholipids? 
4) Does 3) affect 2OV

peak performance? 
5) Does 3) result in changes in 2OV

, tissue saturation Index (TSI %) or deoxy- 








CHAPTER 3 THE CYTOKINE RESPONSE TO TWO 
CYCLING MODALITIES: 1) PRE-LOADED PERFORMANCE 



























Cytokines are a group of proteins that mediate the inflammatory response to 
infection and injury. Cytokine production is also mediated by a number of other 
factors including exercise. Exercise induced changes in cytokine levels play an 
important role in post exercise immune function. During exercise, cytokine changes 
may be triggered by a number of factors such as muscle and tissue damage 
(Nieman et al., 2005), circulating stress hormones, carbohydrate depletion and 
oxidative stress (Cannon, 2000). Cytokines are classified as either pro or anti-
inflammatory. Anti-inflammatory cytokines such as, IL-4, IL-10, MCP-1, IL-1RA 
inhibit the production of pro inflammatory cytokines such as IL-1β and TNF-α. IL-6 
can act as both a pro - and anti-inflammatory cytokine (Peake et al, 2005; Hirose et 
al, 2004). IL-6 increases acutely after exercise and initiates changes in pro-
inflammatory and anti-inflammatory cytokine production post exercise (Nieman et 
al., 2001; Suzuki et al, 2000). For example IL-10 and IL-1ra are thought to be anti-
inflammatory cytokines that may counteract the inflammatory response (Ostrowski, 
et al 1999; Suzuki, 2000), in order to keep the body in homeostasis. 
To our knowledge, there has been no attempt to directly compare acute cytokine 
changes in response to cycling modes that differ in intensity and duration. Much of 
the research has investigated long duration endurance exercise such as marathon 
and ultra-marathon events (Nieman et al., 2003;  Ostrowski et al., 1999), down-hill 
running and eccentric exercise (Peake, 2005). These events produce extensive 
muscle damage likely to cause large changes in the cytokine/ immune response. 
Although it is expected that cycling may produce a lesser magnitude of inflammatory 
response (due to the low impact nature of cycling), athletes may still be prone to 
pro-inflammatory cytokine elevation when engaging in regular moderate training or 
during chronic training periods. Reducing exercise-induced inflammation for cyclists 
is important for a number of reasons. Although inflammation is part of the normal 
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human physiological response to infection and Injury, when it occurs in an 
uncontrolled or inappropriate manner (for example in response to heavy exercise 
loads, long duration exercise or increased frequency of training), damage to tissues, 
loss of function and disease can occur (Calder 2006).  
Few studies have directly compared differing exercise loads for the same mode of 
exercise. Brenner et al. (1999) examined the effect of four different types of exercise 
on inflammatory biomarkers in the same participant group. Out of the four exercise 
conditions which included, all out (5 minutes of cycle ergometer exercise 90% 2OV

max), circuit training (5 types of exercise 3 sets of 10 at 60 -70% RM), long (two hours 
of cycling at 60 - 65% 2OV

max), and control, the long exercise condition resulted in 
significant increases in plasma IL-6 and TNFα. Peake et al. (2005), examined 
plasma cytokine changes in relation to exercise intensity and muscle damage in 
well-trained male runners and triathletes. The exercise conditions included a 1 hour 
run at 60% 2OV

max, a 1-hour run at 80% 2OV

max, and downhill running (10% 
gradient for 45 minutes). High intensity running (80% 2OV

max) had a greater effect 
than 1 hour moderate running or downhill running on plasma levels of IL-1ra, IL10, 
IL-12, and PGE2. The two mentioned studies appear to indicate that inflammatory 
cytokines are most likely to be elevated following long intense exercise, rather than 
short and moderate intensity exercise. 
In contrast Cox (2007), observed no significant difference in the inflammatory 
response to 60min running at 65% 2OV

max  compared to 6 x 3 minute intervals at 
90% 2OV

max in well trained male distance runners. An increase in IL-6 and IL-1ra 
was observed post and at 1-hour post both protocols however, there was no 
significant difference in the magnitude of change pre to post exercise or between 
the two trials.  
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Few studies have examined the cytokine response to cycling, or modes of cycling 
that differ in intensity and duration. The majority of previous research focuses on 
modes of exercise that elicit muscle damage. As the focus of this thesis is on 
endurance cycling and the effects of fish oil on physiological mechanisms (some of 
which are related to exercise induced inflammation), it would be important to begin 
to substantiate the magnitude of the cycling induced inflammatory response. 
In most cases, cytokine concentration is analysed in blood plasma, which can 
become invasive due to the number of repeated samples required. Drawing samples 
from the antecubital vein is reliant on the availability of phlebotomy-trained 
personnel and the costs associated with this. Such factors have resulted in the 
development of different assays for assessing cytokine concentration that are less 
invasive and do not require trained individuals to collect samples. One such method 
includes the analysis of saliva samples (Nishanian et al., 1988). The relationship 
between saliva and plasma IL1-β is elusive. IL-1β levels are known to be much 
higher in saliva than plasma (Brailo, 2012; Llamas Moya, 2006) which might appear 
to be of benefit due to many plasma derived cytokines being below the detection 
limits of high sensitivity assays (Wong, 2008). Although the question why this is the 
case should be carefully considered. It is possible that salivary cytokine levels reflect 
local inflammatory status in the mouth such as periodontitis or upper respiratory 
tract infection (Gaphor et al, 2014). Plasma IL1 β concentrations may be lower, but 
may reflect systemic inflammation more accurately. Few studies have examined the 
relationship between IL-1β plasma and saliva assays or looked at the level of 
agreement between them. Williamson, (2011) observed no significant correlations 
between cytokine plasma samples and filter paper saliva samples (including IL-1β).  
Therefore, the aim of this study was to examine the effect of two different cycling 
trials on well-known plasma inflammatory and anti-inflammatory markers. More 
specifically the study aims to examine firstly if any significant cytokine changes 
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occur in response to acute cycling exercise (and if so if this change differs, in 
response to a 1-hour submaximal-cycling trial compared to a high intensity interval 
trial). A secondary aim of this study was to examine the relationship and level of 




Fourteen moderately healthy male competitive road cyclists and triathletes were 
recruited, and ten participated in the study. Participants were recruited by email from 
cycling and triathlon clubs in London and the South East. Moderate training status 
was defined as 2 ≥ hours of continuous cycling per week and for the past six months. 
Participants were excluded from the study if they had any incidence of illness or 
recent injury, were taking any medication, had a history of hyperlipidaemia, 
hypertension, and diabetes mellitus or were regularly consuming daily fish oil 
supplements or fish containing meals (2 ≥ servings per week). The study was 
approved by the University of Kent Research Advisory Group (REAG). The 
Participant’s physical characteristics are presented in Table 3.1  
Table 3.1 Participant’s physical characteristics  
Physical 
characteristics  
Mean ± SD 
Age (yrs) 39 ± 11 
Height (cm) 176.9 ± 5.9 
Weight (kg) 75.5 ± 9.6 
2OV

peak (ml/ kg/ min) 57.6 ± 7.3 
Peak power (W)  328 ± 48 
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Experimental design  
Participants reported to the laboratory on four occasions over a four-week period. 
All participants completed an informed consent form and a medical questionnaire. 
The first test was used to determine cardiorespiratory fitness ( 2OV

peak) and peak 
power output. The second test was used to familiarise the participants with the two 
cycling protocols. Subsequently, subjects returned to the laboratory for two separate 
visits to complete the experimental testing, which consisted of 1) a pre-loaded 
performance trial and 2) a high intensity interval trial. The two experimental tests 
were performed in a random order over visits three and four. Participants attended 
each visit at the same time of day. Each laboratory session was separated by at 
least 1 week.  Participants were instructed to arrive in a rested and euhydrated state, 
having abstained from alcohol, caffeine and exercise training for the previous 24 





On arrival at the laboratory, participant’s height and weight was recorded. Testing 
was performed on an electronically braked cycle ergometer (SRM Schoberer, 
Germany). The bike was adjusted and the settings recorded so the same bike set 
up could be reproduced for each trial. Participants commenced a 10 minute warm 
up at 100 W, immediately followed by a graded exercise protocol starting at 150 W. 
Power increased by 20 W each minute until volitional exhaustion, as employed by 
Nieman et al. (2009). Participants were instructed to maintain their preferred 
cadence throughout the test, which was terminated when pedal cadence dropped 
more than 10 rpm below the chosen cadence for 10 seconds (despite strong verbal 
encouragement). Breath by breath analysis of oxygen uptake was determined using 
 53 





peak was determined as the highest 2OV
  over a 60-second 
period. Heart rate (HR) (Polar RS400 and wear link) and rating of perceived exertion 
(RPE) (Borg, 1970) was recorded at 1-minute intervals and power output was 
sampled every 0.5 seconds. Peak power was determined as the highest wattage 
recorded over a 60-second period. A fingertip capillary blood sample was obtained 
at rest and immediately post test to determine whole blood glucose and lactate 
levels (Biosin C-line EKF Diagnostic).  
 
Standardisation of diet  
Participants were directed to keep a 24-hour food diary prior to their second 
laboratory visit, and were asked to use this record to repeat the same food and fluid 
intake in the 24 hours prior to visits 2, 3 and 4.  
 
Pre-loaded Performance trial (TT) 
Participants commenced a 10 minute warm up at 100 W, on a cycle ergometer (SRM 
Schoberer, Germany) followed by a 2-minute rest period. Participants then 
commenced a 1-hour pre-loaded performance trial. The cycle ergometer was set to 
hyperbolic mode for the first 45 minutes of the test. Participants cycled at 70% of 
their maximum peak power output (determined in visit 1) at their preferred cadence. 
The cycle ergometer was then switched to linear mode for the final 15 minutes of 
the test (in linear mode, resistance is determined automatically in response to 
cadence so power output could be determined by the participant). Participants were 
instructed to perform as much work as possible during the final 15 minutes of the 
test.  
 54 
High intensity interval trial (INT) 
Participants commenced a 10 minute warm up at 100 W, on a cycle ergometer (SRM 
Schoberer, Germany) followed by a 2-minute rest period. They then completed up 
to 12 x 1-minute cycling intervals (or until volitional exhaustion whichever came first) 
at their maximum peak power output (determined in visit 1) at their preferred 
cadence. Each interval was separated with 75 seconds of cycling at 100 W. The 1-
hour pre-loaded time trial and interval trial were selected as they represent typical 
training sessions that cyclists complete on a regular basis. 
 
Sample collection and analysis  
Blood samples  
 
Immediately pre and post both the pre-loaded performance trial and the interval trial, 
a 7ml venous blood sample was collected by a trained phlebotomist using standard 
venepuncture procedure.  Whole blood was collected directly into EDTA collection 
tubes. Plasma was separated by centrifugation at 10,000 x g for 10 minutes at 5˚C. 
Clear plasma was pipetted into separate 3ml aliquots and stored frozen at -80˚C 
until later analysis.  
Plasma cytokine concentrations were determined using a cytokine 1 high sensitivity 
array for use with an evidence investigator biochip analyser (Randox laboratories 
Ltd UK). According to the manufacturer’s instructions, all samples were analysed in 
duplicate. The cytokine 1 high sensitivity array simultaneously measured the 
following 11 parameters from a single sample aliquot: IL-2, IL-4, IL-6, IL-8, IL-10, 
IFN-y, TNF-α, IL-1α, IL-1β, MCP-1 and VEGF. The lowest concentration for each 
cytokine (in accordance with the assay manual with imprecision of ≤ 20% for 20 




Saliva samples  
 
Unstimulated saliva samples (~0.5ml) were collected pre and post exercise, directly 
into sterile conical collection tubes (Fisher Scientific). Participants were asked to 
allow saliva to collect in their mouth and over time expel it into the collection tube. 
Participants were asked to avoid actively bringing saliva, sputum or phlegm up from 
the back of the throat. Samples were immediately centrifuged at 10,000g for 10 
minutes at 5˚C. Clear saliva was pipetted into aliquots and stored frozen at -80˚C 
until later analysis. 
Salivary IL-1β concentrations were determined using commercially available IL-1β 
immunoassay kit (Salametrics, PA, USA) according to the manufacturer’s 
instructions all samples were analysed in duplicate. Saliva samples were checked 
for osmolality (Sosm) by freezing point depression using an osmometer.  
 
Statistical analysis  
Determination of plasma cytokine concentrations pre & post the performance trial 
(TT) and the high intensity Interval trial (INT). 
 
Blood plasma concentrations of  the following cytokines: IL-2, IL-6, IL-8, IFN-γ, TNF- 
α, IL-1β, MCP-1, VEGF, IL-4, IL-10, IL-1R α, were screened in accordance with 
analysis of variance (ANOVA) assumptions. There were no outliers as assessed by 
examination of studentized residuals for values greater than ± 3. Cytokine 
concentration values were normally distributed for IL-8 and MCP-1 (p >0.05), as 
assessed by Shapiro Wilk test of normality. IL-1, IL-1, IL-2, IL-6, IL-10, values 
were transformed using Log-10. IL-4 and IFN- were reciprocal transformed. 
Cytokine responses to (TT) and (INT) were assessed using a 2 x 2 time (pre/ post) 
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x trial (TT/ INT) ANOVA. Post hoc Bonferroni-corrected paired samples t –tests were 
carried out to identify the location of differences when a main effect of trial or an 
interaction between time and trial was observed. All analysis were completed using 
the statistical package IBM SPSS statistics version 24, with significance accepted 
at p< 0.05.  
 
Comparison of plasma and saliva assays in order to determine IL-1β cytokine 
concentrations  
 
A Pearson’s product moment correlation was carried out to assess the relationship 
between IL1-β values for 1) blood plasma & saliva and 2) blood plasma & saliva 
expressed as concentration: osmolality for the following conditions a) pre-TT b) post 
-TT c) pre-INT d) post-INT.   
 
A Pearson’s product moment correlation was carried out to assess the relationship 
between the magnitude of change (percentage change pre to post exercise relative 
to 100) in IL1-β for TT and INT. Percentage Changes were correlated for the 
following assays 1) blood plasma & saliva and 2) blood plasma & saliva expressed 
as concentration: osmolality. Data was not normally distributed as assessed by 
Shapiro-Wilk’s test (p> 0.05); therefore, a log 10 transformation was applied.  
 
The level of agreement between assays (for percentage change values) were 




Table 3.2 presents plasma Cytokine concentrations pre and post the preloaded time 
trial and interval trial (mean ± standard deviation). The following is a summary of the 
two-way ANOVA results for each cytokine. 
 
IL-1α  
There was no significant main effect of time (pre/ post), F(1, 9) = 1.960, p = 0.195, 
partial η2 = 0.179, or cycling trial, F(1, 9) = 0.051, p = 0.826, partial η2 = 0.006, 
and no significant interaction between cycling trial and time on IL-1α concentration, 
F(1, 9) = 2.684, p = 0.136, η2 = 0.230. 
IL-1β 
There was no significant main effect of time (pre/ post), F(1, 9) = 0.091, p = 0.770, 
partial η2 = 0.01, or cycling trial, F(1, 9) = 1.686 p = 0.226, partial η2 = 0.158 on IL-
1β concentration. There was a significant interaction between cycling trial and 
time, F(1, 9) = 8.058, p = 0.019, η2 = 0.472. In follow up to the interaction, 
Bonferroni corrected post - hoc paired t-tests showed that IL-1 concentration did 
not significantly differ pre to post exercise in the time trial (p = 0.636), or pre to 
post exercise in the interval trial (p = 0.276). Furthermore there was no significant 
difference in IL-1 between trials pre-exercise (p = 0.516), or between trials post 






IL- 2  
There was no significant main effect of time (pre/ post), F(1, 9) = 0.911, p = 0.365, 
partial η2 = 0.092, or cycling trial, F (1, 9) = 1.291, p = 0.285, partial η2 = 0.125, 
and no significant interaction between cycling trial and time on IL-2 concentration, 
F(1, 9) = 0.130, p = 0.727, η2 = 0.014. 
IL-4  
There was a significant main effect of time (pre/ post). IL-4 concentration for both 
trials combined was higher on average post, compared to pre exercise, F(1, 9) = 
9.654, p = 0.013, partial η2 = 0.518. There was no significant main effect of cycling 
trial, F(1, 9) = 0.022, p = 0.886, partial η2 = 0.002. Furthermore there was no 
significant interaction between cycling trial and time on IL-4 concentration, F(1, 9) 
= 3,754, p = 0.085, η2 = 0.294.  
IL-6  
There was a significant main effect of time (pre/ post), F(1, 9) = 25.823, p = 0.001, 
partial η2 = 0.742, and cycling trial, F(1, 9) = 10.80, p = 0.009, partial η2 = 0.545. 
There was a significant interaction between cycling trial and time, F(1, 9) = 8.875, 
p = 0.015, η2 = 0.497. Bonferroni corrected post - hoc paired t – tests showed a 
significant pre to post increase in IL-6 concentration in both the time trial, (p = 
0.008) and the interval trial (p = 0.004). Furthermore, there was no significant 
difference between trials pre exercise (p =1.00) however there was a significant 
difference between trials post exercise, the IL-6 response was significantly higher 





There was no significant main effect of time (pre/ post), F(1, 9) = 0.482, p = 0.505, 
partial η2 = 0.051. There was a significant main effect of cycling trial. IL-8 
concentrations pre and post exercise combined were higher on average for the 
time trial in comparison to the interval trial, F(1, 9) = 10.192, p = 0.011, partial η2 = 
0.531. However, there was no significant interaction between cycling trial and time, 
F(1, 9) = 0.039, p = 0.848, η2 = 0.004.  
IL-10  
There was no significant main effect of time (pre/ post), F(1, 9) = 3.201, p = 0.107, 
partial η2 = 0.262, or cycling trial, F(1, 9) = 0.961, p = 0.353, partial η2 = 0.096 and 
no significant interaction between cycling trial and time, F(1, 9) = 0.464, p = 0.513, 
η2 = 0.049.  
IFN-γ 
There was no significant main effect of time (pre/ post), F(1, 9) = 0.922, p = 0.362, 
partial η2 = 0.093, or cycling trial, F(1, 9) = 0.430, p = 0.528, partial η2 = 0.046, and 
no significant interaction between cycling trial and time, F(1, 9) = 1.143, p = 0.313, 
η2 = 0.113.  
TNF-α 
There was no significant main effect of time (pre/ post), F(1, 9) = 0.710, p = 0.421, 
partial η2 = 0.073, or cycling trial, F(1, 9) = 1.347, p = 0.276, partial η2 = 0.130 and 
no significant interaction between cycling trial and time, F (1, 9) = 1.116, p = 0.318, 





There was a significant main effect of time (pre/ post), F(1, 9) = 18.76, p = 0.002, 
partial η2 = 0.676 and no significant main effect of cycling trial, F(1, 9) = 0.515, p = 
0.491, partial η2 = 0.054. There was a significant interaction between cycling trial 
and time, F(1, 9) = 13.74, p = 0.005, η2 = 0.604. Bonferroni corrected post – hoc 
paired t-tests showed a significant pre to post exercise increase in MCP-1 in the 
time trial (p <0.001). There was no change in MCP – 1 concentration pre to post the 
interval trial (p =1.00). Furthermore, there was no significant difference in MCP-1 
concentration between trials pre exercise (p =1.00) or between trials post exercise 
(p = 0.21).   
VEGF 
There was a significant main effect of time (pre/ post), VEGF concentration for 
both trials on average were higher pre exercise compared to post, F(1, 9) = 8.740, 
p = 0.016, partial η2 = 0.493. There was no significant main effect of cycling trial, 
F(1, 9) = 2.767, p = 0.131, partial η2 = 0.235, and no significant interaction 






















Table 3.2. Plasma Cytokine concentration data pre and post the pre-loaded time 
trial and interval trial.  
     
ANOVA 
Main effects &  Interaction  
 
             95% CI Trial      (TT/ INT)     
    Time     (Pre/ Post)       
Cytokine      Trial                      Mean ± SD Lower Upper  Trial * time  partial η2 
 
IL-1α Pre TT  0.58 ± 0.74 0.05 1.11 F(1, 9) = 0.051, p = 0.826 0.006  
(N = 10) Post TT 0.46 ± 0.47 0.12 0.796 F(1, 9) = 1.960, p = 0.195 0.179  
 Pre INT 0.40 ± 0.42 0.10 0.71 F(1, 9) = 2.684, p = 0.136 0.230  
 Post INT 0.50 ± 0.52 0.13 1.87 
 
  
IL-1β Pre TT 3.43 ± 3.92 0.62 6.24 F(1, 9) = 1.686, p = 0.226 0.158  
(N = 10)  Post TT 2.76 ± 3.74 0.88 5.44 F(1, 9) = 0.091, p = 0.770 0.010   
Pre INT 2.69 ± 3.12 0.46 4.92 F(1, 9) = 8.058 p = 0.019* 0.472   




IL-2  Pre TT 6.14 ± 7.62 0.70 11.59 F(1, 9) = 1.291, p = 0.285 0.125  
(N = 10)         Post TT 5.45 ± 6.67 0.67 10.22 F(1, 9) = 0.911, p = 0.365 0.092  
 Pre INT 4.37 ± 6.01 0.08 8.68 F(1, 9 )= 0.130, p = 0.727 0.014   
Post INT 5.40 ± 6.91 0.45 10.35 
 
 
       
IL-4  Pre TT 5.08 ± 5.20 1.36 8.80 F(1, 9) = 0.022, p = 0.886 0.002  
(N = 10)    Post TT 5.29 ± 5.59 1.29 9.29 F(1, 9) = 9.654, p = 0.013* 0.518  
 Pre INT 4.11 ± 3.45 1.64 6.58 F(1, 9) = 3.754, p = 0.085 0.294  
 Post INT 4.90 ± 4.13 1.95 7.85 
 
  
IL-6  Pre TT 2.56 ± 3.30 0.20 4.92 F(1, 9) = 10.80, p = 0.009** 0.545  
(N = 10)    Post TT 6.68 ±  4.48 3.48 9.88 F(1, 9) = 25.82, p = 0.001** 0.742   
Pre INT 2.16± 2.05 0.69 3.63 F(1, 9) = 8.875, p = 0.015* 0.497   
Post INT 2.95 ± 2.24 1.35 4.55 
 
       
 
 IL-8  Pre TT 7.12 ± 4.29 4.05 10.19 F(1, 9) = 10.192, p = 0.011* 0.531 
(N = 10) Post TT 7.31 ± 4.77 3.90 10.73 F(1, 9) = 0.482, p = 0.505 0.051  
Pre INT 4.29 ± 2.42 2.56 6.02 F(1, 9) = 0.039, p = 0.848 0.004  
Post INT 4.71 ± 2.53 2.90 6.52 
 
 
       
IL-10  Pre TT 2.02 ± 2.39 0.31 3.72 F(1, 9) = 0.961, p = 0.353 0.096  
(N = 10) Post TT 3.06 ± 1.57 0.94 3.19 F(1, 9) = 3.201, p = 0.107 0.262  
 Pre INT 1.08 ± 1.09 0.30 1.86 F(1, 9) = 0.464, p = 0.513 0.049  
 Post INT 2.57 ± 3.47 0.09 5.06 
 
  
IFN-γ Pre TT 0.73 ± 0.57 0.32 1.14 F(1, 9) = 0.430, p = 0.528 0.046  
(N = 4) Post TT 0.60 ± 0.29 0.39 0.80 F(1, 9) = 0.922, p = 0.362 0.093   
Pre INT 0.68 ± 0.39 0.41 0.96 F(1, 9) = 1.143, p = 0.313 0.113   
Post INT 0.75 ± 0.51 0.38 1.11 
 
       
 
TNFα Pre TT 3.49 ± 2.70 1.56 5.42 F(1, 9) = 1.347, p = 0.276 0.130  
(N = 10) Post TT 3.26 ± 1.77 1.99 4.53 F(1, 9) = 0.710, p = 0.421 0.073   
Pre INT 3.06 ± 2.46 1.30 4.82 F (1,9) = 1.116, p = 0.318 0.110   
Post INT 3.05 ± 1.83 1.74 4.36 
 
       
 
MCP-1 Pre TT 74.69 ± 25.34 56.57 92.82 F(1,9) = 0.515, p = 0.491 0.054 
(N = 10) Post TT 102.01± 36.75 75.72 128.31 F(1,9) = 18.762 p = 0.002** 0.676  
Pre INT 84.24 ± 28.32 63.98 104.50 F(1,9) = 13.737 p = 0.005** 0.604  
Post INT 79.33 ± 15.41 68.30 90.35 
 
       
 
VEGF Pre TT 26.45 ± 14.91 15.78 37.11 F(1, 9) = 2.767, p = 0.131 0.235  
(N = 10) Post TT 21.63 ± 12.65 12.59 30.68 F(1, 9) = 8.740, p= 0.016* 0.493   
Pre INT 19.40 ± 4.97 15.84 22.95 F(1, 9) = 0.260, p = 0.622 0.028   
Post INT 16.94 ± 3.63 14.34 19.54 
 
 
Data is reported as mean ± SD. Values are in pg. / mL, TT = pre-loaded time trial, INT = interval trial, 
p < 0.05*, p < 0.01**. 
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Table 3.3. Pearson’s product moment correlation to determine the relationship between IL-1β cytokine concentration in plasma and saliva (and 





Mean ± SD 
Saliva IL-1β 
Mean ± SD 
Saliva C:O 
Mean ± SD 
PLA & SAL 
Pearson’s r 
PLA & SAL 
Sig (2 tailed) 
PLA & C:O 
Pearson’s r 
PLA & C:O 







2.93 ± 3.82 
 
256.90 ± 199.22 
 









     (-0.495 – 0.874)  (-0.269 – 0.863)  
TT post 9 2.68 ± 3.95 292.64 ± 260.47 3.62 ± 2.55 0.807* 0.009* 0.781* 0.013* 
     (0.570 – 0.967)  (0.504 – 0.979)  
INT pre 9 2.44 ± 3.21 270.70 ± 308.98 4.30 ± 3.55 0.432 0.245 0.297 0.437 
     (-0.156 – 0.783)  (-0.362 – 0.708)  
INT post 9 3.38 ± 4.25 233.43 ± 237.64 3.34 ± 2.54 0.245 0.525 0.150 0.701 
     (-0.611 – 0.718)  (-0.562 – 0.679)  
Data is displayed as mean ± SD, IL-1β concentration is expressed as pg/ mL, * p = <0.05, percentile bootstrap 95% CI’s reported in brackets 
TT = pre-loaded time trial, INT = interval trial, PLA = plasma, SAL = saliva, CO = IL-1β expressed as concentration: osmolality 
Data was transformed Log 10 
 
There was not a significant relationship between plasma and saliva IL-1β concentration pre the pre-loaded time trial, however there was a 
significant relationship between them post. When saliva data was expressed as concentration : osmolality, similar results were observed pre 
and post the pre-loaded time trial. There was no significant relationship between measures pre and post the Interval trial (see table 3.3). 
 
 63 
Table 3.4. Pearson’s product moment correlation to determine the relationship between plasma and saliva (and saliva expressed as 





Mean ± SD 
Saliva IL-1β 
Mean ± SD 
Saliva C:O 
Mean ± SD 
PLA & SAL 
Pearson’s r 
PLA & SAL 
Sig (2 tailed) 
PLA & C:O 
Pearson’s r 
PLA & C:O 
Sig (2 tailed) 
N 
 
TT % change pre – post  
 
9 89.40 ± 29.11 116.89 ± 48.86 91.91 ± 36.04 0.044 0.911 0.010 0.981 
     (-0.589 – 0.830)  (-0.537 – 0.688)  
INT % change pre – post 9 173.77 ± 148.57 116.36 ± 87.96 107.83 ± 72.19 0.511 0.160 0.677* 0.045* 
     (-0.659 – 0.882)  (-0.278 – 0.957)  
Data is displayed as mean ± SD, IL-1β values are expressed in % change in pg/ mL pre to post exercise trial relative to 100, * p = <0.05, percentile bootstrap 95% CI’s 
reported in brackets 
TT = pre-loaded time trial, INT = interval trial, PLA = plasma, SAL = saliva, CO = IL-1β expressed as concentration: osmolality 
Data was transformed Log 10 
 
 
There was no significant relationship between plasma and saliva IL-1β percentage change (relative to 100), pre to post the pre-loaded time trial 
or pre to post the Interval trial. However when saliva data was expressed as concentration : osmolality there was a significant relationship 






Table 3.5 Bland and Altman level of agreement between plasma and saliva (and saliva expressed as concentration : osmolality) percentage 
change (relative to 100) in IL-1β concentration pre to post the pre-loaded time trial and interval trial. 
Trial (N) Plasma IL-1 β 
Mean ± SD 
Saliva IL-1β 
Mean ± SD 
Mean % change 
 (SAL+PLA)/2 
Mean diff                               








89.40 ± 29.11 116.89 ± 48.86 
 
103.15 ± 30.94 
 





INT % change pre – post 9 173.77 ± 148.57 116.36 ± 87.96 119.43 ± 40.88 6.13 ± 103.88 -197.48 209.73 
 
Saliva data expressed as concentration: osmolality 
 
TT % change pre – post 9 89.40 ± 29.11 91.91 ± 36.04 90.65 ± 25.03 -2.51 ± 42.28 -85.37 80.35 
INT % change pre – post 9 173.77 ± 148.57 107.83 ± 72.19 14.74 ± 47.93 14.66 ± 81.20 -144.48 173.81 
Data is displayed as mean ± SD, IL-1β values are expressed in % change in pg/ mL pre to post exercise trial relative to 100,  
TT = pre-loaded time trial, INT = interval trial, PLA = plasma, SAL = saliva. 
Data was transformed Log 10 
 
Bland and Altman analysis indicated poor agreement between plasma and saliva IL-1β for % change percentage change (relative to 100) in IL-























Figure 3.1. Bland and Altman level of agreement between plasma and saliva percentage change (relative to 100) in IL1-β concentration pre to post: (A) pre-






The aim of the present study was to examine the influence of two different cycling 
protocols (a pre-loaded time trial and a high intensity interval trial) on changes in 
plasma concentrations of 11 cytokines (IL-1, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-
, TNF-, MCP-1 and VEGF). The main findings of this study demonstrate that IL-6 
concentration significantly increased post both cycling trials compared to pre, and 
the increase following the preloaded time trial was significantly greater than the 
interval trial. When expressed as percentage change, there was a 161% increase 
in IL-6 following the time trial compared to a 37% increase following the interval trial. 
Secondary findings of this study show that there was a main effect of time for IL-4, 
MCP-1 and VEGF. IL-4 and MCP-1 concentration significantly increased and VEGF 
concentration significantly decreased for both trials combined post exercise, these 
changes were not different between trials. No changes in concentrations of IL-1α, 
IL-1β, IL-2, IL-8, IL-10, IFN-ϒ, or TNFα were observed pre to post exercise, or 
between the two trials. 
The elevation in plasma IL-6 concentration observed post both trials and in 
particular, post the 1-hour pre-loaded time trial is consistent with the findings of 
others researchers (Cox, 2007; Suzuki, 2000). Brenner et al. (1999), reported the 
IL-6 response was more marked post 2 hours of cycling at 60%, 2OV

max compared 
to five minutes of high intensity cycling or circuit training. In Brenner et al. (1999), 
the increase in IL-6 was five to six fold greater than baseline levels. In the current 
study the increase was not as high as this (two to three fold that of baseline levels); 
this might be related to the difference in exercise duration between the two studies. 
Scott (2011), found plasma concentrations of IL-6 peaked immediately following an 
acute bout of treadmill running at 75% 2OV

max, and remained elevated for 30 
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minutes post exercise. In marathon running, IL-6 has been observed to peak 
immediately following the race (Ostrowski et al., 1999). Smith et al. (2000) reported 
increased IL-6 concentrations in untrained college males at 6, 12, 24 and 48 hours 
post eccentric bench press and leg curl exercise. Toft et al. (2002) found IL-6 
significantly increased following 60 min of eccentric lower limb exercise in young 
and elderly untrained individuals. The elevated IL-6 response to exercise is well 
documented, IL-6 is considered to be multifunctional, displaying several pro-
inflammatory properties however, it also has anti-inflammatory properties (Smith et 
al., 2000; Pedersen, 2000, 2004). IL-6 appears in the circulation preceding other 
cytokines, and is thought to be responsible for the trigger of other anti-inflammatory 
cytokines including, IL-4 (Cox, 2007), IL-10 and IL-1ra (Smith, 2000; Suzuki, 2002). 
IL-6 is a cytokine released locally in the muscle also described as a myokine 
(Pederson, 2004). Steensberg et al. (2000), measured femoral arterial-venous 
differences across an exercising leg compared to a resting leg, and reported that IL-
6 is only released in the exercising limb. In addition, isolated nuclei from muscle 
biopsy samples show the IL-6 transcription rate increases following the onset of 
exercise (Keller et al. 2001). IL-6 increases exponentially with exercise and is 
related to exercise duration, intensity and the mass of muscle recruited (Febbraio & 
Pederson, 2002). Therefore, there is evidence to support that, IL-6 production is 
associated with the contracting skeletal muscle, and its production is independent 
of muscle damage (Gokhale, 2007). In addition, IL-6 production has been 
associated with muscle glycogen depletion; this may explain the more pronounced 
increase in IL-6 observed post the longer duration 1 hour time trial compared to the 
interval trial in the current study. In support of this, Steesberg et al. (2001) reported 
that IL-6 concentration is elevated earlier in a glycogen depleted leg (detected 60 
min following the onset of exercise), compared to a non-glycogen depleted leg 
(detected 120 minutes following the onset of exercise). Therefore, muscle glycogen 
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status is considered a stimulus for the transcription of the IL-6 gene. It would appear 
that factors other than muscle damage contribute to IL-6 production such as energy 
crisis, metabolic, hormonal alterations and oxidative stress all known to stimulate 
systemic cytokine release (Cannon 2000). 
In the current study, a post exercise increase in anti-inflammatory IL-4 was observed 
for both trials combined. The increase in IL-4 is likely to have been triggered by 
increased IL-6 production following the onset of exercise (Cox, 2007). Few studies 
have examined the acute plasma IL-4 response to exercise, and those that have 
often report no change. Niemen et al. (2001), reported post marathon levels of IL-4, 
IL-1β, IL-2, INF-y and IL-4 remained near pre-race or at non-detectable levels. 
Similarly, Suzuki et al. (2000) reported no change in plasma IL-4 concentration post 
a competitive marathon race. In agreement with the current study, Ostapiuk-
Karolczuk et al. (2012) reported that that IL-4 and IL-6 significantly increased 
immediately following exercise (90 minutes of running at 65% 2OV

max). There are 
equivocal findings in previous literature. Differences may be due to exercise duration 
as Nieman et al. (2001) and Suzuki et al. (2000), both examined more prolonged 
marathon running.   
According to Peake et al, (2005) when examining cytokine kinetics, IL-6 is the first 
cytokine to increase in the circulation during exercise. This is followed by 
proinflammatory IL-1β and TNFα, followed by anti-inflammatory IL-4 and IL-10. Both 
the findings of Ostapiuk-Karolczuk et al. (2012) and the current study show a 
different pattern, with both IL-6 and IL-4 elevated immediately post exercise. In this 
study, no changes in pro inflammatory TNFα or IL1-β were detected. This finding is 
in contrast to previous work that has reported elevated TNFα and IL1-β following 
1.5 and 2 hours of cycling (Cox et al., 2010; Brenner et al., 1999 respectively). In 
contrast, a number of studies have reported that systemic levels of TNFα and IL1β 
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could not be detected, or only very small changes were measurable in plasma after 
eccentric exercise (Smith, 2000; Hirose, 2004). There are several possible 
explanations for variable findings in previous literature. Firstly, the type of exercise 
and its intensity and duration employed in the intervention protocol might affect the 
resulting cytokine profile. Physical exercise that induces muscle damage such as 
prolonged endurance exercise is associated with elevations in pro-inflammatory 
cytokines such as IL-1 and TNFα (Moldoveanu et al., 2000). It is possible the volume 
of the exercise employed in the current study, may not have been substantial 
enough to evoke a pro inflammatory cytokine response. In addition, plasma samples 
were only collected pre and immediately post exercise, therefore possible increases 
in proinflammatory cytokines later in the recovery period cannot be ruled out. For 
example, TNF and IL-1 have been found to gradually increase and peak 6 hours 
into the recovery period following 90 minutes running Ostapiuk-Karolczuk et al. 
(2012). Furthermore, Sprenger et al. (1992), suggested measurement of circulating 
levels of IL-1 might not be an accurate measure of production, since assessment 
is complicated by rapid clearance from the circulation. IL-6 is also known to directly 
inhibit the expression of TNFα (Pedersen, 2000). In the current study, IL-6 and IL-4 
were both elevated in the immediate post exercise period; there is the possibility this 
might have dampened a pro-inflammatory response.  
In this study, there was a main effect of time for MCP-1. Specifically a  post exercise 
increase in MCP-1 was observed in the time trial. This finding is in agreement with 
Peak (2005) who observed an elevation in MCP-1 concentration following 3 exercise 
protocols including, level treadmill running at 60% 2OV

max,1 hr treadmill running at 
85% 2OV

max and downhill running at 60% 2OV

max. In addition, Suzuki et al. (2003) 
reported increased concentration of plasma IL-4 and MCP-1 immediately after a 
marathon race. It was concluded the increase was most likely to mediate recruitment 
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and activation of neutrophils and monocytes to the site of muscle damage from the 
circulation. MCP-1 is a chemokine involved in mediating monocyte chemotaxis 
(Wells et al., 2016). Exercise related myotrauma activates myogenic precursor cells 
associated with training induced muscle growth (Bellamy et al., 2014). It has been 
suggested these cells depend on macrophages derived from monocytes to play a 
supportive role in their action (Seale et al., 2001). In contrast, Ihalainen et al. (2014) 
reported a significant decrease in plasma MCP-1 concentrations following an acute 
bout of leg press exercise (5 sets of 10 at 80% 1RM). Previous research on the MCP 
response to endurance and intermittent/ strength based exercise is limited and 
equivocal; however the differences in findings could be related to the differences 
between exercise protocols and their stimulus.  
In this study, plasma VEGF concentration was higher pre-exercise for both trials 
combined. VEGF is an endothelial cell mitogen that stimulates angiogenesis by 
migration and endothelial cell proliferation (Hiscock 2015). It is important in vascular 
adaptation to exercise stress, depending on the metabolic and oxygen demands of 
the tissues (Gunga, 1999). Skeletal muscle cells/ endothelial cells produce VEGF, 
and a fraction can be secreted into the systemic circulation (Kraus et al., 2004). In 
humans, local VEGF mRNA expression has been reported to be elevated 1-hour 
post leg extension exercise (Richardson et al., 1999; Hiscock et al., 2015). Elevation 
in VEGF mRNA in skeletal muscle may increase VEGF protein synthesis, which is 
then released into the extracellular matrix and the circulation. Hiscock et al. (2015). 
Decreased serum VEGF concentration has been reported post Marathon running at 
high altitude (Gunga 1998). In contrast elevated plasma VEGF concentration has 
been reported immediately post 1 hour cycle ergometer exercise at 50% 2OV

max  
Kraus et al. (2004) and post marathon running at 2300m altitude (Schobersberger 
et al., 2000). Therefore, previous research findings regarding the plasma VEGF 
response to acute exercise are equivocal. Hiscock et al., (2015) observed a 9-fold 
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elevation in skeletal muscle VEGF mRNA post 3 hours of low intensity knee 
extension exercise at 50% peak workload. Femoral vein VEGF concentration 
increased post exercise however there was no change in femoral artery VEGF 
concentration. This suggests that VEGF may be released by the muscle and taken 
up by other tissues. If this is the case then the measurement of circulating VEGF 
might not necessarily reflect its increased release from skeletal muscle.  
There are a number of confounding variables in the current study. Previous studies 
have measured pro and anti - inflammatory mediators at 6, 12, 24 and 72 h intervals 
post exercise (Brenner et al., 1999; Cox, 2007). Alternatively, some previous 
studies, similar to the present study, have measured cytokine responses in the acute 
pre and post exercise period. The time course of appearance of inflammatory and 
anti –inflammatory cytokines varies. For example IL-8 and TNFα peak in the hours 
and days post, exercise (Pedersen, 2000) therefore, the results of the current study) 
have limited precision and may not present the complete picture regarding immune 
changes following a bout of exercise.   
Despite a high sensitivity kit being used in this study, some cytokines were at or 
below the minimum detection limit. This was particularly the case for IL-2, IL-10, 
IFNG, IL1α and IL1-β. It should be taken into consideration that concentrations of 
cytokines in peripheral blood plasma may not reflect local up regulation or down 
regulation in the tissues. Therefore the inclusion of muscle biopsies/ urine samples 
and the measurement of arteriovenous differences across the exercising limb (and 
over more sampling time points), might assist us in understanding the cytokine 
response to exercise more clearly. In addition, the variability in analysis techniques 
employed in previous studies makes it difficult to make comparisons between study 
findings. Often different types of plate analysis are employed ranging from 
suspension array systems to custom manufactured multiple cytokine kits (Cox, 
2010).  
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General day to day variability in plasma cytokine concentration should also be 
appreciated. In this study there was no difference in baseline concentrations of 
cytokines at rest prior to each of the two cycling trials however, a main effect of trial 
for IL-8 concentration (p = 0.011) was observed. Mean results show IL-8 
concentrations were already elevated at rest prior to the time trial (7.12 ± 4.29) 
compared to prior the interval trial (4.29 ± 2.42). It is unknown as to why this 
difference in baseline values occurred. Trials were randomised so it is unlikely this 
was due to an order effect; it could possibly have been due to day-to-day variability 
in measurement or a sampling/ analysis error. Athletes’ cytokine responses to 
exercise are not homogenous and they are influenced by many factors such as 
training status, age (Gokhale, 2006), stress hormones, oxidative stress and 
carbohydrate status (Cannon, 2000). Diet was not controlled to any formal extent in 
the current study, participants were asked to replicate their dietary intake for 24 
hours and fast for 2 hours prior to laboratory visits. It has been established that 
feeding prior to an exercise test can affect hormone and cytokine levels 
(Venkatraman & Pendergast, 2002). Whether an athlete is illness prone may also 
play an important role in their immunological status at rest and during exercise. Cox 
et al, (2007). These factors should be considered when carrying out trials on 
different days or over a more prolonged testing periods.  
The intensity for the cycling protocols employed in the current study, was set as a 
fraction of participants maximal aerobic power obtained in their initial 2OV

peak test.  
Therefore, if participants had not been motivated to reach their maximum power 
output during the initial test, they may have been working at a lower intensity than 





In conclusion, the findings of the current study demonstrate that a 1 hour pre-loaded 
cycling time trial and a high intensity interval trial evoked an increase in IL-6 
concentration post exercise. The magnitude of change was significantly higher in 
the 1-hour trial. This study provides evidence of an acute cytokine response post 
cycling exercise specifically regarding an elevation in IL-6, IL-4, MCP-1 and a 
decrease in VEGF post exercise compared to pre. This study attempted to provide 
a model of acute cytokine changes in response to cycling that represents the training 
sessions that cyclists might complete on a daily basis. The study contributes 
information to the field as the majority of previous research has examined extremely 
prolonged exercise, exercise known to induce muscle damage  (Nieman et al., 2005; 
Gill et al., 2015) or prolonged exercise in hot environments (Cosico-Lima et al., 
2011; Luk et al., 2016). Future studies should consider local and peripheral 
measurement of cytokine concentration at multiple time points post exercise in order 
to present the complete picture regarding immune changes following a bout of 
exercise. 
A secondary aim of the present study was to investigate the relationship between 
saliva and plasma concentration of IL-1β using the plasma values obtained from the 
main study and saliva values analysed using a separate saliva plate (Salimetrics 
UK). The relationship between Saliva and plasma IL-1B values were examined pre 
time trial, post time trial, pre interval trial and post Interval trial (see table 3.3). A 
significant correlation between plasma and saliva measurements of IL-1β was 
observed only in the post time trial data. This relationship between saliva and 
plasma was evident for both original saliva values and when saliva was expressed 
as concentration: Osmolality. When examining the change in IL1-β values, pre to 
post exercise, for both cycling protocols (expressed as percentage change relative 
to 100), there was no relationship between plasma and saliva percentage change 
 74 
in IL-1β for the pre-loaded time trial. However, there was a relationship in 
percentage change for the interval trial; this was only evident when plasma was 
expressed as concentration: osmolality (table 3.4). Why a relationship between 
plasma and saliva assay measurements only existed in the conditions as stated, 
suggests a lack of consistency. Furthermore, Bland and Altman analysis indicated 
poor agreement between the assays when considering percentage change in IL-1β 
for both exercise protocols (table 3.5 and figure 3.1) 
The findings of this study are in agreement with previous work suggesting that the 
relationship between human IL-1β levels in plasma and saliva is generally poor 
(Williamson et al, 2012). It is also possible that salivary samples are more reflective 
of local immune responses in the mouth or upper respiratory tract (Gaphor et al, 
2014) rather than reflective of cytokine levels in the systemic circulation. It should 
be noted, in the current study, salivary flow rate was not measured. IL-1β is not flow 
rate dependent with individuals whose IL-1β levels are considered in the normal 
range. The effect of flow rate on individuals with elevated levels of IL-1β is unknown 
and therefore it may have been relevant to measure salivary flow rate where the 
measured concentration is multiplied by the flow rate to result in product measured 
per unit of time. (Salametrics salivary IL-1β ELISA kit manual) it is important to 
consider the location of samples used when attempting to quantify cytokine changes 
in response to exercise. More recently, research has considered a combination of 
local and peripheral measures including muscle biopsies to quantify myokine mRNA 
expression and muscle protein levels (Chan et al., 2004). In addition, plasma, serum 
and urine samples may provide further information on the concentration and 
clearance of cytokines in the systemic circulation (Nieman et al., 2001). 
In conclusion, the relationship between saliva and plasma assays for the 
determination of IL-1β was not consistent, there was not a good level of agreement 
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between the assays. Therefore, the measurement of IL- 1β values using saliva is 


























CHAPTER 4 VALIDATION OF THE USE OF A FINGERTIP 
DRY BLOOD SPOT METHOD TO DETERMINE CELLULAR 
n-3 AND n-6 PUFA INCORPORATION IN COMPARISON TO 





















In recent decades, omega 3 long chain polyunsaturated fatty acid status (n-3 LC 
PUFA status), in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) have been of interest to scientists. The EPA and DHA status of humans has 
been extensively investigated to determine the influence of these fatty acids on the 
prevention and treatment of chronic diseases such as asthma and exercise induced 
asthma (Mickleborough et al., 2006). There is a great deal of interest surrounding 
n-3 PUFA and its cardio protective effects, it has been reported to be therapeutic in 
the prevention of fatal arrhythmia (Leaf et al., 2008) and in the reduction of 
inflammatory cytokine production (Mickleborough et al., 2009).  
 
In order for researchers to examine the relationships between dietary FA intake and 
biological outcomes, it is important that reliable biomarkers to measure FA status 
are available. Self-reported intakes from food frequency questionnaires (FFQ) and 
diet records can be used to estimate an individual’s FA status, however these 
methods are reliant on memory, knowledge of portion sizes and participant 
motivation to complete data recording (Sun et al., 2007). Biomarkers are objective 
measures. There are a number of methods available to determine the fatty acid 
status of an individual however there is no universally accepted bio-marker to 
determine fatty acid status in response to increased dietary FA intake (Fekete, 
2009).  
 
The use of dried blood spots (DBS) is a convenient, rapid, and inexpensive method 
of sampling whole blood, which can then be analysed for PUFA content using 
traditional gas chromatography methods. DBS analysis was first employed by 
Marangoni et al. (2004), the method enables the analysis of fatty acid status using 
a capillary whole blood sample taken from the fingertip. Several variations of this 
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method have been developed by researchers since (Metherel et al., 2012; Harris & 
Polreis., 2016). However, current DBS blood sampling methods have some 
limitations due to possible contamination, and the stability of the samples is 
questionable due to oxidative losses of n-3 PUFA over time (Metherel, 2013). 
  
Analysis of blood fractions including plasma or erythrocytes are commonly used as 
a surrogate measure of fatty acid tissue incorporation (Baylin & Campos, 2006). 
Serum n-3 PUFA fatty acid concentrations respond more quickly than erythrocytes 
to recent dietary intake due to a slower turnover rate of erythrocytes (Katan et al., 
1997). The lifetime of an erythrocyte is approximately 120 days therefore erythrocyte 
phospholipid FA fractions are likely to be  superior to plasma Fatty acid 
measurement and may provide a valid estimation of n-3 PUFA status that is more 
representative of long term intake (Katan et al., 1997). 
 
Understanding accurately how dietary PUFA intake is reflected in erythrocyte 
phospholipids (or other blood fraction methods) allows us to validate indirect 
measures of self-reported intake, and to determine participant compliance with a 
dietary intervention or supplementation protocol. It may also allow us to determine 
relevant supplement dosage in studies that link disease states to dietary FA intake.  
 
Conducting large epidemiological studies or intervention studies in the field 
(particularly in the case of athletic research) is limited by the need for a trained 
personnel to carry out venous blood collection from the antecubital vein, which in 
itself is invasive especially when multiple samples are necessary. In addition, the 
standard analysis of samples requires a number of time consuming steps. 
Despite these limitations, venous blood erythrocyte percentage fractional content of 
(EPA) and (DHA) is still widely accepted as the most relevant biomarker in humans 
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to reflect long term n-3 PUFA status (Stark et al., 2016) and is considered gold 
standard by many investigators (Harris, & von Schacky, 2004; Poppitt et al, 2005). 
The aim of this study was to determine if alternate methods to venous blood 
sampling could provide a comparable measure of n-3 PUFA status whilst reducing 
some of the logistical limitations of venous blood sampling.  
 
Specifically, the purpose of this study was to validate the use of a whole blood 
fingertip DBS method of blood collection and analysis to determine whole blood fatty 
acid composition and to compare this with the gold standard isolated erythrocyte 
analysis methods obtained via venepuncture. The following fatty acids were profiled 
using both methods (ALA), -linolenic acid; (EPA), eicosapentaenoic acid; (DHA), 
docosahexaenoic acid; (total n-3 PUFA), total Omega 3; (LA), linoleic acid; (AA), 
arachidonic acid; (total n-6), total omega 6. (DHA + EPA), omega 3 index; (n-6/ n-3 

















10 well trained healthy male competitive road cyclists and triathletes aged 42 ± 11 
years (mean ± SD) participated in the study. Participants were recruited via email 
from cycling and triathlon clubs in London and the South East and were a sub-group 
of the participants recruited for chapter 5. Well trained was defined as 6> hours of 
cycling per week for at least 12 months. Participants were excluded from the study 
if they had any incidence of illness or recent injury, evidence of hemodynamic or 
cardiovascular dysfunction, cigarette smoking, diabetes inflammatory or immune 
dysfunction and consumption of more than 2 fish containing meals per week. All 
participants reported they were not taking fish oil supplements, medication or had 
any allergies to fish/ soy or vitamin E related products. The study was approved by 
the University of Kent Research Advisory Group (REAG). The Participant’s physical 
characteristics are presented in table 4.1. 
 
Table 4.1. Participant physical characteristics (mean ± SD)   
Variables Participants (n = 10)  
Age (years) 
Height (cm) 
Body mass (kg) 
42. ± 11 
178.1 ± 7.5 





Participants reported to the laboratory on three occasions over an eight-week 
period. All participants completed an informed consent form and a medical 
questionnaire. The first test was used to obtain baseline pre-supplementation blood 
samples. The second and third visits were used to obtain samples 4 weeks into and 
8 weeks (post), the supplementation period. This is the first study to examine the 
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relationship between DBS and isolated erythrocyte values for fatty acid 
incorporation, over the duration of 8 weeks with a halfway sampling point. 
Participants were instructed to arrive fasted for 2 hours and in a rested, euhydrated 
state with water consumption permitted ad libitum. 
 
Blood sampling procedures 
Venous blood sample   
An 8ml venous blood sample was collected by a trained phlebotomist using standard 
venepuncture procedure. Whole blood was collected directly into EDTA collection 
tubes from the antecubital vein. Red blood cells (RBC) were isolated from whole 
blood. The sample was transferred into a 50ml centrifuge tube with 8ml of Hanks 
balanced salt solution. This mixture was slowly layered on to 12ml of Ficoll-Paque 
premium and centrifuged at 400 x g for 35 minutes at 18˚ C. The concentrated RBC 
layer at the bottom of the tube was pipetted into a new 15ml tube and 3 x the volume 
of balanced salt solution was added and centrifuged at 400 x g for 10 minutes at a 
temperature between 18 – 20 ˚ C. RBC were then suspended in phosphate buffered 
saline (PBS) and aliquots were frozen at -80 ˚C.  
 
Dry blood spot sample (DBS) 
 
Prior to obtaining the DBS sample, Guthrie absorbent filter cards were pre-soaked 
in 5mg/ ml butylated hydroxytoluene (BHT) in methanol (Sigma-Aldrich) and allowed 
to air dry. This was in order to prevent/ limit fatty acid oxidation.  The blood sample 
was collected from the fingertip using a lancing needle. Freely accumulated blood 
was then spotted onto four designated sample areas of the collection card and 
allowed to dry for several hours. Once dry, samples were sealed in zip lock bags. 
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All Samples were then freighted to Loughborough University and stored at -80˚C. 
DBS samples were punched (30mm2) and frozen in Eppendorf’s at -80˚C.  
 
Fatty acid analysis  
A complete methodology for the procedures of fatty acid analysis can be found in 
appendix 1 including Total lipid extraction, lipid separation, transmethylation and 
gas chromatography/ mass spectrometry analysis. 
 
STATISTICAL ANALYSIS 
All statistical analysis was conducted using IBM SPSS version 24. A paired samples 
t-test was calculated to determine differences in FA percentage values for 10 
different pairs of FAs measured by the DBS and venous method (p = <0.05). Simple 
linear regression was calculated to assess the linear relationship between capillary 
DBS FA values and the corresponding within subject fatty acids obtained from 
venous blood sampling. A two-way mixed measures (consistency) intra-class 
correlation was calculated to quantify the degree to which the two methods 
resembled each other. A Bland and Altman agreement test (Bland & Altman, 1986) 
was used to describe the limits of agreement between the methods. Linear 
regression was conducted to examine the relationship between the difference 
between the two methods and the mean of the two methods to correct for any 
proportional bias in the Bland and Altman analysis. 
Analysis of pairs of data at 3 different time points (A) pre, B) 4 weeks and C) 8 
weeks for each participant (30 samples in total)), violated the assumption of 
“independence of residuals” for linear regression (the samples are related or 
correlated). So the following samples were selected to examine if the DBS method 
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could be considered valid in comparison to venous erythrocyte methods across 
the entire supplementation period A, B and C 
 
A = pre supplementation, B = mid supplementation and C = post supplementation 
Participant 1 2 3 4 5 6 7 8 9 10 
Sample time point  A B C A B C A B C A 
 





Analysis of difference in FA percentage values between venous erythrocyte 
analysis and whole blood DBS methods (Paired T-test) 
There were 5 outliers in the data as assessed by inspection of a box plot for 
differences between paired values greater than 1.5 box lengths (table 4.2). The 
outliers were left in the data analysis as they were not considered extreme (not 
greater than 3 times the interquartile range from a quartile). Normal distribution 
was assessed by Shapiro-Wilk test (p = > 0.05). Fatty acid values were normally 
distributed. 
Table 4.2 Outlier identification values and case number  
 
Fatty acid Case 
number 
Venous value DBS value  Difference 
 AA 1 19.97 4.16 15.81 
 2 14.81 8.65 6.16 
EPA 6 6.90 2.30 4.61 
Total n-6 1 38.95 14.88 24.07 
Total n-3 6 22.75 10.21 12.54 




The results of the paired samples t-test indicate the mean values for some of the FA 
differed significantly between methods. Specifically, the venous method, elicited 
statistically significantly higher values for EPA, DHA, AA, EPA + DHA & n-6/ n-3 
PUFA than the DBS method (table 4.3). The DBS method produced a significantly 
higher value for ALA compared to the venous method. There was no difference 
between methods for DHA, LA, total n-3 PUFA or DHA/ EPA. 
 
Relationship between DBS and venous methods  
To assess linearity, a scatter plot of venous blood samples against DBS blood 
samples with superimposed regression line was plotted for each FA. Visual 
inspection of these plots indicated a linear relationship for EPA in particular. 
Residuals were normally distributed, as assessed by visual inspection of a normal 
probability plot.   
 
Linear regressions to examine the relationship between capillary DBS and venous 
erythrocyte methods of measuring individual FA are summarised in table 4.4 and 
Figure 4.2. There was a significant correlation between methods of measurement 
for EPA (R 2 = 0.64, p = 0.005), a large effect size according to Cohen (1988). AA, 
Total n-6 and n-6/ n-3 PUFA correlated with a small non-significant effect size (AA, 
R2 = 0.25, total n-6 PUFA R2 = 0.25 and n-6/ n-3 PUFA, R2 = 0.29. There was no 
association between DBS and venous methods for ALA, DHA, total n-3 PUFA, LA, 
EPA + DHA index or DHA/ EPA ratio. 
 
Intra-class correlation coefficients showed the methods of measurement were 
similar for the determination of EPA status (ICC = 0.72) but not for AA (ICC = 0.49), 




Bland and Altman analysis showed moderate levels of agreement between methods 
for determining EPA % FA composition, mean difference = 1.12% with 95% limits of 
agreement -1.43% – 3.67% without any evidence of proportional bias p = 0.05. The 
remaining FA did not show good agreement between methods, in addition for the 
fatty acids , ALA, DHA, EPA + DHA and n-6/ n-3 PUFA (see table 4.5 and figure 
4.2) there was evidence of proportional bias p = <0.01.
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Table 4.3   Mean difference comparison of blood fatty acid percentage content derived from DBS and venous methods (mean  SD). Significant 
differences between methods was observed in ALA, AA, total n-6 PUFA, EPA + DHA & n-6/ n-3 PUFA ratio. No significant differences were 
observed in DHA, total n-3 PUFA, LA & DHA/ EPA. 
 
 










t df Sig (2 tailed) 
(n-3) PUFA         
ALA 0.26 ± 0.08 6.76 ± 1.64 -6.51 ± 1.64 -7.68 -5.36 -12.56 9 <0.001** 
EPA 2.86 ± 2.08 1.75 ± 1.31 1.12 ± 1.30 0.19 2.04 2.72 9 0.024* 
DHA 5.11 ± 3.66 2.79 ± 0.86 2.33 ± 3.74 -0.35 5.00 1.97 9 0.081 
Total n-3 PUFA 12.41 ± 4.94 12.71 ± 2.43 -0.30 ± 5.84 -4.48 3.87 -0.16 9 0.874 
(n-6) PUFA         
LA 14.20 ± 2.15 14.42 ± 2.81 -0.22 ± 3.30 -2.58 2.14 -0.21 9 0.841 
AA 18.53 ± 2.65 7.70 ± 2.25 10.82 ± 2.48 9.05 12.60 13.81 9 <0.001** 
Total n-6 37.60 ± 3.88 25.42 ± 3.88 12.18 ± 5.13 8.51 15.84 7.51 9 <0.001** 
(Index & ratio)         
EPA + DHA 7.98 ± 4.87 4.53 ± 1.76 3.44 ± 4.55 0.19 2.04 2.72 9 0.024* 
n-6/ n-3 ratio 3.63 ± 1.81 2.00 ± 0.31 1.63 ± 1.66 0.44 2.82 3.09 9 0.013* 
DHA/ EPA 2.24 ± 1.91 2.47 ± 1.44 -0.23 ± 2.10 -1.73 1.27 -0.35 9 0.736 
Data are presented as individual fatty acid (% fraction mean  SD). ALA, -linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; n-3, Omega 3; LA, 








Table 4.4   The relationship between blood fatty acid percentage content derived from DBS and venous methods (mean  SD). There was a 
strong linear relationship between methods for EPA measurement (Cohen 1988) and a good intra-class agreement (Cicchetti 1994) 




R R2 ICC F value p-value Regression equation 
(n-3) PUFA          
ALA 10 0.26 ± 0.08 6.76 ± 1.64 0.053 0.003 0.005 0.023 0.884 Y= 0.24 + (0.002* X) 
EPA 10 2.86 ± 2.08 1.75 ± 1.31 0.802 0.643 0.722 14.39 0.005** Y= 0.63 + (1.28* X) 
DHA 10 5.11 ± 3.66 2.79 ± 0.86 0.018 <0.001 0.008 0.002 0.962 Y= 4.90+ (0.08* X) 
Total n-3 PUFA 10 12.41 ± 4.94 12.71 ± 2.43 0.156 0.024 -0.124 0.201 0.666 Y= 16.44 + (-3.17* X) 
(n-6) PUFA          
LA 10 14.20 ± 2.15 14.42 ± 2.81 0.135 0.018 0.130 0.148 0.711 Y= 12.72 + (0.10* X) 
AA 10 18.53 ± 2.65 7.70 ± 2.25 0.499 0.249 0.493 2.655 0.142 Y= 14.01 + (0.59* X) 
Total n-6 PUFA 10 37.60 ± 3.88 25.42 ± 3.88 0.502 0.252 0.464 2.700 0.139 Y= 29.09 + (0.34* X) 
(Index & ratio)          
(EPA + DHA) 10 7.98 ± 4.87 4.53 ± 1.76 0.358 0.128 0.229 1.173 0.310 Y= 3.35 + (0.99* X) 
n-6/ n-3 ratio 10 3.63 ± 1.81 2.00 ± 0.31 0.573 0.288 0.178 3.239 0.110 Y= -2.69 + (3.15*X) 
DHA/ EPA ratio 10 2.24 ± 1.91 2.47 ± 1.44 0.242 0.059 0.378 0.498 0.500 Y=0.64 + (0.67*X) 
 
Data are presented as individual fatty acid (% fraction mean  SD). ALA, -linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; n-3 PUFA, Omega 3; 









Table 4.5   Bland and Altman agreement between DBS and venous methods and simple linear regression of the mean of the two methods (X) 
and the difference between the two methods (X-Y) to determine the presence of systematic bias. There was good agreement between methods 
for EPA and n6/ n-3 PUFA  




?̅?-1.96s ?̅?+1.96s R R2 F value p-value Regression equation 
(n-3)PUFA           
ALA 10 3.51 ± 0.82 -6.51 ± 1.64 -9.72 -3.30 0.996 0.992 956.76 <0.001** Y= 0.44 + (-1.98* Χ) 
EPA 10 2.30 ± 1.61 1.12 ± 1.30 -1.43 3.67 0.629 0.396 5.251 0.051 Y= -0.05 + (0.51* Χ) 
DHA 10 3.95 ± 1.89 2.33 ± 3.74 -5.00 9.66 0.896 0.803 32.668 <0.001** Y= -4.69 + (1.78* Χ) 
Total n-3 PUFA 10 12.56 ± 2.58 -0.30 ± 5.84 -11.74 11.14 0.614 0.377 4.843 0.059 Y= -17.79 + (1.39* Χ) 
(n-6)PUFA           
LA 10 14.31 ± 1.88 -0.22 ± 3.30 -6.68 6.25 0.266 0.071 0.607 0.458 Y= 6.45 + (-0.47*Χ) 
AA 10 13.11 ± 2.13 10.83 ± 2.48 5.97 15.68 0.184 0.034 0.282 0.610 Y= 8.00 + (0.22* Χ) 
Total n-6 PUFA 10 31.51 ±  4.23 12.17 ± 5.13 2.13 22.22 0.433 0.188 1.850 0.211 Y= 28.72 + (-0.53* Χ) 
Index/ ratio           
EPA+DHA 10 6.25 ± 2.87 3.45 ± 4.55 -5.47 12.36 0.789 0.623 13.211 0.007** Y= -4.37 + (1.250* Χ) 
n6/ n-3 PUFA 10 2.82 ± 1.00 1.63 ± 1.67 -1.64 4.90 0.958 0.918 89.331 <0.001** Y= -290 + (1.61* Χ) 
EPA/ DHA 10 2.36 ± 1.33 -0.23 ± 2.10 -4.34 3.88 0.281 0.079 0.688 0.431 Y= -1.28 + (0.44* Χ) 
Data are presented as individual fatty acid (% fraction mean  SD). ALA, -linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; n-3, Omega 3; LA, linoleic acid; AA, 
















































































+1.96 SD, -3.30 
-1.96 SD, -9.72 
-1.96 SD, -1.43 
-1.96 SD, -5.00 
 
+1.96 SD, 3.67 
Mean, 1.12 
Mean, 2.33 
+1.96 SD, 9.66 
Figure 4.2  The relationship between venous and DBS derived measures of fatty acid percentage 
content. Each case is presented as a regression analysis (column A) and Bland and Altman plot 
where differences are presented as units (column B). Regression equation is expressed as y = a 
(95% CI) + b (95% CI) x.  
Regression relationship. P = <0.05*, P = < 0.01** 
In panel A, the solid line represents the line of identity and in panel (B) the dashed line represents 
the bias 95% limits of agreement. In panel (B) a regression line is the superimposed (dashed line) 





















































































-1.96 SD, 15.68 
-1.96 SD, -6.68 
-1.96 SD, -11.74 
+1.96 SD, 11.14 
+1.96 SD, 5.97 
+1.96 SD, 6.25 
Mean, 10.83 
Figure 4.2 The relationship between venous and DBS derived measures of fatty acid percentage 
content. Each case is presented as a regression analysis (column A) and Bland and Altman plot 
where differences are presented as units (column B). Regression equation is expressed as y = a 
(95% CI) + b (95% CI) x.  
Regression relationship. P = <0.05*, P = < 0.01** 
In panel A, the solid line represents the line of identity and in panel (B) the dashed line represents 
the bias 95% limits of agreement. In panel (B) a regression line is the superimposed (dashed line) 
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-1.96 SD, -5.47 
Mean, 1.63 
Mean, 3.45 
Figure 4.2  The relationship between venous and DBS derived measures of fatty acid percentage 
content. Each case is presented as a regression analysis (column A) and Bland and Altman plot 
where differences are presented as units (column B). Regression equation is expressed as y = a 
(95% CI) + b (95% CI) x.  
Regression relationship. P = <0.05*, P = < 0.01** 
In panel A, the solid line represents the line of identity and in panel (B) the dashed line represents 
the bias 95% limits of agreement. In panel (B) a regression line is the superimposed (dashed line) 
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Figure 4.2  The relationship between venous and DBS derived measures of fatty acid percentage 
content. Each case is presented as a regression analysis (column A) and Bland and Altman plot 
where differences are presented as units (column B). Regression equation is expressed as y = a 
(95% CI) + b (95% CI) x.  
Regression relationship. P = <0.05*, P = < 0.01** 
In panel A, the solid line represents the line of identity and in panel (B) the dashed line represents 
the bias 95% limits of agreement. In panel (B) a regression line is the superimposed (dashed line) 




The aim of this study was to compare whole blood DBS methods analysis against 
conventional gold standard venous erythrocyte analysis for determining FA status.  
 
Difference in FA values between the venous erythrocyte and capillary DBS methods 
of measurement 
When the values for each FA were compared between the two methods of 
measurement (DBS and isolated erythrocytes), a significantly higher mean 
percentage of EPA, AA, total n-6 PUFA, EPA+DHA and n-6/ n-3 PUFA values were 
observed in the isolated erythrocyte method in comparison to DBS. In contrast, ALA 
values were significantly lower in isolated erythrocytes compared to DBS. No 
differences were found between methods for DHA, total n-3 PUFA, LA, and DHA/ 
EPA ratio (table 4.3).  
 
The difference in values observed between methods were expected due to the 
higher RBC cell count in the isolated erythrocyte method of analysis compared to 
the DBS whole blood capillary sample. Whole blood samples contain plasma and a 
number of other cell types including monocytes. It has been reported in previous 
research that PBMC’s readily incorporate EPA and DHA into membrane 
phospholipids when supplementing with n-3 PUFA (Metherel et al., 2009). However, 
the levels of n-3 PUFA fatty acids in PMBCs are lower, as RBCs have a slower 
turnover with a longer lifetime of approximately 120 days in the circulation. 
Furthermore, their FA concentration is not affected acutely by recent dietary 
changes as would be the case with the serum fraction of the whole blood capillary 
sample (Katan et al, 1997). This is further confirmed by observations in previous 
studies that show good agreement between whole blood capillary DBS and whole 
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blood venous FA values (Min et al., 2011; Armstrong et al., 2008). Therefore, if 
capillary and venous whole blood samples had been compared in the current study 
the mean values for each FA may have been similar. It would have been interesting 
if we had dropped some of the whole venous blood sample (prior to erythrocyte 
isolation) onto a Guthrie card. This would have allowed us to determine if it was 
specifically the blood components that caused the differences between methods or 
the sample analytical procedure. In the current study there was no significant 
difference observed between methods for concentrations of DHA although levels 
were generally higher in the venous sample. The mean percentage difference 
between methods of measurement  for EPA, DHA, and AA values in the current 
study are similar to the values reported in previous studies (Bailey-Hall et al., 2008  
and  Bell et al., 2011). See difference column entitled difference (DIFF) in table 4.6 
below.  
 
Table 4.6 Mean percentage blood sample fraction fatty acid content and the 
magnitude of difference between venous erythrocyte and DBS values in the current  
study compared to previous studies. 
Values are presented as fatty acid mean % fraction. 
 
Due to the current study employing  the sample procedure in figure 4.1, the absolute 
mean values in table 4.6 cannot be compared. We employed a systematic sampling 
method over the course of an 8-wk supplementation period, whereas the values 
FA Current study (Bell et al, 2011) (Bailey-Hall et al, 2008) 
 
 VEN DBS DIFF VEN DBS DIFF VEN DBS DIFF 
 EPA 2.86 1.75 0.78 1.49 1.13 0.36 0.76 0.78 -0.02 
DHA 5.11 2.79 2.32 4.84 1.11 3.73 4.89 2.76 2.13 
ALA 0.26 6.76 -6.5 0.15 0.04 0.11 0.320 0.55 -0.23 
Total n-3  12.41 12.71 -0.3 9.21 2.08 7.13    
LA 14.20 14.42 -0.22 9.69 1.33 8.36 14.59 23.66 -9.07 
AA 18.53 7.70 10.83 13.01 1.61 11.4 12.24 8.06 4.18 
Total n-6 37.60 25.42 12.18 27.05 2.61 24.44    
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from Bell et al., (2011) and (Bailey-Hall et al., 2008) were baseline samples taken 
from participants attending a health clinic without supplementation. The difference 
between the values for the venous and DBS method can be compared, assuming 
there is not any systematic bias in either method in its measurement across a range 
of values.  
 
Relationship and agreement between venous erythrocyte and capillary DBS 
methods for the determination of FA concentration  
In the present study the relationship between erythrocyte derived FA values and 
DBS values for EPA correlated well (R = 0.80, R 2 = 0.64, p = 0.005), showing a 
large effect size according to Cohen (1988) (table 4.4). This finding is consistent 
with Bailey-Hall et al. (2008), who reported R 2 = 0.68 for EPA. There was no 
association between DBS and venous methods for ALA, DHA, total n-3 PUFA, LA, 
EPA + DHA Index or DHA/ EPA ratio. In contrast, Bell et al, (2011) reported a good 
correlation between methods for total n-3 PUFA R 2 = 0.95. Furthermore, Bell et al., 
(2011) and Bailey-Hall et al (2008) found good correlation between methods for 
DHA R 2 = 0.58 and 0.74 respectively. The reasons for the difference in findings is 
unclear. The study samples in Bell at al., (2011) were the same as the current study 
(whole blood capillary samples compared against venous erythrocyte samples). 
However, in Bell et al., (2011), resting blood samples were taken from healthy 
participants who were not supplementing with fish oil. Base line samples were 
compared rather than systematically selected samples from three time points of 
supplementation over 8 weeks (as in the current study). Therefore, it is possible that 
supplementation with n-3 PUFA may have changed the general pattern of FA 
incorporation in a dose response manner over the 8 weeks, possibly as a result of 




Intra-class correlation coefficients confirmed excellent similarity between methods 
for EPA measurement (ICC = 0.72) but not for AA (ICC = 0.49) or total n-6 PUFA 
(ICC = 0.46) (Cicchetti 1994). All other fatty acids had poor agreement between the 
two methods. (Table 4.4) 
 
Bland and Altman analysis showed moderate agreement between methods for 
determining EPA% FA composition, mean difference = 1.12% with 95% limits of 
agreement -1.43% – 3.67% without any evidence of proportional bias p = 0.05. The 
remaining FA did not show good agreement between methods. In addition for the 
fatty acids, ALA, DHA, EPA + DHA and n-6/ n-3 PUFA, not only was there poor 
agreement, but there was also evidence of proportional bias p <0.01 which suggests 
that the FA values derived from the two methods do vary through the range of 
measurement (table 4.5 and figure 4.2). 
Some of the variances in measurement values in the current study compared to 
previous studies may be due to inconsistency of analysis steps. Ohta et al. (1990) 
described a method of DBS collection which involved initial separation of whole 
blood into PL and RBC. Thin layer chromatography (TLC) was carried out prior to 
fatty acid methyl ester (FAME) analysis to extract the fatty acids from phospholipids. 
Marangoni et al. (2004), described a whole blood fingertip sampling method that 
was applied directly to chromatography paper similar to the present study with the 
exception that the samples were stored at -80°C rather than at room temperature. 
Studies also vary in their methods of transesterification (Armstrong et al., 2008). 
 
Furthermore, differences in the venous and DBS values in the current study may be 
due to a number of factors. For example, the degradation of samples due to 
oxidation is a known limitation regarding DBS sampling. Bailey-Hall et al. (2008) 
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collected DBS on BHT treated filter paper in order to minimise fatty acid oxidation 
(as in the current study). However Bell et al. (2011), carried out a blood stability trial 
and found no significant difference with the use of blood collection paper pre-treated 
with BHT compared to non-treated paper for analysis of AA, EPA and DHA. DHA 
percentage values reduced over a 4-wk storage period at room temperature from 
2.93% to 1.95% (with most degradation occurring after 48 hours). The other fatty 
acid values reduced in a similar way. This suggests BHT may not necessarily 
improve sample stability.  
 
In conclusion, the finger stick whole blood DBS method is a rapid non-invasive and 
practical field method to determine EPA status in individuals. However, this is not 
the case for other FA. The DBS method is not a replacement method for isolated 
erythrocyte analysis. In addition, due to inconsistencies in methods across studies 
and the concern regarding sample stability and contamination, the use of this 
method should be treated with caution. In relatively small intervention studies, where 
tissue fatty acid status is important for determining the success of a dietary 
intervention or supplementation protocol on tissue levels of n-3 and n-6 PUFA. It is 
likely that venous erythrocyte determination of the fatty acid profile is the most valid 
method. Consequently, for study 3, isolated erythrocytes were analysed from 







CHAPTER 5 THE EFFECT OF A HIGH n-3 PUFA AND LOW 
n-6 PUFA DIETARY INTERVENTION ON ERYTHROCYTE 
N-3 PUFA PHOSPHOLIPID INCORPORATION, AND ITS 
EFFECT ON SUBMAXIMAL CYCLING AT FOUR 
DIFFERENT WORK RATES AND MAXIMAL AEROBIC 



















Increased consumption of eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) may influence a number of physiological parameters related to exercise, 
cardiovascular health and circulatory function. Animal studies have shown that n-3 
PUFA incorporation into myocardial cell membranes enhances the mechanical 
performance of the heart (McLennan et al., 1989), reduces the risk of arrhythmia in 
marmoset monkeys (McLennan et al., 1992), and reduces fatal arrhythmia (Burr et 
al., 1989). Furthermore, fish oil feeding has shown to reduce myocardial oxygen 
consumption by improving the energy efficiency of heart muscle, and lowering 
resting heart rate (HR) and blood pressure (BP) in healthy human participants (Shah 
et al., 2007). 
Within the context of exercise training and performance, there is emerging 
evidence that n-3 PUFA supplementation has the potential to modulate a number 
of cardiovascular responses to exercise that could theoretically enhance 
endurance performance or adaptation to exercise. To date, human studies that 
have examined the influence of n-3 PUFA on performance have been conflicting. 
Zebrowska et al. (2014), observed a reduction in exercising HR, HRmax and 
increased 2OV

max in elite cyclists completing incremental exercise to exhaustion 
following n-3 PUFA supplementation. Cyclists supplemented with 1.3 g/ day of n-3 
PUFA delivering 660 mg EPA and 440 mg DHA for 3 weeks. In addition, 
significant differences between pre and post intervention NO levels were observed 
following n-3 PUFA supplementation compared with the placebo group. NO 
increase was associated with enhanced endothelial function (measured by flow-
mediated dilation (FMD)). It was suggested this mechanism augmented blood flow 
to the exercising skeletal muscle and may have improved 2OV

max performance. N-
3 PUFA supplementation has been shown to enhance endothelial function, local 
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vasodilation and blood flow in skeletal muscle during rhythmic handgrip 
contractions (Walser & Stebbins, 2008).  There are a number of direct and indirect 
mechanisms that may explain the effect of n-3 PUFA on NO production. Three 
isozymes of NO synthase (NOS) are involved in the production of NO. NOS I, 
located in neuronal cells (central and peripheral). NOS II, induced by 
macrophages and a variety of other cell types, and NOS III, an isozyme expressed 
in endothelial cells. These isozymes use L-arginine as a substrate. NOS III is most 
influential in the vasculature, NOS I and II exert effects on the cardiovascular 
system (Li & Forstermann, 2000). EPA increases the synthesis of NOS III derived 
NO in the vascular endothelium; this improves endothelium–dependent 
vasodilation by increasing intracellular Ca2+ concentration (Wu, Cynthia & 
Meininger, 2002). This primes NO synthesis and induces the translocation of 
endothelial NOS (Park et al., 1996). Furthermore, n-3 PUFAs reduce oxidative 
stress. Elevated levels of reactive oxygen species (ROS) can damage the integrity 
of vascular endothelium and can contribute to atherosclerosis. N-3 PUFAs also 
modulate inflammation and produce resolvins and protectins that may contribute to 
decreased leukocyte-endothelial interactions (Casos et al., 2010). Some of these 
indirect actions might contribute to the therapeutic action of n-3 PUFA on the 
cardiovascular system. N-3 PUFA has also been associated with reduced blood 
viscosity (Oostenbrug, 1997). Blood viscosity is an important factor influencing 
maximal cardiac output and peripheral blood flow, both of which are important 
determinants of maximal aerobic capacity (Joyner & Coyle 2008).  
Dietary fish oil may have the potential to modulate cardiovascular function during 
exercise due to the collective mechanisms discussed however; previous authors 
have yet to substantiate an improvement in endurance performance. Leaf and 
Rauch (1988) demonstrated that n-3 fatty acid supplementation increased maximal 
aerobic power ( 2OV

max). This experiment has been criticized  as the researchers 
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used a constant treadmill speed with gradient increments every 3 minutes until 
exhaustion, which may have affected participant motivation and accuracy of 2OV

max measurement (Raastad et al, 1997). In addition, the observations by Leaf and 
Rauch have not been supported by subsequent studies. 2OV

max before and after n-
3 PUFA treatment was unchanged after n-3 PUFA was supplemented with or 
without training (Brilla & Landerholm, 1990; Warner et al., 1989). Oostenbrug et al., 
(1997), found 3 weeks of dietary n-3 PUFA supplementation reduced red blood cell 
deformability by 2% during exercise however; there was no effect on time to 
complete a fixed workload in well-trained male cyclists. 10 weeks of n-3 PUFA 
supplementation did not improve maximal aerobic power, or running performance 
in trained football players (Raastad et al., 1997). Peoples et al. (2008), found no 
change in 2OV

max in endurance trained male cyclists following n-3 PUFA 
supplementation, however whole body O2 consumption was reduced during 
submaximal steady state cycling. Five weeks of supplementation with n-3 PUFA, 
reduced BP (diastolic) and HR during submaximal exercise, however there were no 
observed improvements in time trial running performance (Buckley et al, 2009). In 
trained cyclists, relative oxygen consumption was significantly reduced in the n-3 
PUFA supplemented group  during a 5 minute maximal cycling cycling time trial, 
however there was no difference in time trial performance (Hingley et al, 2017). In 
order to further examine the effect of n-3 PUFA on the 2OV
  cost of submaximal 






1. O2 cost of submaximal exercise  
O2 cost is related to cycling economy and is a significant component of endurance 
performance (Abbiss & Laursen, 2005). Studies that have examined the effect of n-
3 PUFA supplementation on the oxygen cost of exercise are equivocal largely due 
to the number of different exercise modes/ intensities and durations being employed 
in previous work. The O2 cost of exercise has been examined mainly during time 
trial protocols (Buckley et al., 2009; Hingley et al., 2017), time to exhaustion tests 
(Raastad et al, 1997) and during single bouts of fixed intensity exercise (Borlotti et 
al., 2007;  Peoples et al., 2008). Kawabata et al. (2014) used a fixed rate 
submaximal protocol at workloads equivalent to 2 and 3mmol of blood lactate. To 
our knowledge, no studies to date have examined the influence of n-3 PUFA 
supplementation on oxygen consumption during exercise at four different 
submaximal workloads similar to the gross efficiency protocol used by Passfield & 
Doust (2000). Therefore, one of the primary aims of this study was to examine the 
effect of n-3 PUFA supplementation on whole body oxygen cost ( 2OV
 ), HR, BP and 
mean arterial pressure (MAP) at four submaximal workloads, 100 W, 125 W, 150 
W, and 175 W. In previous studies, the oxygen cost of exercise muscle has generally 
been inferred by pulmonary oxygen uptake kinetics. Near infrared spectroscopy 
(NIRS) can be used as a non-invasive method to monitor muscle oxygenation based 
on the principle that the NIR light absorption characteristics of haemoglobin (Hb) 
and myoglobin (Mb) are dependent on oxygen saturation. NIR light absorption 
changes in muscle reflect venous, arterial, capillary and intramuscular oxygenation 
(Van Beekvelt, 2001; Grassi, 2003; Shibuya, 2003). Therefore, a further aim of this 
study was to ascertain local tissue oxygenation (TSI%) and oxygen extraction 
(deoxyhaemoglobin) at the site of tissue under consideration (Vastus lateralis), 
using near–infrared spectroscopy (NIRS) in addition to measurement of pulmonary 
whole body V02. 
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2. Maximal aerobic performance 
Theoretically, n-3 PUFA fatty acid supplementation may enhance the delivery of 
oxygen when an individual is placed under conditions of increased O2 demand, and 
may improve maximal aerobic performance (Zebrowska et al, 2014; Walser & 
Stebbins, 2008). Therefore, this study aimed to examine the effect of n-3 PUFA 
supplementation on maximal aerobic performance 2OV

peak, Powermax, HRmax and 
HR relative to 2OV

max 2OV
 / HRmax. 
 
3. Integrated dietary intervention  
Previous studies that have examined the effect of n-3 PUFA supplementation on 
physiological parameters and exercise performance are lacking control regarding 
the background diet of participants.  Over the past century the human diet has 
become enriched with the intake of n-6 PUFA linoleic acid (LA, 18:2 n-6) with a 
reduction in intake of alpha linolenic acid (ALA, 18:3 n-3 PUFA). Higher dietary LA 
intake has led to a change in the ratio of LA: ALA in the human diet from our 
evolutionary intake (observed in animals) of 2:1 to approximately 15:1 (Simpoloulos 
1991). The Animal and human studies already discussed have demonstrated dietary 
n-6 and n-3 PUFA can alter cellular metabolism and mechanisms. EPA also 
competes with the same desaturase enzyme in the cyclo-oxygenase pathway as 
AA resulting in the production of less inflammatory mediators (Calder 2007).  
Enriched dietary intakes of LA may interfere with the metabolism of ALA into EPA. 
Therefore, the lowering of n-6 PUFA could possibly augment the benefits of parallel 
n-3 PUFA fatty acid supplementation. Ghosh et al, (2007) fed young male pigs with 
one of three diets that differed in n-6: n-3 PUFA ratio: 1) low LA & ALA b) Low LA & 
High ALA c) High LA & High ALA. The cardiovascular benefits of ALA were only 
observed when LA was reduced concurrently. As far as we are aware, few studies 
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have examined a dietary manipulation to lower n-6 PUFA intake in humans. 
MacIntosh et al. (2013), examined an average n-3, low n-6 PUFA diet (L6) and a 
high n-3, low n-6 PUFA diet (H3-L6) on EPA, DHA incorporation into erythrocytes. 
It was found that both the L6 and H3-L6 diets reduced erythrocyte n-6 PUFA content 
but L6 did not influence AA content. EPA and DHA increased in both L6 and H3-L6 
however, H3-L6 increased EPA and DHA significantly more than L6, and reduced 
AA. The changes were attributed to increased consumption and therefore increased 
competition of n-3 EPA and DHA for metabolism. It is possible that a low n-6 PUFA 
dietary intake will augment EPA and DHA incorporation and lower AA desaturation. 
Therefore, a further aim of this study was to create an 8-week integrated dietary 
intervention designed to achieve reductions in background dietary n-6 PUFA whilst 
increasing n-3 PUFA (with supplementation) in the fish oil (FO) treatment group. In 
order to maintain a double blind design, a placebo dietary intervention that did not 
change n-6 PUFA dietary fatty acid intake was designed for the placebo group.  
It was hypothesized that whole body O2 cost ( 2OV
 ) and tissue oxygen extraction 
(deoxy-HHb), HR and BP would be lower in the high n-3 PUFA/ low n-6 PUFA group 
at each submaximal cycling workload in comparison to the placebo group.  In 
addition, it was hypothesized that FO would increase tissue saturation index (TSI 
%), 2OV










18 well trained healthy male competitive road cyclists/ triathletes (well-trained was 
defined as having been involved in cycling training ≥ 6 hours per week for the past 
12 months) aged 44.3 ± 9.5 years participated in the study. 3 participants did not 
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complete the study due to lack of time availability. The exclusion criteria used in 
order to eliminate factors that may have affected cardiovascular parameters were 
as follows: evidence of hemodynamic or cardiovascular dysfunction, cigarette 
smoking, diabetes or impaired regulation of glucose, inflammatory or immune 
dysfunction and consumption of more than 2 fish containing meals per week. All 
participants reported they were not taking fish oil supplements, or had any allergies 
to fish/ soy or vitamin E related products. The participants were competitive road 
cyclists or triathletes competing at club level (n = 10) or cyclists training regularly for 
the past 12 months (≥ 6 hours of cycling per week) (n = 6). The well-trained status 
of this group ensured less variation in muscular fatigue during peak O2 consumption 
testing, (Bassett & Hawley 2000). Data collection was carried out over a 6-month 
period. Participant data for age, height, body mass, 2OV

peak, resting heart rate (HR), 
resting blood pressure (BP) and sum of 7 skinfolds (Jackson and Pollock, 1978) are 
presented in table 5.3. The study was approved by the University of Kent Research 
Ethics Advisory Group (REAG). 
 
Experimental design  
Participants were randomly allocated in a counterbalanced double blind manner to 
two independent groups. Group 1 (FO n = 7) completed 8-weeks supplementation 
of n-3 PUFA combined with a dietary manipulation to lower background n-6 PUFA. 
Group 2 (SO n = 8) completed 8 weeks’ supplementation with organic soy oil 
(placebo) combined with a placebo dietary manipulation designed to maintain the 
participant’s habitual n-6 PUFA intake, treatments were double blind. Participants 
visited the laboratory on four occasions, with a minimum of 7-days rest between visit 
1, familiarity trial and visit 2, pre-supplementation experimental trial. The 8-week 
supplementation and dietary manipulation treatment began on the day following visit 
2. Visit 3 occurred 4 weeks into the supplementation period (halfway point blood 
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sampling), Visit 4, (post-supplementation experimental trial), occurred at the end of 
the 8-week supplementation period. On visits 2, 3 and 4 resting venous blood 
samples were collected in order to quantify the participant’s’ n-3 PUFA and n-6 
PUFA status. This was to establish if there was a dose response relationship in 
tissue incorporation of n-3 PUFA over time. In addition, a dry blood spot (DBS) 
sample was collected at the same time in order to examine the validity of DBS 
sampling in comparison to the traditional venous RBC erythrocyte method (see 
chapter 4 and appendix 1 for more detail on blood sampling methods and analysis).  
 
Figure 5.1. A schematic diagram illustrating the experimental protocol  
 
 
Participants reported to the laboratory in a euhydrated and 2 hour fasted state, 
having abstained from caffeine, alcohol and exercise for 24 hours. Participants 
attended each visit at the laboratory at a similar time of day.  
 
Visit 1  
All Participants completed an informed consent form and a medical questionnaire. 
Participants then completed a familiarity trial according to the procedures detailed 
in experimental trials 2 and 4 (pre/ post supplementation). In addition, participants 
were instructed how to complete a 7-day diet record to be submitted via email to the 
experimenter the day prior to visit 2. A 15-minute discussion covered details 
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regarding how to record dietary intake using weights, household measures and 
portion sizes. A detailed example of what a complete food record should look like 
was also provided in accordance with recommendations for improving food record 
accuracy (Kolar et al., 2005). In addition, participants were asked to provide a list of 
other commonly consumed meals and snacks that may not have been included in 
the 7-day recording period. 
 
Visits 2 and 4 
Pre supplementation and post supplementation experimental procedures 
 
Participants adjusted the Lode cycle ergometer (Excalibur sport version 2 Lode BV 
Groningen, Netherlands); all bike settings were recorded and repeated in the post 
supplementation test. Following a 10 min seated rest, participant’s age, height, body 
mass, resting heart rate (Polar RS400 watch and wear link) and resting blood 
pressure (Tango + stress BP SunTech Medical. Inc. US) were recorded.  
 
Pre-test blood samples were then collected: A 7ml blood sample was taken from the 
participant’s antecubital vein in the forearm in a heparinized EDTA vacutainer for 
the determination of erythrocyte fatty acid status. 2 x 10µl fingertip capillary samples 
were collected from participants using an accucheck needle for the analysis of 
resting whole blood lactate and blood glucose levels (Biosin C-Line EKF 
Diagnostics). The second 10µl finger prick blood sample was applied to a Guthrie 
absorbent filter card to determine the validity of this method compared to traditional 
venous isolated erythrocyte methods of analysis (see chapter 4). 
 
Muscle oxygenation was assessed using a Near Infrared Spectrophotometer (NIRS) 
(Oxymon Mk III Artinis Medical Systems BV, Netherlands). NIRS is a continuous 
 108 
non-invasive optical method that emits continuous wavelengths of 780 and 850-nm  
on the vastus lateralis for the measurement of relative concentration changes in 
tissue oxygenated haemoglobin (O2Hb), and deoxygenated haemoglobin (HHb) 
during exercise (Ryan et al, 2012). The NIRS derived HHb signal measures changes 
in muscle microvascular deoxygenation reflecting the relationship between local 
muscle O2 delivery and muscle O2 utilization at the site of optode placement 
(DeLorey et al, 2003). By definition, [O2Hb] and [HHb] should exist in equilibrium, 
an increase in O2Hb and a decrease in HHb is evidence of improved oxygenation, 
this would be the case if regional blood volume remained constant. However, 
measurement of O2Hb is complicated during exercise due to its reflection of regional 
arterial blood flow (which is mostly oxygenated), whereas the O2Hb signal  reflects 
changes in O2 extraction therefore is unaffected by changes in arterial blood flow 
(Grassi et al, 2003; Kowalchuk et al, 2002) Therefore HHb and TSI% were used for 
analysis. 
The NIRS optode was placed 10cm above the lateral epicondyle on the participant’s 
vastus lateralis with transmitters-receptor probes interspaced by 4.0 cm. The optode 
was taped into position and covered with a bandage to prevent contamination from 
ambient light; the sampling frequency was set to 10 Hz.  A baseline measure of 
resting muscle oxygenation was taken for 2 minutes prior to starting the 4-stage 
submaximal exercise test, data was recorded continuously throughout. Mean 
minute values were analysed (taken from the final minute of the baseline measure 
and from the 4th to 5th minute of each submaximal exercise bout at 100 W, 125 W, 






4 stage submaximal cycling test  
 
Following a standardized warm up at 100 watts for 10 minutes, participants 
completed a series of 4 x 7-minute sub-maximal cycling bouts at 100 W, 125 W, 150 
W, 175 W, at a self-selected cadence on a cycle ergometer. Average cadence for 
each work rate was recorded and participants were asked to repeat the same 
cadence in their post-test (visit 4).  Participants rested passively for 5 minutes 
between each stage. For each of the 4 exercise bouts, HR and expired gases were 
collected during minutes 4-5 in a non-diffusible mylar Douglas bag (Hans Rudolph 
Inc., KS, USA) and analysed (Servomex 5200, Servomex, Crowborough, UK) 
according to the procedures of Hopker et al, (2012). Rating of perceived exertion 
(RPE) (Borg, 1970) was recorded at 4.5 minutes into each exercise bout and blood 
pressure was measured between minutes 6-7.  A fingertip capillary blood sample 





Participants rested for 15 minutes following the 4 stage submaximal test then 
completed another standardized 10-minute warmup at 100 W at a self-selected 
cadence. Participants then performed an incremental ramp protocol at the ramp rate 
of 30 W∙min -1 on a cycle ergometer for the determination of 2OV

 peak. Heart rate 
and breath-by-breath oxygen uptake ( 2OV
 ) were recorded continuously throughout 
the test (Cortex Metalyser 3B Biophysik, GmbH, Leipzig, Germany). RPE (Borg 
1970) was recorded at 1-minute intervals, pre and post-test lactate samples were 





Supplementation protocol  
Participants in the FO group consumed 2600mg of EPA and 1800mg of DHA n-3 
PUFA supplementation by consuming 8 soft gel capsules per day (based on the 
manufacturer’s analytical content) for 8 weeks (Ultimate Omega lemon soft-gels, 
Nordic Naturals, Watsonville CA). Participants in the SO (placebo) group consumed 
8 soft gel capsules per day of organic soybean oil for 8 weeks containing 438.4 mg 
total omega 3, 4052.8 mg total omega 6, 2023.2 mg, total omega 9 and 25.6mg of 
omega 3 from fish oil used as a mask. Participants were instructed to consume the 
soft - gels 3 times per day 3, 3, and 2 with evenly spaced meals. The relative 
composition of fatty acids in the FO capsules was quantified by carrying out a batch 
test. Capsules were analysed by gas chromatography and mass spectrometry in the 
centre for analytical chemistry at Loughborough University.  
Table 5.1 Relative composition of EPA and DHA in each individual FO capsule as 
Determined by Gas Chromatography compared to the manufacturers label 
Fatty Acids Manufacturer mg/ g Analytical mg/ g  Recovery  
EPA 325 257 79% 
DHA 225 171 76% 
 
Dietary manipulation to lower n-6 PUFA levels  
A 7-day food record and list of additional frequently consumed meals and snacks 
was completed by each participant and emailed to the researcher 1 day prior to 
visit 2. The diet record was analysed using Nutritics University Edition (2014). 
Participant diets were screened for high n-6 PUFA containing items. Individual 
foods/ snacks and drinks high in n-6 PUFA were substituted with low n-6 PUFA 
options designed to minimize dietary intake of linoleic acid (LA) and arachidonic 
acid (AA), whilst simultaneously increasing n-3 PUFA intake through 
supplementation. The aim was to achieve a reduction of daily n-6 PUFA levels to 
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the target of <2.5% of energy intake, in accordance with evolutionary levels 
outlined by Macintosh et al, (2012).  
 
Participants in the SO placebo group were instructed to make a few minor dietary 
changes to create a placebo diet designed to maintain participant’s usual n-6 
PUFA intake for 8 weeks. This created a control condition suitable for double 
blinding.  The substituted 7-day diet records were returned to participants and they 
were asked to follow a similar diet throughout the supplementation period, this was 
based on assumption that participants would adhere to the controlled diet. 
Participants revisited the researcher halfway through the supplementation period 
to discuss any issues they were having with adherence. Erythrocyte fatty acids 
levels were analysed to provide evidence of supplementation. Table 5.2 displays 
participant total dietary intake of n-3/ n-6 PUFA in the FO and SO group before the 
dietary manipulation was applied, compared to the diet they were asked to follow 
during the supplementation period (Mean ± SD).  
 
Table 5.2 participant total kcal intake and n-3/ n-6 PUFA levels in the FO and SO 
group before and after the dietary intervention was applied (Mean ± SD). 
 Pre-dietary Manipulation Post-dietary Manipulation  
Group Total  Kcal*      n-3 (g)      n-6 (g) Total  kcal*      n-3 (g)      n-6 (g) 
FO  
SO 
2393 ± 424 
2820 ± 449 
0.9 ± 0.5 
1.7 ± 0.7 
9.4 ± 4.2 
11.7 ± 6.9 
2221 ± 348 
2740 ± 436 
0.7 ± 0.2 
1.7 ± 0.8 
4.8 ± 1.7 
11.8 ± 7.0 
 
* Data is expressed as mean values based on an average dietary intake of 7 days.  
 
Visit 3  
Half way through the 8-week supplementation period, participants returned to the 
laboratory for a venous blood sample and fingertip capillary blood sample (DBS). 
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Participants were asked if they have been in good health status and were adhering 
to their dietary changes and were happy to continue the study.  
 
Visit 4  
Participants attended the laboratory the day following the end of their eight-week 
supplementation period for post supplementation testing using the same procedures 
as detailed in visit 2.  
Red blood cell isolation and DBS procedures  
Please refer to chapter 4 and appendix 1 for detailed procedures for RBC and DBS 
preparation and analysis. Fatty acid analysis was carried out using gas 
chromatography and mass spectrometry in the centre for analytical chemistry at 
Loughborough University.  
Statistical Analysis 
Two - way repeated measures mixed ANOVAs were employed to determine any 
differences in Erythrocyte fatty acid content for the fatty acids of interest (LA, AA, 
EPA, DHA, total n-6 PUFA, total n-3 PUFA, total saturated and total 
monounsaturated FA) at three time points pre supplementation, halfway and eight 
weeks post supplementation between groups.  
Three - way repeated measures mixed ANOVAs were carried out to examine 
differences in physiological variables: 2OV

, TSI%, deoxy-HHb, HR, DBP, SBP, and 
MAP (calculated using the formula MAP = SBP + 2 (DBP) / 3) during the 4 stage 
submaximal cycling bouts, between groups, pre to post supplementation. Baseline 




Two-way repeated measures mixed ANOVAs were carried out to examine 
differences in 2OV

peak, powermax, HRmax, 2OV
 /HRmax, whole blood lactate and 
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glucose, pre to post the intervention period between groups. Prior to analysis all 
data residuals were checked for outliers by inspection of boxplots and normal 
distribution using the Shapiro Wilk test p = <0.05). With regard to NIRS analysis, the 
participant number reduced in the SO group to N = 6 due to NIRS measurement 
error. Specifically no post supplementation recording was obtained for participant 1 
and no pre supplementation recording was obtained for participant 15. Therefore, 
data for both participants was not included for TSI% and deoxy-HHb analysis. 
There were two extreme outliers as determined by boxplots (3 box lengths from 
the edge of the box) for both TSI % and deoxy-HHb data. The outliers were left in 























No differences were observed between groups for age, height, body mass, sum of 
7 skinfolds or resting values for HR, BP, lactate, glucose, 2OV

peak and max power 
(see table 5.3). 
Table 5.3 Participant characteristics 
Participant characteristics  FO (n = 7) SO (n = 8) p-value  
Age (y) 48 ± 6 41 ± 11 0.144 
Height (cm) 176.1 ± 5.5 181.5 ± 7.4 0.142 
Body mass (kg) 74.6 ± 10.0 79.1 ± 6.7 0.316 
2OV

 max ml/ min/ kg 61.7 ± 9.0 56.0 ± 6.9 0.187 
Power Max (W) 380 ± 39.9 379 ± 43.8 0.982 
HR (bpm) 55 ± 8 57 ± 6 0.537 
Systolic BP (mm Hg) 128.4 ± 11.0 124.8 ± 15.2 0.606 
Diastolic BP (mm Hg) 82.1 ± 9.8 77.8 ± 11.2 0.438 
Lactate (mmol/L) 1.7 ± 0.4 1.8 ± 0.6 0.578 
Glucose (mmol/L) 4.3 ± 0.2 4.3 ± 0.4 0.863 
Sum of 7 skinfolds (mm) 
Energy Intake (kcal/d) 
Total n-3 PUFA (g) 
Total n-6 PUFA (g) 
Proportion of n-6 to n-3 (g) 
82.5 ± 33.9 
2393 ± 424 
0.9 ± 0.5 
9.4 ± 4.2 
10.4 
104.7 ± 16.7 
2820 ± 449 
1.7 ± 0.7 




Note: Data are expressed as mean (± SD) 
An independent samples t-test elicited no significant differences in participant 











Changes in erythrocyte fatty acid profile over the course of the supplementation/ 
dietary intervention  
For a comprehensive view of all fatty acid values derived from RBC erythrocyte 
analysis please see table 5.4 and 5.5. Pre-supplementation erythrocyte % fatty 
acid content (LA, AA, EPA, DHA, total n-6 PUFA, total n-3 PUFA and the ratio of 
total n-6 PUFA to total n-3 PUFA) was not different between treatment groups. 
The following is a summary of the main statistical findings. 
 
Erythrocyte LA% content (n-6 PUFA) 
A two way mixed ANOVA elicited a significant main effect of time, F(2, 26) = 7.85, 
p = 0.002, partial η2 = 0.38 and group, F(1, 13) = 7.018, p = 0.020, partial η2 = 0.35. 
There was a significant interaction between time and group, F(2, 26) = 6.92, p = 
0.004, partial η2 = 0.35, on erythrocyte LA % content. 
A one way repeated measures ANOVA on each treatment group found the 
supplementation and dietary intervention elicited significant changes in LA content 
over time in the FO group F(2, 12) = 14.16, p = 0.001, partial η2 = 0.70 with no 
significant change observed in the SO group, F(2, 14) = 1.32, p = 0.29, partial η2 = 
0.16 . Pairwise comparisons in the FO group showed there was an overall decrease 
in LA concentration pre, (15.17 ± 1.92) to four weeks (11.74 ± 0.92) and to (11.98 ± 
1.29) eight weeks post intervention. Post hoc analysis with a Bonferroni adjustment 
revealed that LA content was significantly decreased from pre intervention to four 
weeks 3.43 (95% CI, 0.78, 6.07), p = 0.016, and from pre intervention to eight weeks 
post intervention 3.18 (95% CI, 1.38, 4.99), p = 0.003, But not from four weeks to 
eight weeks post intervention 0.24, (95% CI -2.78, 2.31), p = 1.000.  
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Independent samples t–tests show LA was significantly lower in the FO group than 
the SO group at four weeks, -2.94 (95% CI, -4.86 to 1.02), t(13) = -3.305, p = 0.006 
and at eight weeks, -3.91 (95% CI, -6.03 to -1.79), t(13) = -3.98, p =0.002.  
 
Erythrocyte AA% content (n-6 PUFA) 
 
A two way mixed ANOVA elicited a significant main effect of time F(2, 26) = 8.58, p 
= 0.001, partial η2 = 0.38, and no significant main effect of group F(1, 13) = 2.02, p 
= 0.18, partial η2 = 0.14. There was a significant interaction between time and group, 
F(2, 26) = 15.60, p <0.001, partial η2 = 0.55, on erythrocyte AA % content.  
A one way repeated measures ANOVA on each treatment group shows the 
supplementation and dietary intervention elicited significant changes in AA content 
over time in the FO group, F(2, 12) = 16.30, p <0.001, partial η2 = 0.73, with no 
significant change observed in the SO group, F(2, 14) = 0.85, p = 0.45, partial η2 = 
0.11. Pairwise comparisons in the FO group showed there was an overall decrease 
in AA concentration pre (19.99 ± 2.53) to four weeks (17.29 ± 3.45) and to (15.39 ± 
1.19) eight weeks (post intervention). Post hoc analysis with a Bonferroni 
adjustment revealed that AA content was significantly decreased from pre 
intervention to four weeks 2.70 (95% CI 1.02, 4.39), p = 0.006, and from pre 
intervention to eight weeks post intervention 4.60 (95% CI, 2.05, 7.16), p = 0.003, 
but not from four weeks to eight weeks post intervention 1.90, (95% CI -1.55, 5.35], 
p = 0.361. 
Independent samples t–tests show AA was significantly lower in the FO group than 
the SO at eight weeks, -4.22 (95% CI, -6.50 to -1.94), t(10.09) = -.4.12, p = 0.002, 




Erythrocyte EPA% content (n-3 PUFA) 
 
A two way mixed ANOVA elicited a significant main effect of time F(2, 26) = 39.98, 
p <0.001, partial η2 = 0.76 and group F(1, 13) = 32.54, p <0.001, partial η2 = 0.72. 
There was a significant interaction between time and group, F(2, 26) = 35.99, p 
<0.001, partial η2 = 0.74, on erythrocyte EPA % content. 
A one way repeated measures ANOVA on each treatment group shows the 
supplementation and dietary intervention elicited significant changes in EPA content 
over time in the FO group F(2, 12) = 40.08, p <0.001, partial η2 = 0.87, with no 
significant change observed in the SO group, F(2, 14) = 0.67, p = 0.45, partial η2 = 
0.88. Pairwise comparisons in the FO group showed there was an overall increase 
in EPA concentration pre, (1.30 ± 0.20) to four weeks (4.66 ± 1.05) and to (5.85 ± 
1.68) eight weeks (post intervention). Post hoc analysis with a Bonferroni 
adjustment revealed that EPA content was significantly increased from pre 
intervention to four weeks 3.36 (95% CI 2.07, 4.65), p <0.001, and from pre 
intervention to eight weeks post intervention 4.55 (95% CI, 2.48, 6.63), p = 0.001, 
but not from four weeks to eight weeks post intervention 1.19, (95% CI -0.55, 2.94), 
p = 0.198. 
Independent samples t–tests found EPA was significantly higher in the FO group 
than the SO group at four weeks 2.86 (95% CI, 1.79 to 3.94), t(13) = 5.74, p <0.001, 








Erythrocyte DHA% content (n-3 PUFA) 
 
A two way mixed ANOVA elicited no significant main effect of time F(2, 26) = 0.97, 
p = 0.39, partial η2 = 0.069 or group F(1, 13) = 3.09, p = 0.10, partial η2 = 0.192. 
There was a significant interaction between time and group, F(2, 26) = 8.99, p = 
0.001, partial η2 = 0.41, on erythrocyte DHA % content. 
A one way repeated measures ANOVA on each treatment group shows the 
supplementation and dietary intervention elicited significant changes in DHA content 
over time in the FO group F(2, 12) = 5.22, p = 0.023, partial η2 = 0.47, with no 
significant change observed in the SO group, F(2, 14) = 4.41, p = 0.072, partial η2 
= 0.39. Pairwise comparisons in the FO group showed there was an overall increase 
in DHA concentration pre, (4.97 ± 2.82) to four weeks (7.12 ± 2.86) and to (9.35 ± 
1.12) eight weeks post intervention. Post hoc analysis with a Bonferroni adjustment 
revealed that DHA content significantly increased from pre intervention to eight 
weeks post intervention 4.38 (95% CI, 0.51, 8.24), p = .029, but not pre intervention 
to 4 weeks 2.147 (95% CI, -3.58, 7.874), p = 0.79, or from 4 weeks to 8 weeks post 
intervention 2.23, (95% CI, -1.20, 5.66), p = 0.23. 
Independent samples t-tests show DHA was significantly higher in the FO group 
than the SO group at week eight, 5.34 (95% CI, 3.09 to 7.59), t(13) = 5.12, p  <0.001, 









Erythrocyte total n-6 PUFA content  
 
A two way mixed ANOVA elicited a significant main effect of time F(2, 26) = 16.627, 
p <0.001, partial η2 = 0.561 and group F(1, 13) = 16.48, p = 0.001, partial η2 = 0.56. 
There was a significant interaction between time and group, F(2, 26) = 14.91, p 
<0.001, partial η2 = 0.53, on erythrocyte total n-6 PUFA % content 
A one way repeated measures ANOVA on each treatment group shows the 
supplementation and dietary intervention elicited significant changes in total n-6 
PUFA content over time in the FO group F(2, 12) = 21.96, p <0.001, partial η2 = 
0.79, with no significant change observed in the SO group, F(2, 14) = 1.74, p = 0.21, 
partial η2 = 0.20. Pairwise comparisons in the FO group showed there was an 
overall decrease in n-6 PUFA concentration pre, (40.27 ± 1.85) to four weeks (33.02 
± 4.82) and to (30.75 ± 1.29) eight weeks (post intervention). Post hoc analysis with 
a Bonferroni adjustment revealed that total n-6 PUFA content significantly 
decreased from pre intervention to four weeks 7.23 (95% CI, -2.78, 11.73), p = 
0.005, and pre intervention to eight weeks 9.52 (95% CI,  6.15, 12.89), p <0.001, 
but not from four weeks to eight weeks post intervention 2.26, (95% CI, -4.19, 8.71), 
p = 0.88. 
Independent samples t-tests show total n-6 PUFA was significantly lower in the FO 
group than the SO group at four weeks, -5.74 (95% CI, -10.52 to -.97), t(13) = -2.60, 







Erythrocyte total n-3 PUFA content (n-3) 
 
A two way mixed ANOVA elicited a significant main effect of time F(2, 26) = 7.61, p 
= 0.002, partial η2 = 0.37 and group  F(1, 13) = 18.12, p = 0.001, partial η2 = 0.58. 
There was a significant interaction between time and group, F(2, 26) = 19.14, p  
<0.001, partial η2 = 0.60, on erythrocyte total n-3 PUFA % content. 
A one way repeated measures ANOVA on each treatment group shows the 
supplementation and dietary intervention elicited significant changes in total n-3 
PUFA content over time in the FO group F(2, 12) = 17.02, p  <0.001, partial η2 = 
0.74, with no significant change observed in the SO group, F(2, 14) = 3.99, p = 0.42,  
partial η2 = 0.36. Pairwise comparisons in the FO group showed there was an 
overall increase in n-3 PUFA concentration pre, (10.43 ± 2.53) to four weeks (16.18 
± 2.99) and to (20.13 ± 2.83) eight weeks (post intervention). Post hoc analysis with 
a Bonferroni adjustment revealed that total n-6 PUFA content significantly increased 
from pre intervention to eight weeks 9.70 (95% CI, 4.52, 14.88), p = 0.003, but not 
pre intervention to four weeks 5.75 (95% CI, -0.59, 12.08), p = 0.74, and not from 
four weeks to eight weeks 3.96, (95% CI -0.91, 8.83), p = 0.11. 
Independent samples t-tests show n-3 PUFA was significantly higher in the FO 
group than the SO group at week four, 3.67 (95% CI, 0.13 to 7.22), t(13) = 2.24, p 








Erythrocyte Proportion of n-6 PUFA to n-3 PUFA (n6/ n-3) 
 
A two way mixed ANOVA elicited a significant main effect of time F(2, 26) = 6.515, 
p = 0.005 partial η2= 0.334 and group F(1, 13) = 11.37, p = 0.005, partial η2 = 0.466. 
There was a significant interaction between time and group, F(2, 26) = 17.59, p  
<0.001 partial η2 = 0.575, on erythrocyte proportion of n-6 to n-3 PUFA content. 
A one way repeated measures ANOVA on each treatment group shows the 
supplementation and dietary intervention elicited significant changes in proportion 
of n-6 to n-3 PUFA content over time in the FO group F(2, 12) = 17.39, p <0.001, 
partial η2 = 0.74, with no significant change observed in the SO group, F(1.15, 8.05) 
= 5.64, p = 0.4, partial η2 = 0.45. Pairwise comparisons in the FO group showed 
there was an overall decrease in the proportion of n-6 to n-3 PUFA concentration 
pre, (4.12 ± 1.26) to four weeks (2.09 ± 0.46) and to (1.56 ± 0.30) eight weeks (post 
intervention). Post hoc analysis with a Bonferroni adjustment revealed that the 
proportion of n-6 to n-3 PUFA significantly decreased from pre intervention to 4 
weeks 2.03 (95% CI, 0.17, 3.90), p = 0.034, and from pre intervention to eight weeks 
2.56 (95% CI, 0.84, 4.28), p = 0.008, but not from 4 weeks to eight weeks 5.26, 
(95% CI -0.11, 1.16), p = 0.10. 
Independent samples t–tests show the proportion of n-6 to n-3 PUFA was 
significantly lower in the FO group than the SO group at week four, -1.25 (95% CI, 
-2.21 to -2.87), t(13) = -2.81, p = 0.015, and at week eight, -3.08 (95% CI, -4.24 to -
1.92), t(7.741) = -6.166, p <0.001. 





Table 5.4. Changes in erythrocyte fatty acid content (%) at week 0, week 4 and week 8 of the supplementation period 
 
Note: Data are expressed as means ± SD. *p < 0.05; **p < 0.01 two-way ANOVA interaction 
 
FO-pre FO-4 weeks FO-post SO-pre SO-4weeks SO-post p (time) p  (group) p  (time*group)
Methyl tetradecanoate   0.41 ± 0.08   0.38 ± 0.06   0.42 ± 0.13   0.35 ± 0.08   0.36 ± 0.06   0.28 ± 0.13 0.600 0.041 0.323
Methyl myristoleate   0.92 ± 0.28   1.12 ± 0.51   1.22 ± 0.41   1.10 ± 0.28   1.31 ± 0.51   1.28 ± 0.41 0.310 0.298 0.906
Methyl pentadecanate   0.19 ± 0.09   0.16 ± 0.11   0.25 ± 0.02   0.19 ± 0.09   0.22 ± 0.11   0.16 ± 0.02 0.818 0.642 0.029*
Methyl cis- 10 pentadecanoate   0.27 ± 0.25   0.39 ± 0.50   0.14 ± 0.24   0.28 ± 0.25   0.37 ± 0.50   0.70 ± 0.24 0.488 0.117 0.050
Hexadecanoic acid, methyl ester 24.28 ± 1.51 22.24 ± 3.10 23.32 ± 1.05 23.34 ± 1.51 23.03 ± 3.10 24.33 ± 1.05 0.112 0.608 0.225
cis-10-Heptadecenoic acid, methyl  0.41  ± 0.05   0.41 ± 0.14   0.49 ± 0.12   0.45 ± 0.05   0.51 ± 0.14   0.31 ± 0.12 0.445 0.756 0.062
Methyl stearate 13.31 ± 0.66 12.32 ± 2.38 12.60 ± 2.01 12.56 ± 0.66 12.23 ± 2.38 13.43 ± 2.01 0.498 0.999 0.518
9-Octadecenoic acid (Z)-, methyl ester   7.56 ± 0.85   6.90 ± 0.99   7.08 ± 0.51   7.08 ± 0.85   6.90 ± 0.99   7.54 ± 0.51 0.110 0.982 0.121
LA 15.17 ± 1.92 11.74 ± 0.92 11.98 ± 1.30 15.34 ± 1.92 14.69 ± 0.92 15.90 ± 1.30 0.002** 0.020 0.004**
gamma-Linolenic acid, methyl ester   0.05 ± 0.07   0.02 ± 0.03   0.00 ± 0.00   0.03 ± 0.07   0.04 ± 0.03   0.06 ± 0.00 0.715 0.431 0.062
ALA   0.27 ± 0.06   0.21 ± 0.05   0.20 ± 0.10   0.31 ± 0.06   0.28 ± 0.05   0.23 ± 0.10 0.106 0.181 0.663
 cis-11,14-Eicosadienoic acid, methyl   0.29 ± 0.10   0.33 ± 0.05   0.33 ± 0.06   0.22 ± 0.06   0.41 ± 0.05   0.32 ± 0.06 0.441 0.965 0.407
 8,11,14-Eicosatrienoic acid, methyl e   2.02 ± 0.61   1.39 ± 0.43   1.28 ± 0.23   2.15 ± 0.61   1.94 ± 0.43   2.07 ± 0.23 0.002** 0.132 0.027*
AA 19.99 ± 2.53 17.29 ± 3.45 15.39 ± 1.19 18.91 ± 2.53 19.19 ± 3.45 19.61 ± 1.19 0.001** 0.178 <0.001**
 EPA   1.30 ± 0.20   4.66 ± 1.05   5.85 ± 1.68   1.55 ± 0.20   1.79 ± 1.05   1.62 ± 1.68 <0.001** <0.001** <0.001**
DPA   3.89 ± 0.42   4.19 ± 0.95   4.74 ± 0.59   3.42 ± 0.42   3.45 ± 0.95   3.62 ± 0.59 0.035* 0.004 0.267
DHA   4.97 ± 2.82   7.12 ± 2.86   9.34 ± 1.12   6.76 ± 2.82   6.98 ± 2.86   4.01 ± 1.12 0.394 0.102 0.001**
15-Tetracosenoic acid, methyl ester,   1.99 ± 1.17   2.55 ± 1.18   3.63 ± 1.93   2.33 ± 1.17   3.83 ± 1.19   1.92 ± 1.93 0.198 0.948 0.517
cis-7,10,13,16-Docosatetraenoate   2.70 ± 0.68   2.21 ± 0.70   1.74 ± 0.40   2.50 ± 0.68   2.47 ± 0.70   2.63 ± 0.40 0.016* 0.399 0.002**
Total saturated 38.19 ± 1.99 35.10 ± 5.44 36.58 ± 2.35 36.45 ± 1.99 35.83 ± 5.44 38.20 ± 2.35 0.159 0.825 0.303
Total Monosaturated 11.15 ± 1.01 11.01 ± 2.41 12.56 ± 1.58 11.23 ± 1.01 12.93 ± 2.41 11.74 ± 1.58 0.216 0.472 0.066
Total n -6 40.27 ± 1.85 33.02 ± 4.82 30.75 ± 1.29 40.31 ±1.85 38.76 ± 4.82 40.61 ± 1.29 <0.001** <0.001** <0.001**
Total n -3  10.43 ± 2.53 16.18 ± 3.00 20.13 ± 2.83 12.04 ± 2.53 12.50 ± 3.00†   9.48 ± 2.83 0.002** <0.001** <0.001**
Total n -6/ total n -3 4.12   ± 1.17  2.09  ± 0.43  1.56  ± 0.28   3.52 ± 0.88  3.34  ± 1.09   4.64 ± 1.37 0.005** 0.005** <0.001**
Total saturated 38.19 ± 1.99 35.09 ± 5.44 36.58 ± 2.35 33.02 ± 9.19 33.18 ± 7.99 35.10 ± 9.61 0.351 0.657 0.257




Table 5.5 Changes in erythrocyte fatty acid content % (main fatty acids of focus) at pre, week 4 and week 8 of the supplementation period 
                      2 way mixed ANOVA main effects 
    Week 0 (pre) Week 4 Week 8 (post) p (time) p (group) p (time*group) 
LA FO ‡‡ 15.17 ± 1.92 11.74 ± 0.92  11.98 ± 1.30        
LA SO 15.34 ± 1.92  14.69 ± 0.92 †† 15.90 ± 1.30 †† 0.002** 0.02 0.004** 
AA FO ‡‡ 19.99 ± 2.53 17.29 ± 3.45 15.39 ± 1.19     
AA SO 18.91 ± 2.53 19.19 ± 3.45 19.61 ± 1.19 †† 0.001** 0.18 < 0.001** 
 EPA FO ‡‡   1.30 ± 0.20   4.66 ± 1.05    5.85 ± 1.68    
EPA SO   1.55 ± 0.20   1.79 ± 1.05 ††   1.62 ± 1.68 †† <0.001** <0.001** <0.001** 
DHA FO ‡   4.97 ± 2.82   7.12 ± 2.86   9.34 ± 1.12     
DHA SO   6.76 ± 2.82   6.98 ± 2.86   4.01 ± 1.12 †† 0.39 0.10 0.001** 
Total n-6 FO ‡‡ 40.27 ± 1.85 33.02 ± 4.82  30.75 ± 1.29     
Total n-6 SO  40.31 ±1.85 38.76 ± 4.82 †† 40.61 ± 1.29 †† <0.001** 0.001** <0.001** 
Total n-3  FO ‡‡ 10.43 ± 2.53 16.18 ± 3.00  20.13 ± 2.83     
Total n-3   SO 12.04 ±2.53 12.50 ± 3.00 ††   9.48 ± 2.83 †† 0.002** 0.001** <0.001** 
n-6/ n-3 FO ‡‡ 4.12   ± 1.17 2.09   ± 0.43 1.56   ± 0.28    
n-6/ n-3 SO  3.52   ± 0.88 3.34   ± 1.09 † 4.64   ± 1.37 †† 0.005** 0.005** <0.001** 
Sat FO 38.19 ± 1.99 35.09 ± 5.44 36.58 ± 2.35       
Sat SO 33.02 ± 9.19 33.18 ± 7.99 35.10 ± 9.61 0.351 0.657 0.257 
Mono FO 11.15 ± 1.01 11.01 ± 2.41  12.56 ± 1.58    
Mono SO 11.23 ± 1.80 12.93 ± 1.61 11.74 ± 1.03 0.188 0.597 0.333 
Note: Data are expressed as means ± standard deviation  
*p < 0.05; **p < 0.01, two way mixed ANOVA main effects  
‡p < 0.05; ‡‡p < 0.01, one way repeated measures ANOVA main effect of time within groups 
†p < 0.05; ††p < 0.01, Independent t-test comparison between groups at wk. 0, wk. 4, wk. 8 . Wk = week of 
supplementation 
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The four stage submaximal power test  
2OV
  (L/min) cost of cycling at four submaximal power stages 
 
There was a significant main effect of power level, F(3, 39) = 40.17, p < 0.001, partial 
η2 = 0.76. There was no significant main effect of pre/ post, F(1, 13) = 2.06, p = 
0.18, partial η2 = 0.14 or group, F(1, 13) = 0.309, p = 0.59, partial η2 = 0.023. There 
was no significant two way interaction between power level and group, F(3, 39) = 
0.82, p = 0.49, partial η2 = 0.06, pre/post and group, F(1, 13) = 0.60, p = 0.45, partial 
η 2 = 0.04, or power level and pre/post, F(3, 39) = 0.656, p = 0.57, partial η2 = 0.048. 
Furthermore, there was no significant three way interaction between group, pre/post 
and power level, F(3, 39) = 0.829, p = 0.49, partial η2 = 0.060 (see table 5.6 and 
figure 5.2).  
 
Table 5.6 2OV
  (L/min) values pre and post the intervention in each group  
at each power level 
 Stage  Group  Pre Post  N= 
100 W FO  1.85 ± 0.24 1.66 ± 0.08 7 
 SO 1.89 ± 0.44 1.82 ± 0.44 8 
125 W FO  2.32 ± 0.26 1.98 ± 0.11 7 
 SO 2.07 ± 0.32 2.24 ± 0.54 8 
150 W FO  2.41 ± 0.58 2.01 ± 0.25 7 
 SO 2.48 ± 0.42 2.30 ± 0.60 8 
175 W FO  2.73 ± 0.47 2.47 ± 0.15 7 
 SO 2.71 ± 0.36 2.44 ± 0.65 8 














  (L/ min-1) values pre and post the intervention in  FO and SO group.  
Data is expressed as means ± SD. 
 
Heart rate (bpm) at each submaximal power level  
There was a significant main effect of power level, F(1.39, 18.09) = 294.52, p 
<0.001, partial η2 = 0.96. There was no significant main effect of pre/ post, F(1, 
13) = 0.003, p = 0.960, partial η2 = <0.001, or group, F(1, 13) = 0.427, p = 0.53, 
partial η2 = 0.03. There was no significant two-way interaction between power 
level and group, F(1.39, 18.09) = 0.009, p = 0.968, partial η2 = 0.001, pre/post and 
group F(1, 13) = 0.20, p = 0.89, partial η2 = 0.002, or pre/post and power level 
F(2.59, 33.642) = 2.576, p = 0.078, partial η2 = 0.165. Furthermore, there was no 
significant three way interaction between group, pre/post and power level, F(2.59, 
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Table 5.7. HR (bpm) pre and post intervention in the FO and SO group at each 
power level (including resting measures) 
 
 Stage  Group  Pre Post  N 
Baseline FO 54.9 ± 7.74 54.4 ± 7.53 7 
 SO 57.2 ± 6.24 60.4 ± 6.53 8 
100 W FO  99.9   ±  9.2 103.6 ± 6.34 7 
 
SO 106.4 ± 15.6 104.5 ± 13.2 8 
125 W FO  109.1 ± 14.1 111.4 ± 6.32 7 
 
SO 113.4 ± 15.0 115.3 ± 20.3 8 
150 W FO  122.1 ± 9.7 119.8 ± 5.70 7 
 
SO 125.7 ± 17.1 124.0 ± 17.3 8 
175 W FO  134.5 ± 12.9 129.4 ± 6.57 7 
 
SO 135.5 ± 19.2 135.0 ± 18.3 8 














Figure 5.3 HR (bpm) values pre and post the intervention in FO and SO 
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Tissue saturation index (TSI %) for each power level of the four stage submaximal 
oxygen consumption test 
 
There was a significant main effect of power level, F(1.46, 16.04 ) = 13.01, p = 
0.001, partial η2 = 0.54. There was no significant main effect of pre/ post, F(1, 11 ) 
= 2.541, p = 0.139, partial η2 = 0.18 or group, F(1, 11 ) = 0.015, p = 0.90, partial 
η2 = 0.001. There was no significant two-way interaction between power level and 
group, F(1.46, 16.04) = 0.23, p = 0.72, partial η2 = 0.020,  pre/post and group, F(1, 
11) = 0.078, p = 0.79, partial η2 = 0.007 or power level and pre/ post F (1.85, 
20.38) = 0.15, p = 0.85, partial η2 = 0.013. Furthermore, there was no statistically 
significant three way interaction between group, pre/ post and power level, F(1.85, 
20.38) = 0.87, p = 0.43, partial η2 = 0.073 (see table 5.8 and figure 5.4). 
 
Table 5.8. TSI percentage pre and post the supplementation period in the FO and 
SO group at each power level 
 
Stage Group Pre  Post N 
Baseline FO 68.01 ± 4.43 68.45 ± 4.33 7 
 
SO 67.07 ± 3.61 70.50 ± 4.73 6 
100 W FO 65.16 ± 5.57 67.51 ± 5.29 7 
 
SO 65.37 ± 2.94 67.66 ± 5.66 6 
125W FO 64.99 ± 4.49 65.93 ± 6.20 7 
 
SO 63.83 ± 2.10 66.06 ± 4.57 6 
150 W FO 63.76 ± 5.62 64.94 ± 6.59 7 
 
SO 62.91 ± 2.01 64.82 ± 7.14 6 
175 W FO 61.16 ± 5.75 64.16 ± 6.08 7 
 
SO 60.90 ± 2.55 62.27 ± 7.96 6 




Figure 5.4 TSI% values pre and post the intervention in  FO and SO. 
 Data is expressed as means ± SD 
 
 
Deoxygenated haemoglobin deoxy - HHb for each power level of the four-stage 
submaximal oxygen consumption test. Data is minus baseline levels  
There was a significant main effect of power F(1.18, 12.98) = 16.02, p = 0.001, 
partial η2 = 0.59. There was no significant main effect of pre/ post, F(1, 11) = 2.10, 
p = 0.175, partial η2 = 0.16 or group, F(1, 11) = 0.35, p = 0.566, partial η2 = 0.31. 
There was no statistically significant two-way interaction between power level and 
group, F(1.18, 12.98) = 0.45, p = 0.55, partial η2 = 0.04, or pre/post and group, F(1, 
11) = 2.16, p = 0.17, partial η2 = 0.16. There was a statistically significant two-way 
interaction between power level & pre/ post, F (3, 33) = 3.303, p = 0.032, partial η2 
= 0.23. There was no statistically significant three way interaction between group, 
pre/ post and power level, F(3, 33) = 0.70, p = 0.56, partial η2 = 0.06 (see table 5.9 
and figure 5.5). Post-hoc follow up of the two-way power level and pre/post 
interaction was carried out using paired samples t-tests (with a Bonferroni 
correction) There were no significant  differences between pre and post HHb values 
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Table 5.9 deoxy-HHb pre and post supplementation in the FO and SO group at 
each power level  
 Stage  Group  Pre Post  N 
100 W FO  4.19 ± 4.61 1.67 ± 4.97 7 
 
SO 3.49 ± 9.06 4.50 ± 5.96 6 
125 W FO  5.23 ± 4.44 2.18 ± 3.24 7 
 
SO 5.31 ± 8.52 5.59 ± 6.63 6 
150 W FO  7.60 ± 5.78 3.03 ± 4.02 7 
 
SO 7.64 ± 9.70 7.17 ± 8.58 6 
175 W FO  10.48 ± 5.24 3.88 ± 4.37 7 
 
SO 10.40 ± 10.72 9.70 ± 9.05 6 
Data is expressed as means ± SD. Data for each power level is corrected to baseline calculated 
by: minute average during exercise minus minute average at baseline  
 
Table 5.10 Post Hoc paired samples t-test to examine differences in pre/ post 






Figure 5.5 deoxy- HHb values pre and post the intervention in FO and SO. 
 Data is expressed as means ± SD. Data for each power level is corrected to baseline calculated 
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Power output (W) pre and post intervention
FISH OIL SOY OIL
Pre/ post 
stage 
Mean  Standard 
deviation 
95% CI of the Difference 
Lower         Upper    
t df Significance 
(2 tailed) 
Pre/Post 100 W 0.34 4.89 -2.77 3.45 0.24 11 p = 0.81 
Pre/Post 125 W 1.29 5.21 -2.01 4.60 0.86 11 p = 0.41 
Pre/Post 150 W 2.63 6.73 -1.65 6.91 1.35 11 p = 0.20 
Pre/Post 175 W 3.79 6.80 -0.53 8.11 1.93 11 p = 0.08 
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Systolic BP for each power level of the four-stage submaximal oxygen 
consumption test (Data should be treated with caution due to tango malfunction 
halfway through testing for all participants error of measurement was in both 
directions) 
There was a significant main effect of power level, F(4, 52) = 31.83, p <0.001, partial 
η2 = 0.710. There was no significant main effect of pre/ post, F(1, 13) = 3.56, p = 
0.08, partial η2 = 0.22, or group, F(1, 13) = 4.628, p = 0.051, partial η2 = 0.263. 
There was no significant two-way interaction between power level & group, F(4, 52) 
= 2.16, p = 0.09, partial η2 = 0.14. Pre/post and group F(1, 13) = 3.65, p = 0.08, 
partial η2 = <0.21, or pre/post and power level F(4, 52) = 2.13, p = 0.09, partial η2 
= 0.14 (see table 5.11).  
  
Table 5.11 Systolic BP (mm/Hg) pre and post the supplementation period in the 
FO and SO group at each power level 
 Stage  Group  Pre Post  N 
Baseline FO 128.4 ± 11.0  128.6 ± 22.3 7 
 SO 124.8 ± 15.2  131.1 ± 14.8 8 
100 W FO  174.0 ± 23.8  161.7 ± 21.4 7 
 SO 162.7 ± 20.9  141.6 ± 34.1 8 
125 W FO  176.6 ± 18.6  188.5 ± 27.2 7 
 SO 169.1 ± 23.5  133.7 ± 30.1 8 
150 W FO  186.3 ± 19.0  204.9 ± 31.9 7 
 SO 186.4 ± 30.7  152.5 ± 42 8 
175 W FO   200.6± 20.0  183.0 ± 48.5 7 
 SO 191.3 ± 28.5  158.6 ± 32 8 








Diastolic BP for each power level of the four stage submaximal oxygen 
consumption test (Data should be treated with caution due to tango malfunction 
halfway through testing with all participants). 
There was no significant main effect of power, F(4, 52) = 1.63, p = 0.180, partial η2 
= 0.11, pre/ post, F(1, 13) = 0.008, p = 0.23, partial η2 = 0.001 or group F(1, 13) = 
1.63, p = 0.08, partial η2 = 0.21. There was no two-way interaction between power 
level & group, F(4, 52) = 2.45, p = 0.057, partial η2 = 0.16, pre/post and group F(1, 
13) = <0.001, p = 1.00 partial η2 <0.001, or pre/post and power level F(4, 52) = 0.77, 
p = 0.55, partial η2 = 0.06. Furthermore, there was no three way interaction between 
power level, pre/post and group, F(4, 52) = 1.72, p = 0.16, partial η2 = 0.12 (see 
Table 5.12). 
 
Table 5.12. Diastolic BP (mm/Hg) pre and post the supplementation period in the 
FO and SO group at each power level 
 Stage  Group  Pre Post  N 
Baseline FO  82.1 ± 9.84  80.1 ± 11.33 7 
 SO 77.8 ± 11.23  80.5 ± 12.2 8 
100 W FO    81 ± 11.1  94.3 ± 18.3 7 
 SO 70.7 ± 12.8  68.6 ± 8.1 8 
125 W FO  77.8 ± 4.5  77.0 ± 6.83 7 
 SO 69.4 ± 14.2  68.5 ± 23.4 8 
150 W FO  81.1 ± 15.1  75.0 ± 8.90 7 
 SO 70.4 ± 14.2  74.3 ± 16.3 8 
175 W FO  76.0 ± 15.8  72.8 ± 8.8 7 
 SO 76.0 ± 15.3  73.6 ± 11.0 8 
 






Mean arterial pressure (mmHg) 
There was a significant main effect of power level, F(4, 52) = 7.54, p <0.001 partial 
η2= 0.37, and group, F(1, 13) = 5.19, p = 0.04 partial η2 = 0.285. The dietary 
intervention group had a significantly higher MAP on average than the placebo 
group p = 0.04. There was no significant main effect of pre/ post, F(1, 13) = 1.133, 
p = 0.31 partial η2 = 0.08. There was no significant 2 way interaction between 
power level and group F(4, 52) = 2.40, p = 0.62 partial η2 = 0.16, pre/post and 
group F(1, 13) = 1.26, p = 0.28 partial η2 = 0.09 or power level and pre/ post, F(4, 
52) = 1.38, p =0.25 partial η2 = 0.10.  Furthermore, there was no significant three 
way interaction between group, pre/post & power level, F(4, 52) = 1.36, p = 2.59 
partial η2 = 0.095 (see table 5.13). 
Table 5.13 Mean arterial pressure (MAP mmHg) pre and post the supplementation 
period in the FO and SO group at each power level 
 Stage  Group  Pre Post  N 
Rest FO 97.6 ± 9.5 96.3 ± 14.4 7 
 SO 93.4 ± 12.4 97.3 ± 8.6 8 
100 W FO  112 ± 11.8 116.8 ± 16.1 7 
 SO 101.4 ± 12.9 92.9 ± 14.21 8 
125 W FO  114.3 ± 13.5 114.2 ± 9.0 7 
 SO 102.6 ± 13.9 90.2 ± 24.1 8 
150 W FO  116.2 ± 13.8 124.5 ± 23.1 7 
 SO 109 ± 16.1 100.3 ± 19.4 8 
175 W FO  117.5 ± 15.3 114.2 ± 21.7 7 
 SO 114.4 ± 18.3 101.9 ± 13.9 8 
Note: Data is expressed as means ± SD 
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There were no effects observed in the four-stage power test between group’s pre 
to post test for RPE, whole blood glucose and lactate levels. A summary of these 
statistics is in appendix 3. 
 




A two way mixed ANOVA elicited no significant main effect of pre/ post, F(1, 13) = 
0.034, p = 0.86, partial η2 = 0.003, or group F(1, 13) = 1.672, p = 0.22, partial η2 = 
0.11. There was no two-way interaction between pre/post and group, F(1, 13) = 
0.35, p = 0.56, partial η2 = 0.026 (see table 5.14). 
 
HR max 
A two way mixed ANOVA showed there was no significant main effect of pre/post, 
F(1, 13) = 0.15, p = 0.71 partial η2 = 0.01, or group F(1, 13) = 0.003, p = 0.95 
partial η2 = <0.001. There was no significant interaction between pre/post and 





(1 participant was missing a data point in the SO group so was removed from the 
analysis.) A two way mixed ANOVA showed there was no statistically significant 
main effect of pre/post, F(1, 12) = 0.31, p = 0.59 partial η2 = 0.03 or group F(1, 12) 
= 0.11, p = 0.31 partial η2 = 0.09. There was no significant interaction between 
pre/post*group F(1, 12) = 0.12, p = 0.91 partial η2 = 0.001 (table 5.14). 
 
Powermax 
A two way mixed ANOVA showed there was no significant main effect of 
(pre/post), F (1, 12) = 0.43, p = 0.52 partial η2 = 0.04 or group F (1, 12) = 0.05, p = 
0.82, partial η2 = 0.004. There was no significant interaction between pre/post and 
group F (1, 12) = 1.36, p = 0.27, partial η2 = 0.10 (table 5.14). 
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Table 5.14. Maximal test data pre and post intervention in the FO and SO group 
Dependent 
variable 
 Pre  Post  N 
     
2OV





61.7 ± 9.0 
 
61.0 ± 7.7 
 
7 
 SO 56.0 ± 56.4 56.4 ± 8.1 8 
     
HRmax (bpm) FO 180 ± 9.2 179 ± 6.8 7 
 SO 181 ± 20.2 179 ± 11.7 8 







0.34 ± 0.05 
 
0.34 ± 0.41 
 
7 
 SO 0.31± 0.035 0.31 ± 0.05 7 
     
Powermax (W) FO 380  39.9 383  41.8 7 
 SO 383  45.3 370  44.4 7 



















The results of this study demonstrate that an 8-week dietary intervention designed 
to lower n-6 and raise n-3 PUFA intake (H3, L6), significantly increased 
erythrocyte percentage content of total n-3 PUFA, EPA and DHA in trained 
cyclists. The intervention significantly reduced erythrocyte percentage content of 
total n-6 PUFA, LA and AA. In addition, the proportion of n-6 to n-3 PUFA was 
significantly reduced. Contrary to the hypothesis, the dietary intervention did not 
lower the 2OV
  cost of submaximal cycling over four power stages. No changes 
were observed between groups in measurement of local muscle oxygenation (TSI 
%), and oxygen extraction (deoxy-HHb).  Furthermore, no changes in BP or HR 





peak/ HRmax in the incremental cycling test to exhaustion. Therefore, 
although this study demonstrates a successful dietary intervention to increase n-3 
PUFA incorporation into erythrocytes, n-3 PUFA supplementation did not elicit any 
changes in cardiovascular variables in submaximal cycling.  
 
Integrated Dietary intervention and Erythrocyte percentage content of FA 
 
N-6 LA and total n-6 PUFA significantly decreased in the H3 - L6 group over the 8-
week intervention period with no change observed in the placebo group. The 
decrease in the H3/ L6 group was significant from baseline to 4 weeks (and from 
baseline to 8 weeks but not from 4 weeks to 8 weeks. This is indicative of the 
reduction being more marked in the first 4 weeks of the intervention period and 
plateauing thereafter. Therefore, a 4-week intervention period might have been 
sufficient to lower LA & n-6 PUFA tissue levels. However, it is important to 
consider that the time course of n-6 PUFA reduction in specific tissues might vary. 
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Hodson et al., (2008), reported that adipose tissue n-6 LA has a slow turnover rate 
with a half-life of approximately 1 – 2 years. This suggests a dietary intervention 
designed to lower LA may need to be maintained for an extended period in order 
to achieve maximal alterations in some tissues in the human body.  
AA significantly reduced over the intervention period and took eight weeks to do 
so. These findings are in agreement with Macintosh et al. (2013) who reported that 
12 weeks of a H3-L6 diet reduced erythrocyte fatty acid levels of n-6, LA and AA. It 
was concluded the reduction in AA might be a result of the Low n-6 PUFA diet or 
raised EPA and DHA levels competing for incorporation into the relevant target 
tissues by preventing the conversion of ALA reducing the elongation and 
saturation of n-6 PUFA. 
In the current study, n-3 EPA significantly increased in the H3-L6 group over the 8-
week intervention period, with no change observed in the placebo group. The 
increase was significant from baseline to 4 weeks and from baseline to 8 weeks 
but not from 4 weeks to 8 weeks. This indicates the increase in EPA was more 
marked in the first 4 weeks of the intervention period, and plateaued thereafter. 
Therefore, 4 weeks of n-3 PUFA supplementation may be sufficient to raise EPA 
tissue levels. DHA and total n-3 PUFA took 8 weeks to reach significantly 
increased levels in the H3-L6 group. In the current study, 8 weeks of 
supplementation (2.6g EPA and 1.8g DHA) increased EPA erythrocyte levels by 
350% and DHA by 88%. The large increase in EPA compared to DHA is in 
agreement with previous studies. Raastad et al. (1997), reported that 10 weeks of 
n-3 PUFA supplementation (1.6g EPA and 1g of DHA per day), increased 
erythrocyte EPA levels by 175% and DHA by 40%. 4 weeks of n-3 PUFA 
supplementation (0.1g/ kg of supplement per day, equating to a mean intake of 
4.9g EPA and 1.4g DHA per day), increased EPA levels by 600% and DHA by 
37% (Gravina et al., 2017). Clearly, the dosage of omega 3 and the time course of 
 137 
supplementation dictates the cellular incorporation of EPA and DHA. This 
suggests that studies focusing on increasing cellular saturation of DHA may need 
at least 8 weeks of supplementation when using similar supplement 
concentrations of EPA and DHA to the current study. 
In conclusion the High n-3: Low n-6 PUFA intervention significantly increased 
EPA, DHA, total n-3 PUFA erythrocyte levels and significantly reduced total n-6, 
LA and AA, over the eight-week dietary intervention. No changes observed in the 
placebo group. This suggests that participant compliance to H3-L6 was successful 
and in agreement of our study aims. Previous studies have demonstrated that 
supplementation with n-3 PUFA alone (with no reduction of n-6 PUFA dietary 
intake) significantly reduced n-6 PUFA erythrocyte incorporation and markedly 
increased EPA and DHA incorporation (Gravina et al., 2017). In addition it should 
be noted that Macintosh et al. (2013), showed that LA can be reduced and EPA 
and DHA increased (+51% and +19% respectively) without n-3 PUFA 
supplementation, simply by lowering dietary n-6 PUFA dietary intake over 12 
weeks. This suggests that that high n-6 PUFA diets might interfere with synthesis 
and incorporation of EPA and DHA in human tissue. For future research 
considerations, an additional 3rd group of participants supplementing with n-3 
PUFA alone and a 4th group following a low n-6 PUFA diet (without n-3 PUFA 
supplementation) would provide further evidence regarding the effect of H3-L6. 
Although differences in erythrocyte fatty acid content were observed over the 
intervention period, it is not known whether levels increased in the target tissues 
including the heart, blood vessels and skeletal muscle. Further exercise studies 
that examine muscle biopsies for fibre specific fatty acid content and mitochondrial 
phospholipid fatty acid composition are warranted. McGlory et al. (2014) found that 
4 weeks of supplementation with a high daily dose of n-3 PUFA (5g/ day similar to 
the dosage used in the present study) increased both blood and skeletal muscle n-
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3 PUFA composition. They also noted that changes in n-3 PUFA levels in the 
blood were detectable after 1 week of supplementation however, changes were 
not detected in skeletal muscle tissue until 2 weeks post supplementation. 
Therefore, a minimum, 2 weeks may be required to start to see differences in 
skeletal muscle FA composition. It is clear that n-3 PUFA composition of the 
tissues is related to dose response and the duration of the supplementation 
period. There is a need for future research to examine careful systematic n-3 
PUFA dose response relationship studies that investigate a number of different 
tissues and their uptake of n-3 PUFA. 
 
The effect of the high n-3/ low n-6 PUFA intervention on 2OV
 max and submaximal 
physiological variables 2OV
 , TSI%, BP, HR, RPE, lactate and Glucose  
Contrary to the hypothesis, the H3:L6 dietary intervention had no effect on 2OV
 , 
HR, TSI%, deoxy-HHb, BP or MAP during steady state cycling at four submaximal 
power outputs. Previous studies have reported similar findings to the current study 
outcome. Hingley et al. (2017) reported there was no effect of n-3 PUFA on 
oxygen consumption at rest or during low intensity submaximal exercise. However, 
reduced oxygen consumption was observed in the first 2 minutes of a 5-minute 
cycling time trial in the fish oil group. In contrast, 8g/d of DHA rich fish oil lowered 
the oxygen cost of cycling to failure (Peoples et al., 2008). This suggests that the 
n-3 PUFA mechanism may be revealed more so under conditions of increased 
physiological strain when oxygen delivery to the muscles is compromised, or due 
to cardiovascular changes. Another possibility is the n-3 PUFA mechanism might 
work at a local level improving skeletal muscle M 2OV
  (as has been observed in 
the myocardium of rats fed with an n-3 PUFA diet (Pepe, 2002). In humans, DHA 
is preferentially incorporated into skeletal muscle cell membranes (Peoples et al., 
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2008), (Henry, Peoples, & Mclennan, 2015) and may be associated with increased 
in ADP sensitivity (Herbst et al, 2014). This may be beneficial in athletes that 
already have a high mitochondrial content and may be reaching their ceiling 
regarding further training induced adaptations.  
 Previous researchers examining n-3 PUFA and its effect on oxygen cost of 
exercise have based their findings on 2OV
  or 2OV

max measurements (Raastad et 
al., 1997; Zebrowska et al., 2004; Peoples et al., 2008; Da Boit et al., 2015). 
Whole body O2 consumption measured via expired gases closely reflects O2 
consumption in the active muscles during steady state light to moderate exercise 
(Grassi 1996). Therefore, non-invasive breath-by-breath measurements or 
Douglas bags are commonly used as a proxy measurement of muscle oxygen 
uptake (M 2OV
 ). Direct measurements of M 2OV
  are technically difficult and 
invasive in nature however, inferences on the relationship between 2OV
  and M
2OV

 can be made using non-invasive muscle oxygenation measurement 
techniques. This is the first n-3 PUFA and exercise related study to use near 
infrared spectroscopy (NIRS) in addition to 2OV
  measurement. NIRS provides 
additional information regarding local oxygen delivery and extraction within the 
tissue region of interest (De Lorey et al, 2003). In the current study tissue 
saturation index (TSI%) and deoxy- HHb (a measure of muscle oxygen extraction) 
were examined using NIRS. There was no significant difference in TSI % or 
deoxy-HHb observed between groups, pre/ post supplementation, during steady 
state exercise at any of the four power outputs. This further confirms and 
compliments our findings regarding no significant change in 2OV
  measurement 
using Douglas bags. 
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In the current study a diet rich in n-3 PUFA was not associated with any significant 
differences in 2OV

peak, powermax, HRmax or 2OV
 /HRmax during the ramp based 
incremental test to exhaustion. This finding is in agreement with previous exercise 
studies (Oostenbrug et al., 1997; Raastad et al, 1997; Kawabata, 2014; Hingley 
2017). In contrast, Zebrowska et al. (2014), found that 3 weeks of omega 3 fatty 
acid supplementation increased individual 2OV

max and 2OV
  in relation to maximal 
HR ( 2OV
 /HRmax). The improvements were attributed to an n-3 PUFA supplement 
induced increase in serum NO levels. However it should be noted that Zebrowska 
et al. (2014), used a randomised cross over study design, with a 2-week washout 
period. Cao et al. (2006) suggested that studies with washout periods should 
consider 8 – 16 weeks due to EPA and DHA concentrations remaining marginally 
higher than baseline, 8 weeks after the cessation of supplementation with n-3 
PUFA. 
In the present study there was no difference between the high n-3/ low n-6 PUFA 
group and the placebo group in resting HR or HR during steady state exercise at 
100, 125, 150or 175W or HRmax in the 2OV
 max test. Fish oil supplementation 
has previously resulted in a reduction in resting heart rate  during submaximal 
exercise (Buckley et al., 2009), and during maximal aerobic exercise (Oostenburg 
et al., 1997; Raastad et al., 1997; Zebrowska et al., 2014). This may be due to n-3 
PUFA affecting ion channel function in auto rhythmic cells of the heart potentially 
elongating the diastole phase of the cardiac cycle (McLennan, 2001; Mozaffarian, 
2005). A Reduction in exercising blood pressure has also been observed in a 
couple of previous studies. In both healthy young and older subjects, diastolic BP 
and MAP were reduced in the n-3 PUFA supplemented group, at the onset of 
isometric handgrip exercise (Clark, et al, 2016). The reduction of BP and MAP 
may be due to n-3 PUFA consumption influencing nitric oxide production and the 
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blunting of vasoconstriction in response to norepinephrine (Chin et al, 1993). 
Several studies have reported increased arterial flow mediated dilation (FMD) 
following n-3 PUFA supplementation (Walser, 2006; Zebrowska, 2014). FMD was 
not measured in the current study.  
 
It would be of interest to establish if the observations already discussed would be 
different when participants are exercising in a stressed state such as a pre 
fatigued state or oxygen deficient sate where a supplement that may provide 
physiological compensation can be fully scrutinised. More recently a study by 
Hingley et al. (2017), demonstrated that increasing the omega -3 PUFA Index of 
erythrocytes  lowered oxygen consumption most notably during the first 2 minutes 
of a 5 minute intense cycling time trial (although cycling performance did not 
improve). Hingley supplemented cyclists with DHA rich fish oil (560mg DHA/ 
140mg EPA) for 8 weeks. DHA is a primary fatty acid in mitochondrial 
phospholipids in skeletal muscle and it has been suggested that n-3 PUFA 
supplementation may affect mitochondrial bioenergetics (Herbst, 2014); this raises 




During this study the Tango BP monitor malfunctioned on a number of occasions 
during testing. It was replaced with a manual sphygmomanometer, which may 
have affected the BP recordings for the participants, in particular the post 
supplementation values. As a result of this, the BP findings in the current study 
should be treated with caution.  
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The 8-week dietary intervention was reliant on participant compliance. Participants 
were monitored, four weeks into the supplementation period, where they were 
asked to produce a 3-day diet record, to ensure they were adhering to the dietary 
intervention. This was a burden on participants and not all could complete it to a 
relevant standard. Macintosh et al, (2013) mitigated this issue by providing 
dietitian counselling 6 x 45 minutes once every two weeks and participants were 
provided with a 2-week supply of study foods following each visit. In addition, they 
had access to web based education materials and diet adherence was monitored 
using 24 h telephone on six unannounced occasions. Further measures such as 




The novel 8-week dietary intervention designed to raise n-3 PUFA intake and 
reduce n-6 PUFA successfully achieved this target alteration. Despite changes in 
fatty acid profile, there were no changes observed in 2OV

, TSI % or deoxy HHb 
measurements in the fish oil supplemented group compared to the placebo group. 
Furthermore, no changes was observed in other physiological variables HR, BP, 
RPE, MAP, or 2OV

peak performance. The findings of this study suggest that n-3 
PUFA is unlikely to be a supplement that reduces the oxygen cost or increases 
oxygen extraction during steady state submaximal cycling in trained athletes, nor 
does it improve maximal oxygen consumption. It would be relevant for future 
research to consider the n-3 PUFA action on high intensity aerobic exercise 
(Hingley, 2017) or exercise in an oxygen deficient state, where a supplement that 
may provide physiological compensation could be of benefit. 
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This thesis aimed to investigate the potential mechanisms by which increased 
dietary n-3 PUFA consumption might enhance exercise performance and 
cardiovascular function. N-3 PUFA has gained a great deal of interest from sport 
scientists in the past decade, and is still very much under investigation. There has 
been significant interest in the anti-inflammatory action of n-3 PUFA and prolonged 
high intensity exercise, which can result in immune dysfunction and transient 
inflammation. This is part of the normal response to exercise and is characterised 
partly by the production of anti and pro-inflammatory cytokines (Nieman, 2001, 
2005, 2009). Previous studies have attempted to quantify the acute cytokine 
response to different types of exercise. The majority have focused on exercise 
modalities known to induce muscle damage or extreme inflammatory responses 
including, exercise in hot environments (Cosio-Lima et al., 2011; Luk et al., 2016), 
eccentric exercise (Toft et al., 2002),  unaccustomed exercise (Sorichter et al., 
2006), marathon running and 250-km road cycling (Camus et al., 1997; Gannon et 
al., 1997, cited in Brenner et al., 1999). Acute cytokine responses are known to be 
variable in relation to the duration and intensity of the exercise bout, and the mode 
of exercise performed (Pedersen and Hoffman-Goetz, 2000). Few studies have 
investigated the cytokine response to different durations or intensities of cycling. 
Chapter 3 in this thesis was the first study to examine the plasma cytokine response 
to two cycling protocols that were time trial and interval based. Previous studies 
have compared the cytokine response to different modes of exercise. Brenner et al. 
(1999) reported that 2 hours of submaximal cycling induced acute and significant 
increases in IL-6 and TNFα, whereas no changes were observed for circuit training 
(Brenner et al., 1999). IL-1β, IL-6 and TNFα peaked immediately following 3 hours 
of cycling and inclined walking (Moldoveanu et al., 2000). It was hypothesised that 
1 hour of pre-loaded cycling may result in a more marked inflammatory cytokine 
response compared to interval cycling. The findings that both cycling protocols 
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elicited an increase in IL-6 concentration, and the increase being more marked post 
the 1- hour preloaded time trial compared to the interval trial, confirms the typical IL-
6 response to exercise that has been well documented in previous studies (Brenner, 
1999; Cox, 2007., Suzuki, 2000). However, apart from the observed IL-6 response, 
both cycling protocols did not evoke the acute pro-inflammatory response described 
by Peake at al. (2005), whereby IL-6 is the first cytokine to increase in the circulation 
during exercise, followed by the classic proinflammatory cytokines IL-1β and TNFα. 
This thesis demonstrated that IL-4 (anti – inflammatory) and MCP-1 (a chemokine 
involved in mediating monocyte chemotaxis) concentrations increased and VEGF 
decreased, post both trials on average. No changes were observed in IL-1a, IL-1β, 
IL-2, IL-8, IL-10, IFN-γ, or TNFα. These findings are in agreement with Ostapiuk-
Karolczuk et al. (2012), who observed elevations in IL-6, IL-4 and MCP-1 post 90 
minutes of running (65% 2OV

max), elevations in IL-1β and TNFα were not detected 
until 6 hours post exercise. The acute IL-4 increase could be explained by its release 
from immune cells located in the circulation, whereas pro inflammatory cytokines 
released locally from the muscle may take longer to increase in plasma. Therefore, 
a delayed increase in inflammatory cytokines could not be ruled out, although 
previous research has also reported no change or only small changes in 
inflammatory cytokines post exercise (Hirose et al., 2004).  
Limitations 
Only examining the acute post exercise cytokine response in chapter 3 was a 
limitation in this thesis. Previous research has typically obtained blood samples 
periodically at 6, 12, 24 and 72 hours post exercise (Brenner et al., 1999). The time 
course of appearance of inflammatory and anti-inflammatory cytokines means that 
some peak in the hours following exercise such as IL-8 and TNFα (Pedersen, 2000; 
Ostapiuk-Karolczuk et al., 2012). It would be relevant therefore, in future research 
 146 
to consider sampling over the hours and days post exercise. Furthermore, some 
cytokine values were at or below the minimum detection limit. In these cases the 
standard minimal value for each cytokine was used for analysis. This was 
particularly the case for IL-2, IL-10, IFNG, IL1α and IL1-β. In addition, it has been 
reported that concentrations of cytokines in peripheral blood plasma may not be 
indicative of up or down regulation in the tissues (Sprenger et al., 1992). Therefore 
the combined inclusion of muscle biopsies, urine samples (Sugama et al., 2013; 
Hirose, 2004)  and the measurement of arteriovenous differences across the 
exercising limb (Steesberg, 2000) might assist us in understanding the cytokine 
response to exercise more clearly in future research. 
In addition to the anti-inflammatory action of n-3 PUFA, there has been considerable  
interest in its effects on the cardiovascular system. N-3 PUFA supplementation has 
been reported to reduce oxygen consumption and improve oxygen economy during 
submaximal exercise (Kawabata, 2014; Peoples & McLennan, 2010, 2016).  These 
findings may be as a result of key n-3 PUFA cardiovascular mechanisms reported 
to augment stroke volume, cardiac output and reduce systemic vascular resistance 
(Walser et al, 2008). In addition, n-3 PUFA has been reported to reduce red blood 
cell deformability (Oostenbrug et al., 1997), lower blood pressure and heart rate 
during submaximal exercise (Buckley et al., 2007). Furthermore, n-3 PUFA 
supplementation elevated serum NO concentrations and enhanced vascular 
endothelial function, improving blood flow (Zebrowska, 2014; Walser et al., 2006; 
Wu & Meininger, 2002, 2012). However, there have been few reports of a direct 
benefit of n-3 PUFA supplementation on exercise performance. Only two studies 





performance (Leaf and Rauch, 1988, Zebrowska et al., 2014). Therefore, the 
second main aim of this thesis was to determine if n-3 PUFA supplementation 




performance (Chapter 5). Prior to chapter 5, it was important to validate methods of 
measurement for the determination of an individual’s fatty acid status in chapter 4. 
The use of such biomarkers are important in this field. They provide some objective 
measure of the suitability of a dietary intervention to reach target increases in the 
tissues and furthermore, it determines if participants have adhered to the 
intervention. Traditional methods to quantify an individual’s fatty acid status involve 
the isolation of RBCs from venous whole blood samples as a surrogate marker of 
n-3 PUFA tissue incorporation. This is considered by some as a gold standard 
biomarker for the measurement of n-3 PUFA status (Metcalf et al, 2007). However, 
this method is confounded by limitations such as the requirement for a trained 
phlebotomist and the difficulty in obtaining multiple samples without the procedure 
becoming invasive. The use of dried blood spots (DBS) as a convenient, rapid, and 
inexpensive method of sampling was first employed by Marangoni et al., (2004). 
Therefore, the aim of the second experimental chapter (chapter 4) was to examine 
the relationship between whole blood fingertip DBS blood samples and isolated 
erythrocytes for determining an individual’s fatty acid status. Previous studies have 
compared these methods at one time point for example at rest, without dietary 
manipulation or supplementation (Bailey-Hall et al, 2008; Bell et al, 2011). This is 
the first study that has examined the relationship between measurement methods 
over an 8-week n-3 PUFA supplementation period using data from 3 time points: 
baseline, at 4 weeks and at 8 weeks. Results demonstrated there was poor 
correlation and lack of agreement between methods for the measurement of the 
majority of fatty acids apart from EPA (R2 = 0.64, p = 0.005), intra-class correlation 
demonstrated agreement between methods for EPA (ICC = 0.49). In addition, Bland 
and Altman levels of agreement were good for EPA (mean difference = 1.12% with 
95% limits of agreement -1.43% – 3.67% without any evidence of proportional bias 
p = 0.05). Higher mean percentage values for the fatty acids EPA, AA, total n-6, the 
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omega 3 index (EPA+DHA) and n-6/n-3 PUFA were observed in the venous isolated 
erythrocyte samples in comparison to DBS. This was to be expected due to whole 
capillary blood containing plasma and a number of other cell types including 
monocytes. For example, the levels of n-3 PUFA fatty acids in PMBCs are lower 
than RBCs that have a slower turnover with a longer lifespan of approximately 120 
days in the circulation (Katan et al, 1997). In addition, erythrocyte FA concentration 
is not affected by acute dietary changes, as would be the case with the serum 
fraction of a whole blood capillary sample (Katan et al, 1997). Even though 
erythrocyte fatty acid values were higher than DBS values, we still expected there 
would be a relationship between the methods. Regression analysis showed there 
was only a significant correlation for EPA. In addition, for the other fatty acids there 
was evidence of proportional bias suggesting the difference between methods 
varied throughout the range of measurement. This shows that although there were 
differences between the methods, the differences varied and lacked consistency. 
As a result of these findings, RBC isolation was adopted to determine the fatty acid 
status of participants in chapter 5.  
There were a number of limitations to consider in chapter 4. If capillary and venous 
whole blood samples (rather than isolated RBCs) had been compared, there may 
have been a relationship between the methods. Alternatively it would have been 
interesting if isolated RBCs had been spotted onto a Guthrie card. This would have 
allowed determination of whether differences in the ratio of blood components 
between the two sampling methods were responsible for the lack of relationship, or 
if it was a result of the sample procedure and subsequent analysis. For example, 
the degradation of samples due to oxidation is a known limitation with DBS samples. 
Bailey-Hall et al. (2008) collected DBS on BHT treated filter paper in order to 
minimise fatty acid oxidation. However (Bell et al., 2011), found no significant 
difference with the use of blood collection paper pre-treated with BHT compared to 
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non-treated paper for analysis of fatty acids. AA, EPA and DHA percentage values 
reduced over a 4-wk storage period at room temperature from 2.93% to 1.95% (with 
most degradation occurring after 48 hours) the other fatty acid values reduced in a 
similar way. This suggests BHT may not necessarily improve sample stability.  
 
In chapter 5, the aims of this thesis were two-fold. Firstly, to investigate the effect of 
a high n-3, low n-6 PUFA (L3-H6) dietary intervention, on isolated erythrocyte PUFA 
levels. Secondly, to examine the effect of this dietary intervention on oxygen 
consumption during submaximal exercise and 2OV

peak performance. It is apparent 
that modern diets have an unbalanced ratio of n-6 PUFA to n-3 PUFA of 
approximately 16:1, rather than 1:1. The latter is the ratio observed in the diet of wild 
animals and the presumed traditional ratio of fats required in the human diet (Eaton, 
1985., Simopoulos, 1991). Increased n-3 PUFA intake results in changes in cell 
membrane phospholipid fatty acid composition. This may influence the physical 
properties of the cell membrane resulting in changes in cell signalling pathways, 
membrane receptors, gene expression and the production of inflammatory lipid 
mediators (Calder, 2006). N-3 and n-6 PUFA compete for the same elongase and 
desaturase enzymes for incorporation into cell phospholipids (Mickleborough, 
2008). This raises the question of whether n-3 PUFA incorporation could be further 
augmented by reducing dietary n-6 LA intake. The majority of previous studies have 
adopted n-3 PUFA  supplementation for a period of 3-10-weeks at approximate daily 
dosages of between 2 - 6.5g/ day of fish oil typically containing approximately 2g 
EPA and 1.5g DHA (Buckley et al., 2007; Walser et al., 2008; Da Boit et al., 2015; 
Kawabata, 2014; Gravia et al., 2017). A couple of studies have supplemented with 
higher DHA than EPA (Nieman et al., 2009; Hingley, 2017). Only one clinical study 
to date has reported methods to lower dietary n-6 PUFA, whilst maintaining or 
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increasing n-3 PUFA intake. Macintosh et al. (2013), investigated two dietary 
interventions, 1) average n-3, Low n-6 (L6) and 2) high n-3, low n-6 (H3-L6). In both 
interventions n-6 LA was lowered to ≤ 2.5% of daily average energy intake. The L6 
diet not only reduced n-6 PUFA but also in increased n-3 PUFA EPA (+51%) and 
DHA (+19%) erythrocyte incorporation. This suggests that high n-6 PUFA diets may 
interfere with the incorporation of n-3 PUFA in human tissues. The H3-L6 diet 
markedly increased n-3 PUFA EPA and DHA and reduced n-6 PUFA erythrocyte 
incorporation when compared with the L6 diet. Based on these findings a novel H3-
L6 dietary intervention was adopted in chapter 5 that reduced dietary n-6 PUFA to 
≤ 2.5% of average daily energy intake and enhanced n-3 PUFA fatty acid intake  by 
supplementing with EPA (2600mg) and DHA (1800mg) daily for 8 weeks. The diet 
intervention successfully increased EPA (pre to post: 1.30 ± 0.20 to 5.85 ± 1.68, p 
<0.001), DHA (4.97 ± 2.82 to 9.35 ± 1.12, p = 0.001) and total n-3 PUFA (10.43 ± 
2.53 to 20.13 ± 2.83 p <0.001). Furthermore, the intervention reduced LA (15.17 ± 
1.92, to 11.98 ± 1.30 p = 0.004), AA (19.99 ± 2.53 to 15.39 ± 1.19  p <0.001) and 
total n-6 PUFA (40.27 ± 1.85 to 30.75 ± 1.29 p <0.001). Interestingly, in the fish oil 
group, n-3 PUFA EPA and DHA increased and n-6 LA and AA reduced most 
markedly by week 4 of the supplementation period after which their levels plateaued 
apart from DHA, which took 8 weeks to significantly increase in concentration. DHA 
may be taken up by erythrocytes at a slower rate than EPA. An important 
methodological point in randomised controlled trials is consideration of the target 
tissue and its degree of n-3 PUFA uptake. An individual’s fatty acid status is often 
measured in isolated erythrocytes as a surrogate marker of human tissue status. 
However it has been established that the myocardium and skeletal muscle tissue 
readily take up DHA preferentially to EPA (Herbst, 2013). Therefore, measurement 
of fatty acid status in erythrocytes may not be representative of the fatty acid status 




Fatty acid analysis confirmed that the participants had adhered to n-3 PUFA 
supplementation however, it is difficult to substantiate if the low n-6 PUFA diet had 
any additional effect on the lowering of LA, AA or total n-6 compared to n-3 PUFA 
supplementation alone (as we didn’t employ an n-3 PUFA supplementation only 
group). Previous studies that report increases in n-3 PUFA through supplementation 
also observe decreases in n-6 PUFA without any background dietary manipulation. 
It is also difficult to compare the current study values to other reported values, due 
to the variety of supplementation protocols employed in previous research. 
Rather than using food frequency questionnaires as employed by Macintosh et al., 
(2013), seven-day food records were analysed (Nutritics University edition). Food 
records are a more valid measure of nutrient intake however, they may be 
unsuitable for large studies or when sufficient instruction is not provided (Kolar et al, 
2005). From participant’s diet records, high n-6 PUFA foods were identified and 
substituted for low n-6 PUFA alternatives. The substituted 7-day diet was returned 
to the participants and they were asked to follow this dietary intake for the 8-week 
supplementation period. Even small changes to dietary intake can be a burden to 
participants, and this dietary intervention was highly reliant on subject compliance. 
Macintosh et al., (2013) mitigated this burden somewhat by providing meals for a 2-
week dietary intervention, the participants also attended nutrition counselling 
sessions every 2 weeks. In the current study participants met with the researcher 4 
weeks into the intervention period to discuss how the dietary intervention was 
progressing and if they needed any alternative meal/ snack suggestions. 
Convenient self-report measures such as 24-hour recall could have been 
implemented to encourage further participant compliance.  
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The effects of the novel H3-L6 dietary intervention on submaximal oxygen 
consumption and performance of 2OV

peak was investigated in chapter 5. It has been 
reported that human heart tissue readily incorporates n-3 PUFA DHA (Metcalf et al., 
2007; Owen et al., 2004). Increased DHA in myocardial phospholipids has been 
shown to enhance ventricular function by reducing the oxygen requirement to 
produce any given work output, without affecting the work rate of the heart (Pepe & 
McLennan, 2002). Furthermore, Incorporation of n-3 PUFA, has been shown to 
reduce heart rate and improve the function of the heart both at rest (Mozzafarian et 
al, 2005) and when oxygen demand is elevated (McLennan, 2014). Previous studies 
have shown that FO supplementation lowers heart rate during submaximal exercise 
in healthy and trained participants (Buckley et al. 2009., Peoples et al, 2008) 
Peoples et al, (2008), reported that trained cyclists who supplemented with n-3 
PUFA had lower heart rates during a 2OV

peak test and throughout ~60min 
submaximal exercise at sustained intensity to exhaustion. Furthermore, Peoples 
and McLennan (2008), observed reduced whole body oxygen consumption by 
skeletal muscle whilst muscular work did not change during sustained submaximal 
exercise at 55% 2OV

peak to exhaustion. Kawabata (2014), observed improved 
exercise efficiency during steady state exercise and a reduction in perceived 
exertion. Collectively these studies provide evidence that n-3 PUFA may modify 
oxygen utilization by the heart and skeletal muscle due to increased efficiency or 
enhanced blood flow. A number of studies have suggested that n-3 PUFA 
supplementation may augment blood flow and oxygen delivery to the exercising 
muscles via enhanced vasodilation, possibly through enhanced endothelial NO 
release (Walser et al., 2006; Zebrowska et al 2014). Therefore a main aim of this 
thesis was to investigate the effect of a novel H3 – L6 dietary intervention on oxygen 
consumption over 4 submaximal workloads (100 W, 125 W, 150 W, 175 W) similar 
to those used to determine the gross efficiency protocol (Passfield and Doust, 2000). 
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Previous research has often examined oxygen consumption during fixed intensity 
exercise (Peoples and McLennan, 2008). Walser and Stebbins (2008) employed a 
10 minute cycling protocol at a low (90 – 100 bpm) and moderate (> 125 bpm) 
intensities. DHA and EPA supplementation augmented increases in stroke volume 
and cardiac output in the moderate exercise condition only. Therefore, a range of 
submaximal workloads was selected. Although the dietary intervention successfully 
achieved the target increase in n-3 PUFA and decrease in n-6 PUFA, it did not elicit 
changes in 2OV

peak performance or oxygen consumption during submaximal 
exercise at 4 submaximal work rates. No changes in local tissue oxygen saturation 
index (TSI %) or deoxy HHb were detected using NIRS analysis, furthermore there 
were no changes in HR or BP when compared to the control group. These findings 
are in contrast to those of Leaf and Rauch (1988), and Zebrowska et al (2014), who 
observed an increase in V02max in trained men. In addition, this study does not 
support the findings of previous research that observed reduced oxygen 
consumption during exercise following n-3 PUFA supplementation (Kawabata, 
2014; Peoples and McLennan 2008, 2010; Hingley, 2017). The findings of the 
current study are in agreement with Oostenbrug et al. (1997), Raastad (1997), 
Buckley (2007) and Nieman et al. (2009), who failed to report any improvement in 
2OV

max or associated physiological variables following n-3 PUFA supplementation. 
However, it should be considered there is large variation between studies regarding 
n-3 PUFA daily dosage and duration of supplementation as well as the type of 




For the submaximal exercise test, absolute workloads were employed of 100, 125, 
150 and 175 watts for 7 minutes. These are relatively low work rates for a short 
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duration of time. Peoples and McLennan (2008), employed a submaximal cycling 
protocol at a work rate of 55% of peak work load (approximately 240 watts taken 
from the mean pre supplementation Wpeak figures) this is a higher intensity than the 
current study and participants exercised for a longer duration until exhaustion ~60 
minutes. It is possible that, if the main n-3 PUFA mechanism is oxygen delivery, the 
current exercise protocol may not have been intense enough. The oxygen supply to 
meet demand was easily met under these conditions. An athlete may need to be in 
a state of fatigue or oxygen deficit to observe the possible cardiovascular 
compensatory effects of n-3 PUFA. Hingley, (2017) found there was no effect of 
DHA rich fish oil on oxygen consumption during low and moderate intensity exercise 
which agrees with previous findings (Gerling et al., 2014). However, reduced oxygen 
consumption was observed during a 5 minute cycling time trial when the 
physiological effort was much higher (See future recommendations). 
 
Future research recommendations  
 
High intensity aerobic exercise  
 
A number of studies have begun to investigate the effects of n-3 PUFA on intense 
exercise performance. Hingley, (2017) examined the effect of n-3 PUFA on the 
performance of a time trial when athletes were in a fatigued state, theorising that the 
oxygen efficiency/ utilisation related mechanisms linked to n-3 PUFA might reveal 
themselves or compensate an athlete performing a time trial under such conditions. 
This was unique in comparison to previous research examining submaximal low 
intensity exercise. Hingley et al, (2017) reported that 8-weeks of n-3 PUFA 
supplementation, did not influence maximal cycling power (3 x 6 seconds), or 
repeated Wingate cycling (6 x 30 seconds with 150 seconds active recovery). There 
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was no observed effect of supplementation on time trial performance (5 minutes 
cycling as hard and as fast as possible in a fatigued state) or isometric strength of 
the quadriceps (determined by three maximal voluntary quadriceps contractions). 
However, mean oxygen consumption relative to workload was significantly lower 
over the 5 minute cycling time trial, with most notable reduction occurring during the 
first 2 minutes of exercise performance, when participants were under severe 
physiological strain. This suggests that the n-3 PUFA, in particular DHA, is important 
for skeletal muscle function during high intensity activity. No changes were observed 
in the n-3 PUFA group during the moderate 10-minute steady state exercise test. It 
should be noted this study used a low dose of FO compared to previous studies. 2g/ 
day fish oil of which 140mg was EPA and 560mg DHA. Follow up studies would be 
interesting that examine DHA and supra- maximal constant load cycling or a 
protocol that will allow the separation of peripheral and centrally induced fatigue 
mechanisms. It would also be interesting to examine n-3 PUFA and its effect in 
conditions of oxygen deprivation, where oxygen delivery to the muscle might be 
compromised such as, exercise in hypoxic conditions or in individuals with exercise 
induced asthma. In addition, it is important for future research to question if the 
potential n-3 PUFA mechanisms (related to lowered 2OV
  cost) are due to n-3 PUFA 
affecting the delivery of oxygen to the skeletal muscle via improvements in blood 
flow or due to improved mechanical efficiency of the heart and skeletal and muscle 
respiratory mechanics. 
 
N-3 PUFA and post exercise immune recovery  
 
A further area of research related to n-3 PUFA that requires more examination is 
the benefit of n-3 PUFA’s in the post exercise recovery period when the immune 
system can be compromised affecting recovery time (Walsh et al, 2011; Nieman & 
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Mimesser, 2017). It is well documented that dietary enrichment of n-3 PUFA reduces 
the production of arachidonic acid-derived (AA) eicosanoid mediators due to 
reduced levels of AA and competitive incorporation of n-3 PUFA FA in the 
desaturation elongation cascade. In addition, it appears that long-term n-3 PUFA 
supplementation alters the EPA and DHA membrane composition of immune cells, 
influencing factors such as phagocytosis. Altered gene expression increases the 
number of phagocyte surface receptors increasing their uptake of target material 
Calder, (2003). A 6-month supplementation period of 1.5g EPA and DHA increased 
neutrophil and monocyte phagocytic activity by approximately 40% and 200% 
respectively (Kew, et al, 2003).  
In addition, It has been established that n-3 PUFA’s induce the production of 
inflammation resolving mediators called E series resolvins (from EPA) and 
maresins, D series resolvins and protectins (from DHA) (Nieman & Mimesser, 
2017). Resolvins, protectins and maresins decrease the production of PGE2, and 
pro-inflammatory cytokines (Yaqoob, 1995). These pro-resolving mediators help 
regulate and resolve acute inflammation (Kelley et al., 1998). High intensity cycling 
for 75-km, resulted in post exercise elevation in most inflammatory mediators that 
reduced back to baseline levels by the following morning. Maresin 1 was elevated 
during this recovery process, which may suggest its importance in recovery from 
inflammation (Nieman, 2017).  
The research conducted to date establishes the importance of immune cell 
membrane fatty acid composition and the influence of n-3 PUFAs on cell function. 
However many immune function studies are carried out in-vitro. Further research is 
required to investigate the effect of n-3 PUFA on inflammatory mediators over 
chronic periods of training. Few studies have examined the effect of fish oil on post 
exercise recovery of immune function and the evidence available is conflicting, 
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mainly due to differences in research designs. The research field is lacking large 
studies in athletic groups. 
 
N-3 PUFA and strength speed and power exercise  
 
It is clear that previous exercise and training studies have focused on n-3 PUFA and 
its therapeutic effect on cardiovascular function. Few studies have assessed n-3 
PUFA in relation to muscle function and the performance of strength, speed and 
power based exercise, which are also important components of intermittent team 
based sport performance. In studies of this nature, it is important to consider the 
diverse requirements of team sport performance with a multifactorial exercise 
testing approach. Recently Gravina et al., (2017) examined a 4 week 
supplementation intervention with high dose n-3 PUFA 0.1g/kg per day on 
adaptations in strength, speed, power and anaerobic endurance capacity in 
International soccer players. The results demonstrated a potential benefit of n-3 
PUFA on anaerobic endurance capacity in a yo yo intermittent test, where more 
distance was covered following the training and supplementation intervention this 
was theorised to be due possibly to improved blood flow to skeletal muscle which 
may have prolonged time to fatigue. However, there were no observed 
improvements in strength, power or speed assessments.  
 
N-3 PUFA and skeletal muscle metabolism  
 
N-3 PUFA supplementation and its effect on human skeletal muscle metabolism is 
an area of contemporary investigation especially with regard to muscle protein 
synthesis. There is evidence to suggest that n-3 PUFA intake positively affects 
strength gains following resistance training in the elderly (Smith et al, 2011). There 
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may be an anabolic effect of n-3 PUFA supplementation, the mechanisms mediated 
by increased activation of mTOR - p70 ribosomal protein S6 kinase (p70S6K) 
signalling (this signal can be blunted in older age due to increased inflammation). 
McGlory et al. (2014) investigated the effect of n-3 PUFA supplementation for a 
period of 8-weeks on myofibrillar protein synthesis (MPS). In addition, the influence 
of n-3 PUFA combined with protein feeding and exercise on MPS was examined. 
Fish oil supplementation did not influence myofibrillar protein synthesis rate at rest, 
in combination with protein feeding or with protein feeding post exercise. Reduced 
PKB and p70S6K1 activity was observed 3 hours post exercise suggesting that n-3 
PUFA supplementation might influence anabolic signalling without any change in 
MPS. This area warrants further research. 
 
CONCLUSIONS & CONTRIBUTION TO THE FIELD 
 
Firstly, this thesis examined the acute cytokine response to two novel time trial and 
interval cycling protocols. This thesis contributes knowledge to the field that both a 
1-hour time trial and an interval cycling trial elicit an increase in IL-6, and the 
increase was more marked in the time trial compared to the interval trial. This finding 
is typical of the frequently reported IL-6 response to exercise. In addition, anti-
inflammatory IL-4 and MCP-1 increased and VEGF decreased post exercise. 
Neither protocol response supports the traditional view that IL-6 production triggers 
the acute production of pro-inflammatory TNFα or IL-1 β (Peake, 2005). The findings 
were however in agreement with more recent research that has failed to detect 
changes or only slight increases in pro-inflammatory cytokines post 90 minutes 
running, eccentric and exhaustive exercise (Ostapiuk-Karolczuk et al., 2012; Hirose 
et al., 2004 & Suzuki et al., 2002). Therefore, cycling protocols of this nature do not 
appear to be acutely inflammatory, although a delayed increase in the appearance 
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of inflammatory cytokines could not be ruled out in this study due to the limited 
sampling time points post exercise. Additional blood sample collections in the hours 
and days post exercise would provide further knowledge regarding cytokine kinetics 
in response to different cycling protocols.  
Due to the potential influence of n-3 PUFA on cardiovascular variables, this thesis 
investigated its effect on oxygen consumption and cardiovascular variables during 
cycling exercise. This research question presents a number of methodological 
considerations regarding the relevant daily dosage of n-3 PUFA and the duration of 
supplementation. It is important for studies to be able to accurately quantify the 
extent of n-3 PUFA tissue incorporation resulting from a supplementation protocol 
using rapid convenient methods. Therefore, this thesis examined the relationship 
between rapid fingertip capillary DBS and gold standard isolated erythrocyte 
methods of measurement to quantify an individual’s fatty acid status. The study was 
novel as it correlated samples from 3 time points over an 8 week supplementation 
period (Baseline, 4 weeks and at 8 weeks) whereas previous research has 
examined levels at rest (without supplementation) (Bailey-Hall et al., 2008). This 
study provides evidence that the rapid DBS method is suitable for the measurement 
of EPA only, but not other fatty acids. Isolated erythrocyte analysis is the most valid 
method of measurement for studies that need to quantify the incorporation of 
multiple PUFAs or over a prolonged supplementation protocol; therefore this method 
of analysis was adopted in chapter 5. 
In relation to the “ideal dose” and dose duration of n-3 PUFA, previous studies have 
employed a variety of different protocols. However, given that n-3 and n-6 PUFA 
compete for the same desaturase elongation enzyme for incorporation into 
phospholipid membranes, it was relevant to consider lowering background dietary 
n-6 PUFA intake whilst supplementing with n-3 PUFA. Furthermore, to examine 
dose response over an 8-week supplementation protocol, fatty acid incorporation 
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was measured at baseline, 4 weeks and 8 weeks into the supplementation period. 
Previous studies have only considered pre and post measures. A novel dietary 
intervention that lowered n-6 and increased n-3 PUFA dietary intake through 
supplementation with 2600mg EPA and 1800mg DHA/ day of fish oil successfully 
increased erythrocyte membrane levels of EPA and DHA and reduced n-6 AA and 
LA. Although the dietary intervention was successful in achieving its target n-3 and 
n-6 PUFA levels, it did not reduce oxygen consumption during steady state 
submaximal exercise or associated cardiovascular variables. In addition, there was 
no change in 2OV

peak performance following the dietary intervention over 4 
submaximal cycling intensities. This work contributes to the field in a number of 
ways. Previous studies have measured oxygen consumption data using gas 
exchange methods (Douglas bag or online breath-by-breath systems). This was the 
first study to combine gas exchange methods with local muscle oxygenation (TSI 
%) and oxygen extraction (deoxy HHb) using NIRS analysis. Local measurements 
in the current thesis appeared to compliment the findings at the gas exchange level 
i.e. no change in 2OV
  consumption, TSI % or deoxy HHb. It is suggested that future 
work should focus on the influence of n-3 PUFA on skeletal muscle respiration and 
mitochondrial bioenergetics at higher workloads where oxygen delivery is 
compromised to see if the possible compensatory cardiovascular effects of n-3 
PUFA reveal themselves during physiologically stressful exercise. 
In short. This thesis has contributed new investigative work regarding exercise 
induced inflammation and the influence of n-3 PUFAs on oxygen consumption and 
cardiovascular variables. The findings suggest n-3 PUFA does not reduce oxygen 
consumption during submaximal cycling or influence the performance of 2OV

peak. 
The work in this thesis has uncovered a number of important methodological 
considerations regarding the limited use of DBS methods. In addition, a novel and 
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successful dietary model has been created that considers the modulation of 
background dietary n-6 PUFA intake. These findings are important for future 
research design. Whilst n-3 PUFA has been recommended to athletic populations, 
based on the findings of some of the exercise literature discussed in this thesis. It 
cannot be concluded from these findings if such a recommendation is warranted. 
There is still much research to uncover regarding the mechanisms of n-3PUFA in 
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The following procedures for fatty acid analysis (Chapter 4) were carried out by the 
analytical chemistry department at Loughborough University  
 
Reagent and biological materials  
 
Reagents that were used in preparing samples include; acetyl chloride, potassium 
carbonate (K2CO3), and butylated hydroxyl toluene (BHT). HPLC grade n-hexane, 
methanol and heptadecanoic acid methyl ester was used as internal standard along 
with 9 ml Ace pressure tubes were all purchased from Sigma Aldrich. Supelco 37 
Mix FAME standard (Sigma Aldrich) was used as the certified reference material for 
GC-MS analysis of complex mixture of saturated, monounsaturated and 
polyunsaturated fatty acids.  50 µg/ml BHT-methanol was prepared and added to all 
samples to prevent oxidation of fatty acids 
  
Sample preparation  
 
Samples were removed from the -80 °C freezer, thawed and vortexed to ensure 
sample homogenization, 100 µl of the sample (RBCs or PBMCs) was added to the 
reaction tube containing the reaction medium which was composed of 3.4 ml of 
50µg/ml BHT in methanol and 200 μL of acetyl chloride and sealed. BHT was not 
added to the reaction medium used for DBS analysis as Guthrie cards were treated 
with BHT prior to sampling. For DBS samples, one of the 30 mm2 punched samples 
was derivatised by adding 200 μL of acetyl chloride to 3.4 ml of methanol. 
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The reaction medium of BHT/ Methanol /Acetyl chloride was freshly prepared in the 
reaction tubes while the sample was thawed. The reaction was heated at 70 °C for 
60 minutes in a water bath and 5 ml of 6% (K2CO3) was added to stop and neutralize 
the reaction. 1.5 ml of n-hexane was added and the mixture was centrifuged at 2500 
rpm for 10 minutes after which the top hexane layer was taken. The washing step 
was repeated and the combined hexane layers were evaporated to dryness using 
nitrogen gas. Samples were reconstituted in 100 µl of hexane containing 10 µg/ml 
of internal standard.  1 µl aliquot of sample was then injected on the GC-MS by a 
CTC Analytics Combi-Pal auto sampler. 
 
Analysis of Fatty acids  
 
Fatty acid composition of RBC, DBS and PBMCs was determined by gas 
chromatography (GC) mass spectrometry (MS). The GC oven temperature program 
began at 130 °C and increased from 130 °C to 208 °C at a rate of 6 °C /min. The 
temperature program then increased from 208 °C at 2 °C /min until it reached 225 
°C where it was held for 10 min with a total analysis time of 31.5 min. Injector 
temperature was set at 220 °C with a split ratio of 10:1. Helium was used as carrier 
gas at constant flow rate of 1.5 ml/min. 1 µl aliquot of fatty acid methyl ester (FAME) 
sample was injected on the GC by a CTC Analytics Combipal auto sampler.  FAMEs 














Two way mixed ANOVA analysis summary of total saturated fat and 
monounsaturated fat  
 
Total Saturated fat 
A two way mixed ANOVA elicited no significant main effect of time, F(2, 26) = 
1.98, p = 0.16, partial η2 = 0.13 or group, F(1, 13) = 0.051, p = 0.825, partial η2 = 
0.004. There was no significant interaction between time and group, F(2, 26) = 
1.251, p = 0.30, partial η2 = 0.88, on erythrocyte total saturated fat content. 
 
Total Monounsaturated fat   
A two way mixed ANOVA elicited no significant main effect of time, F(2, 26) = 
1.625, p = 0.22, partial η2= 0.11 or group F(1, 13) = 0.548, p = 0.472, partial η2 = 
0.04. There was no significant interaction between time and group, F(2, 26) = 3.03, 



















Three way mixed ANOVA analysis summary of RPE, lactate and glucose changes 
over the four - stage power test between groups, pre to post supplementation with 
n-3 PUFA.  
 
RPE 
There was a significant main effect of power, F(1.541, 20.038) = 162.49, p <0.001, 
partial η2 = 0.92. There was no significant main effect of pre/ post, F(1,13) = 
0.009, p = 0.93, partial η2 = 0.001, or group, F(1, 13) = 0.001, p = 0.98, partial η2 
= <0.001. There was no statistically significant two-way interaction between power 
& group, F(1.541, 20.038) = 2.97, p = 0.085 , partial η2 = 0.19, between pre/post 
and group F(1, 13) = 0.45, p = 0.84, partial η2 = 0.003, or pre/post and power F(3, 
39) = 0.506, p = 0.68, partial η2 = 0.037. Furthermore there was no significant 
three way interaction between group, pre/post and power level, F(3, 39) = 0.14, p 
= 0.94, partial η2 = 0.01.  
 
Table 18. RPE values pre and post the supplementation period in the FO and SO 
group at each power level 
 
     Pre Post  N 
100 W FO  8.9   ± 1.5 9.1   ± 2.19 7 
 SO 8.4   ± 1.3 8.4   ± 1.7 8 
125 W FO  10.4 ± 1.9 10.4 ± 2.07 7 
 SO 10.4 ± 1.5 10.5 ±1.6 8 
150 W FO  11.4 ± 1.5 11.4 ± 1.62 7 
 SO 11.8 ± 1.3 11.6 ± 1.4 8 
175 W FO  12.6 ± 1.1 12.4 ± 1.13 7 
 SO 13.1 ± 0.9 12.8 ± 1.1 8 








Whole blood lactate levels (mmol/L) during the four stage submaximal test (power 
level).  
There was a significant main effect of power, F(4, 52) = 5.229, p = 0.001, partial 
η2 =0.29. There was no significant main effect of pre/ post, F(1, 13) = 0.198, p = 
0.66, partial η2 =0.02 or group, F(1, 13) = 2.08, p = 0.17, partial η2 =0.138. There 
was no significant two-way interaction between power level & group, F(4, 52) = 
1.14, p = 0.35, partial η2 = 0.08, pre/post and group F(1, 13) = 0.19, p = 0.66, 
partial η2 = 0.015, or pre/post and power, F(1.759, 22.87) = 0.84, p = 0.43, partial 
η 2 = 0.06. Furthermore there was no significant three way interaction between 
power level, pre/post and group F(1.759, 22.87) = 0.84, p = 0.43, partial η2 =0.06 
(Tables 21 and 22).  
 
Glucose (BG mmol/L) during the four stage submaximal test (power level).   
There was a significant main effect of power, F(1.529, 19.877) = 6.748, p = 0.009, 
partial η2 = 0.342. There was no significant main effect of pre/ post, F(1,13) = 
0.217, p = 0.65, partial η2 = 0.16 or group, F(1,13) = 0.219, p = 0.65, η2 = 0.17. 
There was no statistically significant two-way interaction between power level & 
group, F(1.53, 19.88) = 2.46, p = 0.057, partial η2 = 0.159 or between pre/post and 
group F(1, 13) = 0.005, p = 0.94, partial η2 = <0.001. There was a significant two 
way interaction between pre/post and power level F(1.76, 22.93) = 4.12, p = 0.006, 
partial η2 = 0.24. Furthermore, there was no significant three way interaction 
between power level, pre/post and group F(1.764, 22.93) = 2.27, p = 0.13, partial 
η2 = 0.15 (Tables 23 & 24).  
Table 21. Lactate (mmol/L) pre and post the supplementation period in the FO and 
SO group at each power level  
     Pre Post  N 
Baseline FO 1.69± 0.39 1.70± 0.35 7 
 SO 1.87±0.50 1.59±0.72 8 
100 W FO  1.81± 0.67 2.21± 0.73 7 
 SO 2.11± 0.61 2.39±1.41 8 
125 W FO  1.53± 0.56 1.49± 0.49  7 
 SO 2.05± 0.58 2.06± 0.67 8 
150 W FO  2.09± 0.76 1.78± 0.48 7 
 SO 2.17± 0.61 2.04± 0.51 8 
175 W FO  2.64± 1.44 2.03± 0.53 7 
 SO 2.81± 0.70 2.33± 0.65 8 
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MAXIMAL OXYGEN UPTAKE TEST  
 
RPE 
A 3 way mixed ANOVA was performed to examine any interaction between groups 
pre and post the supplementation period (pre/post), on RPE values each minute of 
the 2OV
  max test (time). The first 10 minutes of the test was included in the 
analysis.  
There was a significant main effect of time F(1.567, 17.24) = 172.80, p = <0.001, 
partial η2 = 0.94. There was no significant effect of pre/ post, F(1, 11) = 0.041, p = 
0.84, partial η2 = 0.004 or group, F(1, 11) = 0.199, p = 0.664, partial η2 = 0.018. 
There was no statistically significant two-way interaction between pre/post and 
group F(1, 11) = 4.186, p = 0.065, partial η2 = <0.28, between time & group, 
F(1.57, 17.24) = 1.249, p = 0.30, partial η2 = 0.10 or pre/post and time F(3.73, 
40.99) = 0.191, p = 0.093, partial η2 = 0.017. Furthermore, there was no 
statistically significant three way interaction between time, pre/ post and group 





A two-way mixed ANOVA was performed to examine any interaction between 
group and whole blood lactate levels following the completion of the 2OV

max test 
pre and post the supplementation period. There was a significant main effect of 
time (pre/ post) F (1, 13) = 10.99, p = 0.006 partial η2 = 0.458, and no significant 
main effect of group on whole blood lactate levels, F (1, 13) = 0.014, p = 0.907 
partial η2 = 0.001. Furthermore, there was no statistically significant two way 
interaction between group and time (pre/ post), F(1, 13) = 0.21, p = 0.65 partial η2 
= 0.016. 
A paired samples t-test indicated that blood lactate was significantly higher post 
the 2OV

max compared to pre (as to be expected). Post value (mean ± stdev) = 8.9 
mmol/ L  2.86), pre value = 10.74 mmol/ L  2.35. A statistically significant mean 




 max Glucose  
A 2 way mixed ANOVA was performed to examine any interaction between the 
intervention group SO/FO and post max test whole blood glucose levels pre and 
post the supplementation period. There was no significant main effect of time (pre 
or post the supplementation period) F(1, 13) = 1.908, p = 0.190 partial η2 = 0.128, 
and no significant main effect of group F(1, 13) = 6.41, p = 0.025 partial η2 = 0.33. 
Furthermore, there was no significant two way interaction between the group and 
pre/ post F(1, 13) = 1.989, p = 0.182 partial η2 = 0.133.  
